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The advances in exogenous insulin therapy has been able to improve the lifestyle of Type-1 diabetic 
(T1DM) patients, but no formulation till date is yet to mimic the nyctohemeral rhythms of this hormone. In 
spite of all engineering progresses, a mechanical replacement of pancreatic β cell is still out of reach. 
Pancreatic islet or the whole pancreas transplantation are the only realistic approach towards finding the 
‘cure’ of the disease. In pancreas, only 1-1.5% cells are insulin secreting; therefore, islet transplantation 
arises as a more realistic alternative. After the introduction of ‘Edmonton protocol’ in 2000, clinical islet 
transplantation is now considered as one of the safest and least invasive transplantation procedures. The 
protocol proposed several modifications to the existing procedures, such as transplantation of freshly 
isolated islets from more than one donor pancreas, and use of a steroid-free immunosuppressive drug 
protocol, which increased the initial success rate significantly. A five-year follow-up study confirmed 
improved glycemic control in a significant number of recipients, however, only 7.5% of them have attained 
insulin independence. Therefore, continuous researches have been carried out to improve the protocol in 
the preservation of the efficacy of the transplanted islets. In order to have an improved outcome and 
availability of this technology we still have to tackle with the problems related with donor shortage and 
immunogenicity. Porcine islet xenotransplantation has arisen as a potential alternative source of clinical 
islet transplantation due to its structural and anatomical similarities with human islets. Moreover, to get 
around immunogenicity, islet nano-shielding with biocompatible polymers has offered a great promise to 
increase survival time in combination with immunosuppressive drugs.  
In this thesis, islet nano-shielding was performed with polymers, such as gelatin, polyethylene 
glycol (PEG), heparin (Hep), and tannic acid (TA); and validated in different animal models. Nano-
shielding with an artificial extracellular matrix (A. ECM) based material stabilized inherently fragile 
porcine islets from dissociation after isolation, when PEG was incorporated into the shielding composition, 




nano-shielded surfaces, reduced instant blood-mediated inflammatory reactions (IBMIR) and immune cell 
activation while exerting no cytotoxic effects on the islets. Finally, nano-shielded non-human primate (NHP) 
islets demonstrated excellent success rate in both allo- and xeno-recipients with less immune infiltration.  
One of the benefits of employing nano-shielding technology for islet immunoisolation is it restricts 
the increment of cell size more than a few nanometers, which makes clinical transplantation feasible 
through the conventional portal vein. Moreover, the nano-shielding has synergistic effects on increasing 
survival time with an appropriate immunosuppressive drug regimen. We believe this is the cutting-edge 
technology with immense potential in clinical transplantation at the moment. If applied with the current 
immunosuppressive drug protocol, clinical islet transplantation would enter into a new dimension. 
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cells. Quantification of secreted cytokines, (B) IL-1ß, and (C) TNF-α in the co-culture 
supernatant (n=5). *p < 0.05, **p < 0.005 and ***p < 0.0002. 
 
Figure 4.10 (A) Non-fasting blood glucose (NBG) level of the transplanted recipients. Four 
recipients were sacrificed after one week (■) and the rest four after four weeks (●) of 
transplantation for graft microenvironment analysis. (B) H&E staining of the 
transplanted grafts. (C) Illustration for the re-establishment of islet microenvironment 
and immune protection by the nano-shielding. 
 
Figure 5.1 Systemic immunosuppressant and anti-inflammatory agent regimens. Diabetes was 
induced one month prior to transplantation, and 5 mg/kg rATG was administered 
daily for 4 days beginning from the day of the transplant. Etanercept was administered 
3 times (transplant day and post-transplant days 3 and 6). Anakinra was administered 
daily for 7 days beginning from the day of the transplant. Single doses of rituximab 
were administered to PEG-Hep 5- PEG-Hep 10. Tacrolimus and mycophenolate 
mofetil were administered to maintain immunosuppression while drug levels were 
monitored. 
 
Figure 5.2 1H NMR characterization of (A) SH-6-arm-PEG-NHS, (B) 6-arm-PEG-catechol, and 
(C) heparin-SH. 
 
Figure 5.3 Synthesis schematics, polymeric nano-shielding on the islet surface, and surface 
characterization of the PEG-Hep surface. Synthesis of (A) SH-6-arm-PEG-NHS, (B) 
6-arm-PEG-catechol, and (C) heparin-SH. (D) Chemical structure of linear PEG-SH. 
(E) Formation of PEG or PEG-Hep nano-shielding on islet surface. AFM imaging (4 
µm x 4 µm) of (F) collagen surface (control), (G) PEG-Hep surface in the dry state, 
and (H) PEG-Hep surface in the wet state after incubating the PEG-Hep surface with 
PBS for 1 h at room temperature. The height profile is indicated along the line within 
the image. 
 
Figure 5.4 CLSM images of PEG-Hep nano-shielded islets that were tagged with FITC-labeled 
PEGs and heparin, and their viability per analysis with a live/dead 
viability/cytotoxicity assay kit. Optical (top), merge (middle), and live/dead (bottom) 
images of islets treated with (A) SH-6-arm-PEG-NHS at 0.25%, 0.5%, 1% and 2% 
w/v; (B) SH-6-arm-PEG-NHS at 0.5% w/v as the first layer and 6-arm-PEG-catechol 
at 0.25%, 0.5%, 1% and 2% w/v as the second layer; (C) SH-6-arm-PEG-NHS at 





heparin-SH at 0.25%, 0.5%, 1% and 2% w/v. 
Figure 5.5 Characterization and the effects of PEG-Hep nano-shielding on IBMIR reduction in 
vitro. (A) CLSM images of PEG-Hep islets; intensity profile along the line. Scale bar: 
100 µm. (B) Qualitative viability assessment of unshielded (control) and PEG-Hep 
islets, performed using a live/dead viability/cytotoxicity assay kit. Scale bar: 100 µm. 
(C) The relative viabilities of the control and PEG-Hep islets quantified using cell 
counting kit-8 (CCK-8/DNA, n = 5) assay. (D) The glucose-stimulated insulin 
secretion test performed to compare the functionality of PEG-Hep with that of control 
islets in a low (□, 2.8 mM) and a high (■, 28 mM) glucose Krebs-Ringer bicarbonate 
buffer solution (n = 5). (E) Stimulation index for glucose stimulation (n = 5). (F) 
Platelet adhesion on the collagen (control) and PEG-Hep nano-shielded collagen 
surfaces. Scale bar: 10 µm. (G) Reduction in adhered platelets on the PEG-Hep 
surface compared with the control surface (*** p < 0.001). (H-J) Islet damage through 
complement activation. (H) C3a generated while islets were cultured in 50% monkey 
serum. The higher C3a concentration in the control group (* p < 0.05) resulted in 
reduced (I) viability and (J) insulin secretory capability compared with those of the 
PEG-Hep group (** p < 0.01). (K, L) Islet co-culture with splenocyte. (K) 
Concentration of secreted IL-1ß from the splenocytes cultured with control and PEG-
Hep islets (* p < 0.05). (L) Control islets were more damaged by immune cell activity, 
in contrast to the PEG-Hep (** p < 0.01). 
 
Figure 5.6 Blood glucose level (■, mg/dl) of the allogenic islet transplanted cynomolgus 
monkeys. Administration of exogenous insulin (|, IU/kg/d) was initiated on post-
transplant days 9 and 2 in (A) Control 1 and (B) Control 2, respectively. (C) Control 
3 and (D) control 4 required insulin injections from post-transplant days 37 and 40, 
respectively. (E-I) All subjects in the PEG group became insulin dependent within 3 
weeks of transplantation. (J) PEG-Hep 1 and (K) PEG-Hep 2 did not require insulin 
until 3 months post-transplant. (L) PEG-Hep 3 became insulin dependent on post-
transplant day 11 and showed similar blood glucose levels to those of subjects in the 
control or PEG groups. (M) PEG-Hep 4 exhibited a severe blood glucose fluctuation 
and began using insulin on post-transplant day 71. (N) PEG-Hep 5 did not require 
insulin until 44 days post-transplant but was sacrificed due to asphyxia. Rituximab 
was added to the regimen for (O-S) PEG-Hep 6 to PEG-Hep 10. (O-R) PEG-Hep 6, 
7, 8, and 9 became insulin dependent on post-transplant days 58, 51, 43 and 36, 





sacrificed on post-transplant day 34 due to a catheter-related infection. 
Figure 5.7 C-peptide level (■, ng/ml) of the allogenic islet transplanted cynomolgus monkeys. 
(A) Control 1 and (B) control 2 had detectable C-peptide levels above 0.5 ng/ml until 
post-transplant days 56 and 27. (C) Control 3 and (D) control 4 had detectable C-
peptide until post-transplant days 93 and 98. (E-I) Animals in the PEG group had C-
peptide positive graft survival for 35 to 98 days. (J-N) PEG-Hep 1 to PEG-Hep 5 had 
detectable C-peptide levels above 0.5 ng/ml for 44 to 172 days. (O-S) PEG-Hep 6 to 
PEG-Hep 10 had additional induction immunosuppression with Rituximab and had 
detectable C-peptide levels for 34 to 138 days. 
 
Figure 5.8 Survival rate, metabolic parameters and representative histologic sections of the 
recipients. (A) C-peptide positive graft survival comparison between the control, 
PEG and PEG-Hep groups. The mean islet survival was significantly longer in the 
PEG-Hep group (p < 0.05). (B) Comparison of IVGTTglu (left) and IVGTTc-pep 
(right) 1 month post-transplantation. The data show a 0.59%/min glucose 
disappearance rate in the control group, and KG 0.95%/min and KG 0.68%/min rates 
in the PEG and PEG-Hep groups, respectively (partial response). An acute C-peptide 
response was not observed in any group. However, the C-peptide levels were above 
2 ng/ml in the PEG-Hep group. (C) Representative histologic sections of liver biopsy 
specimens one month after islet transplantation. Numerous islets were evident in the 
liver sections from PEG-Hep 1, 2 and 5. CD3+ T cells or CD20+ B cells were nearly 
absent around the insulin- and glucagon-stained islets. Scale bar: 100 µm. 
 
Figure 5.9 Lymphocyte subset analysis in the peripheral blood.  
Figure 5.10 Lymphocyte analysis in liver histology. (A) CD3 T cell staining (brown) shows 
moderate infiltration around the islets in the PEG group. CD3 T cell staining was 
evident in small areas for the PEG-Hep group, with most islets showing no 
infiltration. (B) Comparison of CD3 T cell and CD20 B cell infiltration in the livers 
between the PEG and PEG-Hep groups. CD3 T cell staining was markedly decreased 
in the PEG-Hep group (*p < 0.001). 
 
Figure 5.11 Illustration of the convergent protocol for islet immunoprotection.  
Figure 6.1 (A) Chemical structure of tannic acid (TA), and formation of hydrogen bonds between 
islet surface collagen and TA. LbL nano-shielding with (B) TA-PEG-Hep, and (C) 
(TA-PEG)2Hep on islet surface.  
 
Figure 6.2 Confocal laser scanning microscopic images of islets nano-shielded with TA, PEG, 





Figure 6.3 (A) Live/Dead viability/cytotoxicity kit, and (B) cell counting kit-8 (CCK-8/DNA, 
n=5) assays of nano-shielded islets. (C) Functionality of the nano-shielded islets was 
checked by glucose-stimulated insulin secretion (GSIS) test at a low (□, 2.8 mM), 
and a high (■, 28 mM) glucose solution for 2 h (n=5). 
 
Figure 6.4 (A) Islets were isolated from SD rats and transplanted (500 IEQ) into the kidney 
subcapsular space of diabetic C57BL/6 mouse. Non-fasting blood glucose level 
(NBG) of (B) naked (control, n=9), (C) TA-PEG-Hep (n=8), and (D) (TA-PEG)2Hep 
(n=8) islet recipients. (E) Graft survival rate of each group. (F) Intraperitoneal glucose 
tolerance test (IPGTT) after overnight fasting of diabetic mice (n = 3), normal mice 
(n = 3), naked islet recipients (control, n = 9), TA-PEG-Hep recipients (n = 8), and 
(TA-PEG)2Hep (n=8) recipients. 
 
Figure 6.5 (A) C-peptide, and (B) insulin concentrations were measured by enzyme-linked 
immunosorbent assay (ELISA) from the serum of all three recipient groups. (C) 
Hematoxylin and eosin (H&E), and insulin staining of the transplanted kidney. Scale 
bar 100 µm. *p < 0.05. 
 
Figure 6.6 Migration of immune cells is reduced in TA-PEG-Hep nano-shielded collagen well 
inserts. (A, B) Millicell® hanging cell culture insert (3 µm pore size, 24-well plate) 
were coated with rat tail collagen I, and the three-layer (TA-PEG-Hep) nano-shielding 
was formed on the collagen layer. Isolated splenocytes (5x104) were incubated in the 
inserts for 24 h and counted with trypan blue staining. (C) Percentage of total 
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1.1    Diabetes mellitus  
Diabetes mellitus (DM), the Latin name for Diabetes, is a chronic metabolic disease associated 
with persistently high glucose level in the blood. It arises when the body is unable to produce enough 
insulin or utilize them in cellular level, or both. It is one of the greatest health crisis of the 21st century 
claiming more lives per year than HIV-AIDS with nearly one death in 10 seconds [1]. According to a 
latest study, 415 million people world-wide is suffering from diabetes and 318 million people are in a 
risk of developing the disease in future [2]. DM prevents our body from using energy derived from 
consumed food. Cells in our body require food in a simple form to produce energy. Glucose in the blood 
cannot enter the cell without the help of insulin. Pancreas produces insulin that serves as the “key” for 
glucose to entrance into the cell to generate energy. When glucose leaves the bloodstream, and enters 
into the cells, blood glucose level (BGL) drops. Inadequate production of insulin or reduced sensitivity 
of cells to the insulin cause high blood glucose level. A persistent rise of BGL leads to hyperglycemia 
or DM. Type-1 diabetes mellitus (T1DM) is caused by the autoimmune destruction of insulin producing 
pancreatic ß cells. As a result, not enough insulin is produced to lower the BGL. T1DM makes up 5-
10% of all diabetic cases. Type-2 diabetes mellitus (T2DM) starts with insulin resistance. T2DM occurs 
when the pancreas cannot produce enough insulin or the produced insulin cannot work properly. Nine 
out of ten diabetic patients have T2DM. 
 
1.2    Type-1 diabetes mellitus 
1.2.1    Symptoms 
Type-1 diabetes mellitus (T1DM) is a disease with both biochemical and anatomic 
consequences. It is a chronic disease of fat, carbohydrate and protein metabolism caused by lack of 
insulin that results from the progressive destruction of pancreatic ß cells by activated immune cells [3]. 
T1DM, also referred to as insulin dependent diabetes mellitus (IDDM) or juvenile onset diabetes 
mellitus. Onset occurs mostly in childhood but the disease can also develop in late 30s or early 40s. 
Reports published by American Diabetes Association (ADA) say that there are 3 million children and 
adults suffering from T1DM only in the USA [4]. The symptoms of T1DM are, dry mouth and abnormal 
thirst, polyuria, constant hunger, lack of energy and tiredness, weight loss, blurred vision etc. Two 
distinct features of T1DM from the T2DM are – usually patients are not obese, and present initially 





1.2.2    Pathophysiology 
Autoimmunity is the key factor for the pathophysiology of T1DM. Pancreatic ß cells are 
destroyed by activated CD4+, CD8+ T cells and macrophages infiltrating the pancreatic islets [3]. 
Genetic studies revealed that human leucocyte antigen (HLA) gene is closely linked with T1DM. HLA 
proteins express on cell surface and help immune cells to distinguish body’s normal cells from foreign 
invaders. In T1DM, abnormalities in HLA gene leads to activation of immune cells against the cells. 
Lymphocyte infiltration causes the culmination of T1DM. Insulin production declines with the declined 
mass of beta cells. Hyperglycemia develops after 80-90% beta cells are destroyed. Apart from the 
genetic and environmental reasons, certain viral infections are also responsible for triggering the 
autoimmune response in T1DM [5]. Patients with other autoimmune diseases, such as, Graves’ disease, 
Hashimoto thyroiditis, and Addison disease have a higher chance to develop T1DM [6]. 
 
1.2.3    Diagnostic criteria 
A sustained elevation of blood glucose level is considered as diabetic state. The blood glucose 
concentration often raises above the normal glucose limit. Therefore, the popular and easy method to 
diagnose the disease is to measure the glucose level in blood. T1DM is diagnosed to the patients having 
the following three finding, ketoacidosis, a high blood glucose and a low C-peptide level in blood or 
urine. A person is considered as diabetic when his random blood glucose level exceeds 200 mg/dl (11.1 
mmol/L), and the fasting blood glucose level is over 126 mg/dl (7 mmol/L) [1]. Ketoacidosis is a unique 
feature of T1DM when patients show increased level of ketone bodies in serum and/or urine. The patient 
will also show urinary C-peptide level less than 10 µg/day or fasting serum C-peptide level below 0.3 
ng/mL or a peak serum C-peptide level below 0.5 ng/mL after a meal [7]. 
 
1.2.4    Treatment options 
The treatment options are mostly involved in maintaining the blood glucose level as close as 
possible to the normal level. T1DM patients are treated with different forms of insulin, such as, oral, 
injectable, inhalable, or nanotechnology based delivery systems [8-10]. Avoiding high fluctuations of 
blood glucose level, and consequently preventing arterial and microvascular complications are the main 
purpose of insulin therapy.  
The basis of treatment of T2DM is changing lifestyle by adopting healthy diet, exercise and 
maintain body weight in normal range. In contrast to the T1DM patients, most patients with T2DM do 
not require daily administration of insulin, rather a number of oral medications are available to 
maintaining blood glucose level. However, if the blood glucose level continues to rise out of control, 




1.2.5    Insulin therapy 
1.2.5.1    Insulin action 
Insulin is a peptide hormone produced by the beta cells of islets of Langerhans in pancreas. It 
helps the metabolism of carbohydrate, fat and protein and promotes absorption of glucose into fat, liver 
and skeletal muscles. In these tissues glucose is then converted into glycogen or fat cells. Insulin in the 
blood strongly regulates the production and release of glucose by the liver. Therefore, insulin is 
considered as the most important anabolic hormone of body as it converts small molecules in blood into 
larger molecules inside the cells [11]. 
 
1.2.5.2    History  
Patients with T1DM need an uninterrupted supply of insulin for their survival. Some patients 
with T2DM also need insulin therapy. In 1921 scientist Frederick Banting and Charles best isolated a 
compound from dog pancreas and named it as ‘isletin’ that we now know as insulin. Isletin was found 
to be able to keep dogs alive that had undergone through pancreatectomy. The first case of insulin 
therapy happened in the following year. A 14-year-old boy, Leonard Thompson, was treated with an 
insulin injection that improved his situation significantly. Before insulin was invented there was no 
hope for diabetes patients to survive and they were put in a starvation diet. 
 
1.2.5.3    Types of insulin 
Various types of insulin are available depending on their onset of action and duration in blood. 
Regular insulin is a short-acting insulin that starts its action within 30-60 minutes and lasts 4-6 hours. 
Intravenous form of regular insulin is useful in critically ill patients and in the treatment of diabetic 
ketoacidosis. It is also indicated for the treatment of diabetic ketoacidosis, hyperglycemic hyperosmolar 
state and during perioperative management of diabetes [12].  NPH (Neutral Protamine Hagedorn) 
insulin acts as an intermediate-acting insulin having onset of action within 2-4 hours after 
administration. Its duration of action is in a range of 10-20 hours, thus, two injections per day is required 
to maintain a sustained effect. Rapid-acting insulin analogs include- insulin lispro, insulin aspart, insulin 
glulisine whose onset of action starts within 5-15 minutes and lasts for 2 hours [13, 14]. 
 
1.2.5.4    Insulin pump  
Chronic elevation of high blood glucose level is the reason for arising long term complications, 
such as, blindness, heart disease, kidney failure. On the other hand, a tight control of blood glucose 
level causes hypoglycemia [15-18]. Therefore, the requirement of an efficient blood glucose monitoring 
and insulin delivery led to the discovery of continuous subcutaneous insulin infusion (CSII) pumps. 
Progressive development of modern technology had led the size of insulin pump portable that consists 
of an insulin reservoir, a micro-computer to monitor the blood glucose level, batteries, an infusion set 
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including a cannula, and a connector tube between the insulin reservoir and the cannula. The pump 
software automatically adjusts insulin doses throughout the day [19]. Despite being a superior system 
than the conventional insulin delivery system, the pump device still possesses drawbacks, such as, 
obstruction of the catheters, display problems, bent cannula. Itching and inflammation at the injected 
site are the common problems associated with an insulin pump [20]. 
 
1.2.5.5    Pitfalls of insulin therapy  
Low blood glucose level is known as hypoglycemia. This is the most prevalent complication 
of insulin therapy [1]. The common reason for hypoglycemia is errors in dosage of insulin. Severe 
hypoglycemia sometimes leads to hypoglycemic shock which may seem mild at first. If not treated 
immediately, this can lead to coma and death to the patient [21]. Repeated insulin injection at a specific 
site cause localized hypertrophy of subcutaneous fat, referred to as lipohypertrophy. Lipoatrophy, on 
the other hand, is the loss of subcutaneous fat and suspected to be caused by immunologic reasons. 
However, newer insulins have reduced the prevalence of both of these problems. Edema occurs to the 
insulin recipients as a result of sodium-retaining effect of it on the kidney. Weight gain is an inevitable 
unexpected result of the anabolic effect of this hormone [1]. 
 
1.2.6    Pancreas transplantation 
Insulin has been considered as the standard therapeutic option since its discovery. However, 
the drawbacks of insulin therapy accelerated the search for a ‘cure’ of diabetes. Pancreas transplantation 
is the only option that assures to cure the disease. However, this process is only limited to the patients 
with late stage diabetes with kidney failure due to its requirement of life-long immunosuppression and 
invasive surgery [22]. This simultaneous pancreas kidney transplantation, therefore, is not an available 
therapeutic option to a vast majority of diabetes patients [23]. Here, islet transplantation is proposed as 
a great promise to be a cure to the disease. Islet transplantation is as effective as pancreas transplantation 
with much less invasiveness and immunogenicity. As a result, the favorable therapeutic option is now 
moving towards islet transplantation from the whole pancreas transplantation. 
 
1.3    Pancreatic islet transplantation  
Islet transplantation involves isolation of pancreatic islets from cadaveric donors and injecting 
them through the portal vein of a diabetic recipient. The transplanted islets deposit and reside in the 
liver sinuses. Transplanted islets are different from other transplanted organs in being a heterotropic 
graft that is located on a site other than its native tissue [24]. Although islets are retrieved from the 
pancreas, it is not a good site for transplanting islets. Pancreas is a highly sensitive organ and prone to 
be inflamed accompanying pain and tissue destruction by any small injury [25]. 
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There are certain advantages of islet transplantation over pancreas transplantation including 
gene delivery to modulate immunity or enhance efficacy of islet, surface encapsulation to mask antigens, 
transplantation to an immune privileged site and options to use different sources including xeno-islets 
and ß-cells [26].  
Islet transplantation has been advanced in recent years by the relentless research of scientists. 
In 2000, a study was published by James Shapiro et al. from the University of Alberta claiming an 
exceptionally successful case of islet transplantation where 7 islet recipients remained insulin free for 
over a year [27]. Later on, their phase ii trial showed 82% success rate which is comparable to the 
success rate of whole pancreas transplantation [28]. However, this procedure is still not widespread 
clinically due to its use of lifelong immunosuppression and the need for several donor pancreases for 
one recipient [26]. 
 
1.3.1    Obstacles to islet transplantation  
The complete islet transplantation procedure involves obtaining a donor pancreas from a 
cadaveric donor (allotransplantation) or from animals (xenotransplantation). The pancreases are then 
digested with collagenase enzyme to dissolve the collagen matrix of the pancreas, as a result, islets are 
released out. At this stage, the islets are mixed with other exocrine and endocrine cells of the pancreas 
and cellular debris. Density gradient solutions are used to purify islets. The purified islets are 
transplanted by a single infusion into the liver through the portal vein. The final clinical outcome greatly 
depends on each step from islet isolation to transplantation [29-31].  
 
1.3.1.1    Loss of islet viability  
The pancreas is composed of exocrine, endocrine and ductal cells. Enzyme digestion step 
during the islet isolation process disrupts the connection between islet-to-exocrine tissues [32]. 
Therefore, lower digestion time or inappropriate enzyme composition lead to impure islet contaminated 
with exocrine cells, and higher digestion time loosens intra islet cell-to-cell adhesion leading 
disintegrated islets with reduced viability. The association of cells within islets or between islets and 
exocrine tissues are of two types, cell-to-cell and cell-to-matrix. The interaction between islet-to-
exocrine tissue is cell-to-cell in pig pancreas, and call-to-matrix in canine pancreas. In humans and rats, 
the condition is predominantly cell-to-matrix. These findings explain that pig islet isolation is hard and 
different protocols should be carefully developed to isolate islets from different species [33, 34]. 
 
1.3.1.2    Loss of intra-islet vasculature 
Islets are miniature organs having own vasculatures which is essential for supplying foods and 
nutrients into the core of the islet cluster [35, 36]. Islets constitute only 1% of the total mass of the 
pancreas by weight, still they receive 5-15% of the total blood flow of the pancreas [37, 38]. However, 
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this vascular network gets disrupted during the isolation procedure that leads to poor transplantation 
outcome. Therefore, rapid growth of the vascular network is vital for islet survival and function after 
transplantation [39]. Islets secret vascular endothelial growth factor (VEGF) and its receptors and 
revascularize themselves within a few days after transplantation [40, 41]. Revascularization process 
occurs from the host tissue surrounding the transplanted graft that is being promoted by the secreted 
proangiogenic mediators such as VEGF [42]. Attempts have been made to promote the 
revascularization process by ex vivo VEGF gene delivery to islets or co-encapsulating VEGF with islets 
within encapsulation barrier [43, 44]. 
 
1.3.1.3    Immune rejection 
The biggest problem associated with organ transplantation is alloimmune destruction (Fig. 1.1). 
However, with transplanted islets, the immunological challenge is two-fold higher: alloimmune 
destruction and autoimmune rejection. T1DM itself is originated from autoimmune responses and 
characterized by the presence of autoreactive antibodies and T cells in the patients. When islets are 
transplanted, the cells are being recognized as foreign antigens to the host through an event called 
‘antigen presentation’. Donor antigen presentation to the host immune cells are mediated either via 
direct or indirect pathway. Direct pathway occurs predominantly in allotransplantation, where the donor 
antigen presenting cells (APCs) migrated from the transplanted graft present antigens to the host T cells 
that initiates the development of CD4 helper Th1 cells [45, 46]. Th1 cells, in turn, produce a bunch of 
cytokines that help the expansion and activation of cytotoxic CD8 T cells. These activated CD8 T cells 
play the most critical role in allogenic islet damage.  On the other hand, the indirect pathway is involved 
in a xenotransplantation where antigens shed by the donor islets are uptaken by the host APCs and 
display on major histocompatibility (MHC) class ii molecules [46, 47]. In xenotransplantation, the 
humoral responses against the surface antigen α-(1,3)-galactose moiety already exist. Consequently, 
hyperacute rejection of the xenograft occurs by the preformed antibodies [48, 49]. Here, donor APCs 
are not able to activate host T cells efficiently to initiate the direct pathway [50, 51]. 
 
1.3.1.4    Instant-blood mediated inflammatory reactions (IBMIR) 
Transplanted Islets, when come in contact to the direct contact with blood, initiate innate 
immune reactions called the instant blood-mediated inflammatory reactions (IBMIR, Fig. 1.2) [52-54]. 
This series of inflammatory reactions is characterized by activation of blood coagulation factors and 
complement systems, activation and adhere of platelets onto islet, leukocyte infiltration etc. As a result, 
within 15 minutes after transplantation, islets are coated with blood clots, and an hour later, lymphocyte 























































Tissue factor (TF) is the key factor in allogenic IBMIR. Ji et al. demonstrated that a reduction 
in TF expression led to a reduced formation of platelet aggregation, fibrin formation, and complement 
activation when neonatal islet cell clusters (NICCs) were cultured with human blood in vitro [56]. 
Whereas, xenogenic IBMIR is predominantly initiated by preexisting antibodies and complement 
systems. A pig-to-monkey study demonstrated that complement activation by the antibodies through 
classical pathway mediated the binding of C3b to the islet surface and led to the destruction of beta cells 
[57, 58]. IBMIR is a common reaction to all cell therapies in which cells are infused into the blood 
stream. Studies with human MSCs demonstrated to trigger complement system in contact to ABO-
compatible human blood that is similar to clinical islet transplantation [59].  
 
1.3.2    Strategies for improving the outcome of islet transplantation 
Two major drawbacks to clinically successful islet transplantation are the shortage of cadaveric 
donor and the immune destruction of transplanted islets. Different approaches have been proposed and 
applied to address these issues. Use of immunosuppressive drugs and regimens to induce immune 
tolerance is one of the biological strategies to get around the immunogenicity. Immunoisolation of 
transplanted islets using biomaterials to improve engraftment is another attractive approach apart from 
using immunosuppressive drugs.   
 
1.3.2.1    Immunosuppressive drugs  
Currently the application of generalized drug protocol is the standard protocol to prevent graft 
rejection in the recipient. First generation immunosuppressive drugs, such as, azathioprine, 
glucocorticoids, and antilymphocyte serum (ALS) were highly effective, but the significant toxicity 
limits the usage in clinical transplantation studies. Second generation drugs including cyclosporine and 
tacrolimus (FK506) have higher potencies and larger therapeutic window [24]. However, these agents 
have been found to be toxic to the islets [60]. In a study published in the year 2000, Shapiro et al. 
reported a high survival rate by using a glucocorticoid free immunosuppressive drug protocol, named 
as Edmonton protocol which includes daclizumab (an IL-2 receptor antibody), sirolimus and a low dose 
of tacrolimus to avoid adverse effects related to its toxicity [27]. All seven patients were reported to 
achieve insulin independence when transplanted with an 11,500 IEQ/kg body weight of islet mass. In a 
follow-up study, they reported an 80% survival rate in 12 out of 15 patients for 1 year transplanted with 
9,500 IEQ of islet mass per kg body weight [61, 62]. 
 
1.3.2.2    Immunoisolation of islets 
Immunoisolation of islets with biocompatible polymers requires special considerations because 
of the delicacy of this tissue. Alginate encapsulation is the most widely used microencapsulation method, 
however, there is a possibility of contamination of pyrogens and lot-to-lot variation. A major challenge 
to the clinical application of alginate microencapsulated islets is the increment of transplantable cell 
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volume that limits the route of transplantation. Although Alginate encapsulated islets transplanted into 
the peritoneal cavity normalized the blood glucose level in human subjects, studies have been conducted 
to reduce the volume. In an attempt to do that, researchers have focused on increasing insulin releasing 
capability of islets microencapsulated with alginate or decreasing the size of the encapsulation system 
itself by adding polyethylene glycol (PEG) in it [63, 64].   
Camouflage of islet surface with polymers using chemical bond formation instead of enclosing 
them into a barrier is another tactic to both immunoisolation and immunoprotection. This procedure 
involves attachment of hydrophilic polymeric chains to the surface to achieve molecular coating of the 
islets. Surface modification doesn’t increase the size of the islet more than a few nano-meters, and thus, 
several problems related to encapsulation can be avoided. A diffusion barrier over 200 µm causes loss 
of cell viability due to the interruption in diffusive transport of oxygen, and nutrients. In alginate 
encapsulation, the problems related to the diffusion barrier cannot be avoided since the average diameter 
of the islets after encapsulation becomes 500-800 µm [64]. Moreover, surface modification of islets, 
referred to as islet ‘nano-shielding’, reduces the volume of cells making it feasible to transplant through 
the portal vein in clinical setting. 
 
1.3.3    Islet nano-shielding with PEG and heparin 
Islet nano-shielding involves the surface coating of islets using hydrophilic polymers, such as, 
PEG, heparin, gelatin with an active functional group that reacts and binds to the functional groups 
located on islet surface through a mild reaction. Studies previously performed on nano-shielding with 
PEG demonstrated that it has effects on reducing plasma protein adsorption, platelet adhesion and 
making cells less immunogenic [65]. Islet nano-shielding with PEG was first stated by Panza et al. who 
used monoisocyanate as a functional group on the polymer [66]. He reported that islet viability and 
functionality was preserved through the PEG nano-shielding process. Later, Xie et al. used a more 
specific functional group, succinimide [67]. Both functional groups react with the amines located in the 
islet surface collagen, however, succinimide is more stable to be degraded by hydrolysis. Xie et al. 
demonstrated that the shielded islets are cytoprotected against activated human complement systems 
and efficient in in vivo mouse model. In a two-pronged approach, islets were both genetically modified 
with Bcl-2 gene and nano-shielded with PEG expecting to get cytoprotective effect of Bcl-2 gene 
expression in the islets and to block host immune reactions against PEGylated surface, respectively [68]. 
Islet viability and functionality were not affected and a reduction in complement mediated cytotoxicity 
was observed with normalized blood glucose level in transplanted mouse model.  
PEG nano-shielded islets transplanted into the liver of a mouse model showed significant 
increase in graft survival compared to the naked islets. Various proteins and cells are being conjugated 
onto islet surface employing this technique. Soluble complement receptor 1 (sCR1), thrombomodulin 
and urokinase have been ligated onto islet surface that resulted in diminished complement and blood 
coagulation when islets come in contact to the blood [69-72]. Techniques for conjugating heparin on 
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islet surface also gives protections against IBMIR in both in vitro and in allotransplanted porcine model 
[73]. Additionally, heparin binding growth factors can be conjugated in order to promote angiogenesis 
and islet engraftment [74].  
Our group previously reported many in vivo and in vitro studies on the immunoprotective 
effects of PEG and heparin nano-shielding on islets. Lee et al. optimized the reaction condition for the 
nano-shielding procedure and demonstrated that PEG nano-shielding covers islet surface antigens while 
maintaining viability and insulin secretory capability [75]. In later studies, it was revealed that PEG 
nano-shielded islets, when co-cultured with immune cells, reduced activation and lowered secretion of 
pro-inflammatory cytokines [75, 76]. When allotransplanted, PEG nano-shielded islets showed stable 
blood glucose level over one-year post-transplantation when treated with a lower than the clinical level 
dose of cyclosporine A. Immunohistochemical investigations showed that PEG nano-shielding makes 
transplanted grafts unrecognizable to the recipient immune system, and thus reduces immune 
infiltration into the grafts [77-79]. Studies on rat-to-mouse xenotransplantation also demonstrated 
superior outcomes of this system on islets using different immunosuppressive drug combinations [80-
82]. 
 
1.3.3.1    Advantages and disadvantages of nano-shielding  
Although a wide variety of immunosuppressive drug protocols have been developed for 
transplant patients, the chronic administration leads to significant side effects involving impaired ß-cell 
function, higher chance of opportunistic infections etc. [26, 83]. To get around this issue, 
immunoisolation methods, such as, microencapsulation, and nano-shielding commonly known as 
surface modification are useful alternatives. Microencapsulation involves enclosing islets with a 
semipermeable membrane that masks islet surface antigens while allowing oxygen and nutrient transfer 
[84-86]. However, the thickness of most of the microencapsulation ranges between 5-50 µm in diameter 
that results in diffusion barrier and causes islet necrosis [87-90]. In this respect, nano-shielding is a 
powerful tool that provides islets with oxygen and nutrients without creating diffusion barrier, therefore, 
preserves islet viability and functionality [91, 92]. Moreover, nano-shielding of islets reduces the 
volume of islets per unit, thus, making them feasible to transplant via the portal vein [26].  Nano-
shielding with covalently bonded polymers in a Layer-by-Layer (LbL) fashioin is an attractive 
technique to provide optimum coverage of polymers on islet surface. Recent LbL technique involves 
employing electrostatically-bound systems where positive and negatively charged polymers are used to 
form layers. However, this technique causes cytotoxicity to the cells by polycationic compounds [93]. 
In contrast, covalently bonded LbL technique provides cytocompatible protection upon incorporating 
polymers carrying no charge [94, 95].  
Apart from having tons of benefits, covalent nano-shielding is reported to be unstable in long 
term due to fast degradation of the conjugation bonds [96, 97]. Careful selection of anchoring moieties 
is another important issue, since the material itself might penetrate through the cell membrane causing 
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loss of cellular integrity. Time for the nano-shielding procedure, pH of the medium, and concentration 
of the polymers are some critical factors that need careful optimization to preserve cellular viability and 
functionality. 
 
1.3.4    Xenotransplantation  
Islet transplantation face a great challenge on tackling the balance between an increasing 
transplant waiting list and the supply of donor pancreas. Records form Organ Procurement and 
Transplant Network, from 2003 to 2015, reveals 145% increase of recipients in the waiting list for all 
organs compared to only 113% increase in donor availability [98]. Likewise, the availability of pancreas 
is inadequate to meet the need for islet allotransplantation [99-101]. 
Transplantation of islets from nonhuman species was thus warranted to get around the donor 
shortage problem. Among various species that have been studied as a candidate for xenotransplantation, 
pig has been considered as the potential alternative due to its structural and physiological similarities 
with humans [26]. Moreover, there is only one amino acid difference in the insulin structure between 
pig and human and has been used in clinical practice for quite a long time [102, 103].  The similarities 
in insulin pattern and the availability made porcine islets a promising replacement for human islets 
[104]. The major advantages of using porcine islets are- similar physiology, unlimited availability, easy 
to breed, possibility to breed in pathogen free environment, lower risk of zoonosis, possibility of genetic 
modification to lower antigenicity etc. [98].  
Immunological challenges in xenotransplantation are much more complex than in 
allotransplantation [105]. One of the major reasons related with porcine islets is that they express 
different surface proteins that act as potential antigens in human recipients and cause hyperacute 
rejection (HAR) following transplantation [106]. 
Porcine islets express Gal and non-gal proteins as surface proteins which causes hyperacute 
rejection due to the presence of pre-existing antibodies in humans [107-109]. The Gal epitope is 
nonexistence in humans and old-world monkeys, however, it is expressed in pig, non-human primates, 
new-world monkeys and many bacteria [105, 109-111].  Constant exposure to the microorganisms lets 
human body develop antibodies against the Gal epitope, which constitutes about 1% of the total 
circulating antibodies [105]. Transplanted porcine islets are rapidly being recognized and destroyed by 
the complement system causing in islet loss [105, 106, 112]. 
 
1.4    Research rationale 
Currently, insulin therapy is the most widely used treatment option for treating T1DM patient. 
There have been many improvements in the formulations and delivery systems for insulin. However, 
poor patient compliance, unavoidable complications of certain devices, and specially the risk of 
hypoglycemia have accelerated the pursuit for a ‘cure’ of diabetes. Pancreas transplantation comes 
along with the ‘cure’, but also with unnecessary drawbacks, such as, major invasive surgery and 
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administration with lifelong immunosuppressive drugs [22]. Thus, pancreas transplantation is indicated 
for the patients with late stage diabetic conditions undergoing kidney transplantation, which is called 
as pancreas after kidney transplantation [23, 113, 114]. Therefore, this option is not available to a vast 
majority of diabetic patients. Whereas, islet transplantation has the potential to be the cure having 
similar survival rate with pancreas transplantation while being much less invasive and immunogenic 
[23, 113, 114]. In last two-decades there have been a revitalization in the field of islet transplantation 
since the success of Edmonton protocol. In 2000, James Shapiro et al. reported and extraordinary 
successful case of islet transplantation where patient survival rate was 100% after 1 year of 
transplantation [27]. A follow-up study on their phase ii trials demonstrated 82% survival rate that 
matches to that of the pancreas transplantation [23, 28]. However, the successful application of this 
technology is still limited by the fact that a patient needs islets from two to four donor pancreases and 
have to stay under life-long immunosuppression. 
To tackle the problem related with donor shortage, xenotransplantation of porcine islets is an 
alternative approach. However, dealing with porcine islet is troublesome by the fact that the intra-islet 
cell connection in porcine islet is weak, thus, they dissociate easily after isolation. Additionally, 
presence of Gal and non-Gal epitope on the surface make it harder to survive for a long time in recipient 
body. Here, the first study suggests a novel method of stabilizing fragile porcine islets to prevent the 
dissociation and reducing immune cell invasion in a combination therapy of ‘surface camouflaging’ 
and immunosuppressive drugs (FK506, Rapamycin, MR-1, anti-CD19 mAb, and Clodrosome®) to 
effectively alleviate overall immune reactions against xenotransplanted porcine islets. The surface 
camouflage of pancreatic islets using biocompatible materials improved stabilization of pancreatic islet 
and prevented the infiltration of immune cells. Firstly, the surface of porcine islets was camouflaged by 
SH-6-arm-PEG-lipid and gelatin-catechol (artificial extracellular matrix) in order to stabilize the fragile 
isolated islets. Secondly, three different PEG layers (6-arm-PEG-SH, 6-arm-PEG-catechol, and linear 
PEG-SH) were chemically conjugated onto the surface of the stabilized porcine islets. Both artificial 
extracellular matrix (A. ECM) and PEG effectively covered the surface without affecting the viability 
and functionality of the islets. The multi-layer modification significantly reduced the attachment of 
human serum albumin, fibronectin, and immunoglobulin G in comparison to the control collagen 
surface. The combination effect of multi-layer nano-shielding and cocktailed immunosuppressive drugs 
on the survival time of the transplanted islets was assessed in a xenogeneic pig-to-mouse model. The 
median survival time (MST) of ‘A. ECM + PEG’ group was 4-fold increased compared to that of control 
group. In addition, the MST of ‘A. ECM + PEG + drug’ group was 2.16-fold increased, compared to 
the ‘control + drug’ group (Chapter 2).  
Non-human primates (NHP) are the closest to the humans in terms of phylogenetic and 
immunological relationship. Therefore, for the next study (Chapter 3), the layer-by-layer nano-shielding 
system with the previously used three-layer PEG system was validated on NHP islets in aspects of 
reducing immunogenicity. AFM imaging confirmed the thickness of coating as less than one nano-
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meter in diameter, thereby, the term ‘nano-shielding’ was coined for the layer-by-layer surface 
modification system. The PEG nano-shielding showed a uniform coverage on NHP islets without the 
loss of viability or function of the cell. An immunosuppressive drug protocol was also combined to 
improve the survival rate of the transplanted islets in vivo. A xenorecipient (C57BL/6 mice) of PEG 
islet transplanted along with an immunosuppressive drug protocol showed 100% survival rate for 150 
days after transplantation. On the other hand, naked islet recipients showed poor survival time of 5.5 ± 
1.4 days without drugs and 77.5 ± 42 days with the drug protocol. Immunohistochemistry of the 
transplanted grafts and serum cytokine concentration demonstrated less immunogenicity in the PEG 
islet recipients compared with the naked islet ones. 
The microenvironment of pancreatic islets gets disrupted during enzyme digestion and causes 
islets to remain in vulnerable state, leading to poor outcome in the initial days of transplantation. To 
avoid immune invasion while allowing the reconstruction of microenvironment of the transplanted site, 
immunoisolation polymers were proposed, which can nano-shield islets quickly without cytotoxicity. 
In the next study (Chapter 4), nano-shielding composition was modified from previously used three-
layer of PEG to two-layer of PEG and one-layer of heparin (SH-6-arm-PEG-Lipid, 6-arm-PEG-catechol, 
and Heparin-SH) to combat against both cellular and humoral immunity. Heparin is a potent thrombin 
inhibitor and reduces platelet and complement activation, and thus expected to reduce propagation of 
IBMIR [115]. The PEG-Heparin (PEG-Hep) nano-shielded NHP islets were transplanted into the 
kidney subcapsular space of diabetic C57BL/6 mice. An immunosuppressive drug protocol was applied 
to increase the survival time until the animals were sacrificed. The recipients of NHP islets exhibited 
high non-fasting blood glucose level (BGL) for 2-3 weeks, which was normalized afterwards. 
Immunohistochemical (IHC) analysis revealed an immature vascular basement membrane and cell 
surface integrins directly associated with poor initial insulin production. The transplanted grafts 
regained their own microenvironment within a month without any outside stimuli. No lymphocyte 
infiltration was observed in the grafts at any time. Innate and adaptive immune responses were 
prominently diminished by the PEG-Hep islets as checked in vitro.  
Intraportal pancreatic islet transplantation incurs huge cell losses during its early stages due to 
IBMIRs, which may also drive regulation of the adaptive immune system. Therefore, a method that 
evades IBMIR will improve clinical islet transplantation. In chapter 5, the immunoprotective effects of 
both PEG and PEG-Hep nano-shielding were compared and contrasted in an allotransplanted NHP 
model. Islets ranging from 10,000 to 20,000 IEQ/kg body weight were transplanted into 19 cynomolgus 
monkeys (n = 4, control; n = 5, PEG; and n = 10, PEG-Hep). The mean C-peptide positive graft survival 
times were 68.5, 64, and 108 days for the control, PEG, and PEG-Hep (P<0.05 vs control and PEG) 
groups, respectively. PEG-Hep also reduced the factors responsible for IBMIR in vitro. Based on the 
data presented here, it is claimed that PEG-Hep nano-shielding in conjunction with clinically 
established immunosuppressive drug regimens would prolong the survival rate in humans compared to 
the existing clinical outcome with naked islets. 
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Although nano-shielding with PEG or PEG-Hep is effective on reducing the activation of 
immune cells, it has little effect from the damaging effects of cytokines and free-radicals released by 
the already activated immune cells [75, 76]. Therefore, finding a nano-shielding material that can act 
as a scavenger of free-radicals was warranted. Tannic acid (TA) is a natural polyphenol that inhibits 
oxidation provoked by free-radicals [116, 117]. In the final chapter (Chapter 6) a LbL nano-shielding 
system composed of TA, PEG, and heparin was designed that is assumed to be capable on lessening 
immune activation, IBMIR, and oxidative stress generated by free-radicals. Preliminary data on this 
system show improved survival time with reduced immune infiltration in a rat-to-mouse 
xenotransplantation study. Currently further studies are being conducted to confirm the complete 
properties of this system.  
In the thesis, the goal was to develop a nano-shielding system that is compatible with human 
islets and capable to go to clinical trials. Therefore, the potentials of nano-shielding techniques were 
studied with different compositions in porcine and NHP islets (Table 1.1). Pig is an alternative source 
of islets for human xenotranplantation and has the potential to resolve donor shortage issue. However, 
porcine islets are inherently fragile and tend to disintegrate into single cell after isolation. Nano-
shielding with A. ECM showed improved stability upon a 7-day culture period over naked islets. PEG 
nano-shielding onto the A. ECM significantly reduced blood protein adhesion and improved graft 
survival time in pig-to-mouse model. The similar PEG nano-shielding system also validated its 
immunoprotective effects in NHP-to-mouse model. When xenotransplanted, PEG nano-shielding 
demonstrated reduced immune cell infiltration into the transplanted grafts resulting in excellent blood 
glucose level for 150 days after transplantation. The survival rate was 100% in PEG nano-shielded islet 
transplanted recipients compared to 50% of the control group. In pursuit of improving the system the 
third layer was modified with heparin, for the next study, to attain a two-fold effect against cellular 
activation and IBMIR. When allotransplanted in the liver of NHPs, PEG nano-shielded islets failed to 
achieve outcome any better than the control islets, however, PEG-Hep resulted in a significantly higher 
survival rate with less activation of immune cells in peripheral blood. Furthermore, PEG-Hep nano-
shielding was able to demonstrate significant reduction of all the factors related to IBMIR, such as, 
blood coagulation, and activation of platelet, complement, and immune cells in vitro. Previously, our 
group already performed and validated the conditions for PEG or heparin nano-shielding in different 
rodent models. In this thesis, it has been proved that nano-shielding is effective in pig and NHP islets 
as well. Among different nano-shielding compositions, the PEG-Hep showed outstanding outcome in 
NHP portal vein transplantation study. NHPs are the closest to the humans in phylogenetic relationship. 
Therefore, it can be argued, if the PEG-Hep nano-shielding system is applied in clinical trials, the 
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2. Gelatin-catechol 0.5% 
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1. Reduces immune cell 
activation and infiltration 
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1. TA 0.04% 
2. 6-arm-PEG-catechol 1% 





1. Improves survival time. 
2. Reduces splenocyte 
migration 
(TA-PEG)2Hep Fails to increase survival time 
 
Note. A. ECM = artificial extracellular matrix, PEG = Polyethylene glycol, TA = Tannic acid. 
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Combination strategy of multi-layered nano-shielding using artificial 
extracellular matrix and hyperbranched polyethylene glycol for 
simultaneous reduction of islet dissociation and improvement in 
immunoprotection 
 
2.1    Introduction 
Although many advanced insulin therapies have been developed in diabetes care, T1DM cannot 
be cured to alleviate episodes of hypoglycemia. Pancreatic islet transplantation has been suggested as 
an alternative and promising method for the treatment of T1DM [1, 2]. However, the clinical application 
of islet transplantation has two major hurdles, shortage of islet donors and immune rejection of the 
transplanted graft [3-5]. To improve the pancreatic islet donor shortage, several alternatives have been 
suggested; for example, genetically engineered islet transplantation [6], peptide drug injection for 
functional enhancement of beta cell [7] and stem cell delivery [8].  
Xenotransplantation of porcine pancreatic islets has been proposed as another solution as they 
can be supplied without limitation and there is a similarity between human and porcine insulin [9].  
Porcine islets from healthy, young, living, and designated pathogen-free donor pigs would be of 
predictably high quality [10]. In contrast, human islets are mostly obtained from co-morbid, brain dead, 
aged and cold ischemia conditions. In addition, porcine islets can be modified by genetic engineering 
before isolation, which could help to reduce immune reaction after islet transplantation [11]. Thus, 
porcine islets would be a source for solving the problem of islet supply for the treatment of T1DM in 
the future. However, the possibility of pig to human xenotransplantation is greatly decreased due to 
difficulties in the isolation process because of their brittleness and diverse range of yield [12]. Several 
parameters affect the yield of porcine islet isolation including blood exsanguination, warm ischemic 
time, preservation solution, digestion methods, enzymes and also histomorphometry before and after 
isolation [13]. During the isolation process, islet clusters are being separated from exocrine cells and 
basement membrane of pancreas [14, 15]. Collagenase digestions induce the destruction of islets 
structure, generating heterogeneous islet morphology, diverse sizes, and many cell fragments. In 
addition, porcine islets are extremely fragile and their morphologies are difficult to retain after isolation 
[16, 17]; the dissociated islet single cells lose their biological function due to the alleviation of cell-to-
cell interaction [18].  
Apart from the donor shortage of human islets and the stability of isolated porcine islets, 
immune rejection still remains as a major problem in xenotransplantation. Living Cell Technology 
(LCT) has conducted a clinical trial using alginate-encapsulated porcine islets that were transplanted 
into the peritoneal cavity of a 41-year old Caucasian male with a history of 18 years of T1DM. 
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Laparoscopic results after 9.5 years of transplantation showed opacified capsules containing cell 
clusters in the transplanted area that stained insulin and glucagon upon immunohistological staining 
[19, 20]. In addition, many researchers have reported that graft rejection could be markedly delayed in 
non-human primate models transplanted with porcine islets by inducing antigen specific T cell tolerance 
of T cell specific immunosuppression [21, 22]. 
Microencapsulation of islets using alginate system has been used predominantly as an 
immunoisolation technique [23]. The first alginate encapsulation method comprised of a micro-capsule 
containing islets of 800-1000 µm diameter. For instance, an islet with 150 µm diameter is encapsulated 
in a 1000 µm diameter capsule, which increased the volume of islet 296 times [24]. This excess sized 
encapsulated islet had a poor outcome in both dogs and humans in clinical trials [25-27]. On the other 
hand, islet surface camouflage has been proposed as a different approach to prevent immunoreactions 
against transplanted islets [23]. A Diffusion barrier of more than 200 µm in length can lower islet 
viability since it interferes with diffusive transport of nutrients and metabolites. The surface 
modification can eliminate the problem regarding this diffusion barrier by reducing the volume of tissue 
per Islet Equivalent (IEQ). Moreover, this reduced size also makes it easy for islets to be transplanted 
into human recipients via portal vain [23]. Therefore, this molecular shielding technique is referred to 
as ‘nano-shielding’ of islets. PEG and heparin derivatives have been predominantly used for the nano-
shielding of islets [18, 28-30]. The first trial of islet nano-shielding using PEG was reported by Panza 
et al., where they demonstrated that rat islet viability was not compromised upon PEG nano-shielding 
and glucose responsiveness can be maintained in vitro [31].  Later on, the PEG nano-shielding method 
was proven to be cytoprotective for porcine islet xenotransplantation in diabetic SCID mice [32]. Islets 
decorated with PEG linked nanoparticles loaded with anti-inflammatory agents showed superior 
survival advantages over naked islets [33]. Recently, PEG has been used on islets to serve various 
purposes along with immunoprotection. They are used, for example, to deliver VEGF to enhance 
vascularization of the transplanted islet, to exert antifibrotic effect by containing rapamycin, to create 
local immunosuppression linking regulatory T cell on islet surface, to use as a marker of islet viability 
and functionality by conjugating with fluorescence dye, and so on [34-37]. However, very few works 
have been done on porcine islet nano-shielding focusing only on reducing immunogenicity [32, 38, 39]. 
The PEG nano-shielding method was proven to be cytoprotective in vitro in human serum and in vivo 
in diabetic SCID mice to porcine islets [38]. Compared to the unshielded ones, the viability of porcine 
islets was improved by Nano-shielding against xenoreactive natural antibodies (XNA) and complement 
mediated cytotoxicity. However, research on stabilizing porcine islets using PEG or any other 
biomaterials is completely void. In previous studies, the effect of PEG nano-shielding on the survival 
rate of transplanted islets had been reported using rats and mice model. In cases of rat and mouse, beta 
cells of islet secret collagen in one-day culture, thereby, forming a collagen matrix at the islet surface. 
That is, the isolated islets are completely covered by collagen matrix, and become very solid without 
dissociation into single cells. On the other hand, beta cells of porcine islets do not secret collagen, and 
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as a result, isolated porcine islets cannot be covered by collagen matrix and are easily dissociated. It is 
thus important to stabilize isolated porcine islets when used in transplantation.  
In this study, an artificial extracellular matrix (A. ECM) was prepared that can maintain the 
stability of porcine islets using nano-shielding technology. Apart from maintaining stability, 
immunogenicity was tried to be reduced using an additional multilayered PEG nano-shielding system. 
Biocompatible materials (SH-6-arm-PEG-Lipid and gelatin-catechol) were used to stabilize the porcine 
islet structure. Lipid moiety of SH-6-arm-PEG-Lipid integrates with the cell membrane of porcine islet 
via hydrophobic interactions. The catechol group on gelatin-catechol conjugates with the thiol group of 
SH-6-arm-PEG-Lipid forms a very thin bi-layer on the surface of porcine islets, which helps to prevent 
islet dissociation. These two layers are together referred to as an artificial extracellular matrix (artificial 
ECM). Gelatin is a protein obtained by partial denaturation of collagen, which is a major component of 
extracellular matrix of skin, bone, ligament, connective tissues, bone and cartilage [40]. When 
compared to collagen, gelatin has less antigenicity [41]. Gelatin is hydrophilic in nature and maintains 
cell viability and functionality in vitro [42]. Gelatin was chosen because it contains an Arg-Gly-Asp 
(R-G-D) sequence that binds with integrins such as, α5β1 and α5β3 of porcine islets and stabilizes their 
structure [43].  
On this robust surface of artificial ECM coated porcine islets, additional three layers of PEG 
derivatives were conjugated for improving immunoprotection. PEG has been proposed to reduce 
surface antigenicity by “camouflage” effect [31, 44]. PEG has low interfacial free energy with water, 
unique property in aqueous solutions, high surface mobility, and steric stabilization effects. These 
properties enable PEG to reduce plasma protein adsorption, platelet adhesion, complement activation 
and xenoreactive natural antibody (XNA) activation on nano-shielded surface [32, 45]. The PEG layer 
formation was inspired by Michael-type addition reaction. In slightly alkaline condition (~pH 8), the 
catechol moieties become oxidized to form quinones, which is highly reactive with the functional group 
thiol via Michael-type addition [46, 47]. Other unreacted quinones on the PEG and gelatin also bind 
with each other via radical coupling reactions (Figure. 2.2 F, G). Furthermore, the recipients were 
injected with immunosuppressive drugs to evaluate the overall synergistic effect for treatment of T1DM 
in a xenograft model.  
In this study, the aim was to develop a nano-shielding system that reduces both porcine islet 
disintegration and immunogenicity. Since porcine islet lose its supportive collagen layer from surface 
during enzyme digestion procedure, they tend to disintegrate easily after isolation. It was hypothesized 
that formation of an A. ECM could act as an alternative to the naturally formed collagen, therefore, islet 
disintegration could be prevented. On the other hand, the hypothesis behind using PEG was for its well-
known capability as surface antigen masking agent reported in many previous studies [31, 32, 44, 45]. 
Collectively, when both A. ECM and PEG nano-shielding technique were combined on islet surface, 
we anticipated to attain a greater outcome compared with naked islets. C57BL/6 mouse model was used 
to confirm the hypothesis because they have a fully developed immune system which makes them an 
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attractive animal model for immune modulation studies.  
 
2.2    Materials and methods 
2.2.1    Animals 
Sprague–Dawley (SD) rats (male, 8 weeks old) and inbred C57BL/6 mice (male, 7–8 weeks 
old) were purchased from Orient Bio Inc. (Seongnam, Korea) and housed under pathogen-free 
conditions. Donor pancreas was obtained from female pigs (Micropig; Medi Kinetics Co., Ltd., 
Gyeonggi-do, Korea) aging more than three years with several breeding, weighing 60-80 kg. All 
experimental and surgical procedures were performed according to the guidelines of Institute of 
Laboratory Animal Resources, Seoul National University (IACUC no. SNU-070822-5). 
 
2.2.2    Diabetic modeling 
C57BL/6 mice were chemically induced to feature T1DM, with a single intraperitoneal 
administration of 180 mg/kg streptozotocin (STZ, Sigma, St. Louis, MO) that was freshly prepared by 
dissolving in citrate buffer (pH 4.5) three days before transplantation. Mice exhibiting blood glucose 
levels higher than 300 mg/dl for two consecutive days were chosen as diabetic recipients for 
transplantation.  
 
2.2.3    Synthesis of SH-6-arm-PEG-Lipid 
1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine (500 mg; DOPE, Avanti Polar Lipids, Inc., 
ALABASTER, AL) was dissolved in chloroform (Sigma, St. Louis, MO). Triethylamine (Sigma) was 
added drop-wise to the solution. 3-maleimidobenzoic acid N-hydroxysuccinimide ester (MBS, Sigma) 
was dissolved in chloroform and added to the mixture. The reactants were stirred overnight in an ice 
bath under nitrogen atmosphere, followed by freeze-drying. The obtained product is referred as lipid- 
maleimide (Lipid-Mal). One gram of 6-arm-PEG-SH (SunBio, Seoul, Korea) and 0.168 g of Lipid-Mal 
were dissolved in chloroform and reacted overnight. The reactants were collected and dialyzed (MWCO 
2 kDa, Spectra Por. SPECTRUM® LABORATORIES Inc. CA), followed by freeze-drying to yield SH-
6-arm-PEG-Lipid. Fluorescein isothiocyanate (FITC) linked SH-6-arm-PEG-Lipid was obtained by 
reacting fluorescein-5-maleimide (17.0 mg, Sigma) with SH-6-arm-PEG-Lipid (250 mg) in 
dimethylformamide (DMF, Sigma) overnight, followed by dialysis and freeze-drying.  
 
2.2.4    Synthesis of gelatin-catechol   
Gelatin (1 g, Sigma) was dissolved in distilled water (50 ml, pH 5.0). EDC (110 mg, Sigma), 
NHS (70 mg, Sigma) and 3, 4-dihydroxycinnamic acid (DHCA; 100 mg, Sigma) was dissolved in water 
separately and then reacted in the gelatin solution for overnight at 50°C. The reacted solution was 
dialyzed (MWCO: 1 kDa, Spectra Por) for three days to remove all the unreacted DHCA. After 
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purification, the product solution was freeze-dried and gelatin-catechol was obtained as white powder 
(yield 89.3%). FITC linked gelatin-catechol was prepared by reacting NHS-Fluorescein (Pierce 
Biotechnology, Rockford, IL) with already prepared gelatin-catechol, followed by dialysis and freeze 
drying.  
 
2.2.5    Synthesis of SH-6-arm-PEG-FITC, SH-6-arm-PEG-NHS and 6-arm-PEG-
catechol 
6-arm-PEG-SH (MW 15 kDa) was purchased from SunBio. FITC was labeled by reacting 6 
mg of fluorescein-5-maleimide (Pierce Biotechnology) with 100 mg of 6-arm-PEG-SH in DMF 
overnight. Residual FITC was removed by dialysis (MWCO 2 kDa) for three days, which was followed 
by freeze-drying.     
6-arm-PEG-SH (1 g, SunBio) was dissolved in DMF and poured into the reaction flask. 3-
maleimidobenzoic acid N-hydroxysuccinimide ester (MBS; 50.28 mg, Sigma) was also dissolved in 
DMF and added to the PEG solution. The reaction was continued overnight under nitrogen atmosphere 
in an ice bath. The unreacted MBS was precipitated with double distilled water. The resultant solution 
was filtered out and dried in a freeze drier to get SH-6-arm-PEG-NHS. FITC labeled SH-6-arm-PEG-
NHS was obtained by conjugating MBS to SH-6-arm-PEG-FITC instead of SH-6-arm-PEG.  
6-arm-PEG-catechol was synthesized by dissolving 3, 4-dihydroxyhydrocinnamic acid (DHCA, 
145.74 mg, Sigma) in DMF (1 ml). N, N'-dicyclohexylcarbodiimide (DCC, 330.73 mg, Sigma), N-
hydroxysuccinimide (NHS, 184.78 mg, Sigma) and 1 g of 6-arm-PEG-NH2 were added to the flask 
sequentially. After precipitation in cold diethyl ether (Sigma) and freeze drying 6-arm-PEG-catechol 
was obtained. FITC was labeled with 6-arm-PEG-catechol by reacting NHS-fluorescein (19 mg) with 
6-arm-PEG-catechol (200 mg) in DMF Followed by dialysis and freeze-drying to get FITC-6-arm-
PEG-catechol. Both of the reactions were conducted on ice overnight. 
  
2.2.6    Isolation of porcine islets  
Pigs were anesthetized and subjected to laparotomy with complete exsanguination. The 
pancreas was carefully cut apart from the surrounding tissue. It was then trimmed, placed in chilled (4 
ºC) histidine-tryptophan-ketoglutarate (HTK, Dr Franz Köhler Chemie GmbH, Germany) solution. 
Meanwhile, 100 mg of digestion enzyme (Liberase DL, Roche, Indianapolis, IN) was constituted to a 
volume of 250 ml with HTK solution. The constituted enzyme was maintained in an ice bath until it 
was perfused through the cannula inserted in the common duct of the pancreas. The swelled pancreas 
was cut into 7-9 pieces and placed in a Ricordi chamber (1 liter, BioRep Technologies Inc., Miami, FL) 
preloaded with 500 µl of Hank’s balanced salt solution (HBSS, Sigma). The chamber contains 4 marble 
balls to provide a uniform shaking force. It was then shaken manually throughout the digestion 
procedure. A water bath maintained the temperature in the chamber constantly at 37 ºC. A pump 
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(Masterflex L/S, East Bunker Court Vernon Hills, IL) drove the cell suspension from the Ricordi 
chamber to the collecting flask through an interconnected network of tubes (Masterflex, size 17). Under 
controlled conditions of temperature and flow rate, pancreatic tissue was digested gradually to liberate 
islets with the aid of mechanical agitation. Digestion end point was determined by periodic sampling 
of the tissue digest from the collecting flask. Dithizone (Sigma, St. Louis, MO) staining allowed 
visualization of islet purity and percentage of released islets under the microscope. Enzyme digestion 
was stopped when a substantial quantity of islets was released. Stoppage of enzyme digestion consisted 
of a dilution phase with 3 L of cold M199 (Sigma), supplemented with 10% porcine serum (Life 
technologies, Grand Island, NY) along with reduction of temperature using ice. Tissue digest was 
collected through a 500 µm mesh to remove any remaining undigested tissue part and then washed 
several times by centrifugation (3 min, 1200 rpm at 4°C) with cold M199 with porcine serum. Tissue 
pellet was finally consolidated in a 250-ml tube and re-washed with HTK solution to proceed for 
purification.    
Islet purification technique was based on density gradient centrifugation performed using 
COBE 2991 (Gambro BCT, Lakewood, CO). By mixing Optiprep (Axis-Shield PoC AS, Oslo, Norway) 
with HTK solution, three different densities of gradient solution were prepared as 1.090, 1.085 and 
1.075. Cells were mixed with 1.085 density optiprep and loaded onto COBE from the lowest to highest 
density, and centrifuged at 2400 rpm for 5 min. The purified islets were collected sequentially in fifteen 
50 ml conical tubes preloaded with 25 ml of M199 with porcine serum. Samples were taken from all 
the tubes and mixed with dithizone solution (Sigma) to observe under the microscope, in order to 
determine the purest islet-containing fractions. The fractions with highest purity of islets were gathered, 
washed and cultured in M199 with porcine serum for further experiments.  
 
2.2.7    Nano-shielding of pancreatic islets using biomaterials 
Islets surface was modified in two stages. In the first stage, the first two layers SH-6-arm-PEG-
Lipid and gelatin-catechol was formed to aid stabilization of islets against dissociation. Since porcine 
islets lack a collagen layer on the cell surface, SH-6 arm-PEG-Lipid was anchored on the lipid bilayer 
of the cell membrane through hydrophobic interactions. The outer layer was formed by gelatin-catechol 
through catechol-thiol interaction with the first layer. Gelatin is expected to maintain the integrated 
porcine islets by forming a thin coating on the cell surface. Thus, these two layers are referred to as an 
artificial extracellular matrix (artificial ECM). The free catechol groups exposed on gelatin were 
blocked by culturing islets with M199 with 10% porcine serum albumin for 30 min.  In the second stage, 
three layers of PEGs, 6-arm-PEG-SH, 6-arm-PEG-catechol and linear PEG-SH were applied onto the 
artificial ECM coated islets for a surface camouflage effect (artificial ECM + PEG). The goal for PEG 
nano-shielding on islet surface was to reduce immunogenicity to the recipient body.  
All biomaterials were used at 0.5% wt/vol. concentration, except for the 6-arm-PEG-catechol 
which showed well coverage at 1 w/v% without alteration in islet viability. Islets were washed and re-
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suspended with HBSS at pH 8.0. The biomaterials were mixed in 2 ml of HBSS at pH 8.0 and added to 
the cell suspension to make the desired final concentration 0.5% or 1%. The suspension was then 
incubated at 37°C in the humidified atmosphere of 5% CO2 for 1 h. After 1 h the cells were retrieved 
and washed well to remove leftover previous biomaterials. Similarly, the next layer was incorporated 
to the islets and incubated for 1 h again. After finishing all five layers, the islets were washed twice and 
prepared for in vivo or in vitro experiments. Control islets were cultured for the same period of time 
without modifying the surface. Coverage of the biomaterials on the islet surface was confirmed by using 
fluorescein labeled biomaterials that have the same reactive functional groups. Using confocal laser 
scanning microscopy (CLSM, Leica DM IRB/E, Wetzler, Germany), coated islets were inspected for 
fluorescence. The yield after nano-shielding with artificial ECM and artificial ECM + PEG was 82 ± 
3.5% and 69 ± 2.9%, respectively.            
 
2.2.8    Monitoring islet stability 
To monitor morphological stability, islets were divided into two groups, unmodified islets 
(control) and artificial ECM coated islets. One hundred IEQ islets were placed in wells of a multi-well 
plate and cultured in M199 supplemented with 10% porcine serum for seven days. Morphological 
stability and viability were measured at different time points, on days of surface coating (day 0), day 1, 
day 3 and day 7, by examining under microscope. Dithizone staining helped visualizing islet 
morphology and integrity. The quantitative size distribution of islets was measured by a COULTER 
COUNTER Analyzer (Beckman Coulter, Inc., CA).            
  
2.2.9    Cell viability assay 
Quantitative analysis of islet viability was done by Live/Dead viability/cytotoxicity kit assay 
(Molecular Probes, Eugene, OR). In this assay, the live cells can be stained with green fluorescence by 
the conversion of nonfluorescent cell-permeate calcein AM to the intensely fluorescent calcein due to 
the activity of the intracellular esterase. Ethidium homodimer-1 (EthD-1) enters the cell through 
damaged membranes and binds to the nucleic acids to produce a 40-fold enhanced red fluorescence in 
dead cells. To check cell viability, artificial ECM coated islets were brought out of the incubator at days 
0, 1, 3 and 7 along with the control unmodified islets. Islets were washed twice with HBSS and 
suspended in 1 mL HBSS containing 2 µl of 50 µM calcein AM and 2 µl of 2 mM EthD-1 and incubated 
at room temperature for 15 min. The islets stained with calcein AM and EthD-1 were observed under 
the light microscope (Eclipse TE2000-S, Nikon, Japan). 
Quantitative viability of islets was verified by Cell Counting Kit-8 (CCK-8, Dojindo Molecular 
Technologies Inc, MD) assay. 100 IEQ islets were equally distributed in each well of a 96-well plate, 
suspended in 100 µl HBSS. 10 µL of WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H-tetrazolium, monosodium salt] was then added to each well and they were kept in 
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the incubator for 2.5 h. The absorbance was measured at 450 nm using a microplate reader. The CCK-
8 data was normalized by DNA contents of each well. The DNA content in tested islets was measured 
by Quanti-iTTM Picogreen® dsDNA kit (Invitrogen, OR). 
 
2.2.10    Glucose-stimulated insulin secretion (GSIS) assay  
To evaluate whether if the islets were functioning after coating with the artificial ECM, a 
glucose-stimulated insulin secretion (GSIS) assay was performed. Both coated and uncoated islets were 
plated in Millicell inserts (100 IEQ islets/insert; Millipore corp., Billerica, MA). Islets were washed and 
incubated in Krebs-Ringer bicarbonate buffer (KRBB, pH 7.4) containing 2.8 mM glucose under the 
humidified atmosphere containing 5% CO2 gas. After 1 h, the medium was exchanged with the same 
buffer to measure the glucose stimulated insulin secretion at low glucose solution (2.8 mM) and 
incubated for 2 h. The medium was exchanged again with the high glucose solution (28 mM) to further 
incubation for 2 h. The concentration of secreted insulin was measured in response to low and high 
glucose solutions, by using a porcine insulin ELISA kit (Marcodia, Upsala, Sweden). The stimulation 
index was calculated by dividing the amount of secreted insulin at high glucose solution by that of low 
glucose solution.   
 
2.2.11    In vitro protein adsorption study  
Collagen glasses were coated similarly and incubated 1 h with PBS (Life technologies, Grand 
Island, NY). Dissolved proteins, human serum albumin (HSA, Sigma), human plasma fibronectin 
(Sigma), and human serum immunoglobulin G (IgG, Sigma) at 100 µg/ml concentrations were added 
onto the dishes. Protein adsorption was allowed to take place for 2 h at 37 ºC. Weakly adsorbed proteins 
were washed out by rinsing the dishes with PBS. The adsorbed proteins were extracted by sonication 
in 5 ml of 1 wt% of sodium dodecyl sulfate (SDS, Amresco Inc., Cochran road solon, OH) solution for 
1 h. In a 96-well plate, 50 µL of each eluted protein was sampled, and a standard curve was prepared 
using bovine serum albumin from a BCA protein assay kit (Pierce Biotechnology, Rockford, IL). 
Absorbance was quantified at 526 nm using a microplate reader.      
  
2.2.12    Nano-shielded islet xenotransplantation 
To evaluate the effect of islet nano-shielding, four groups of islets transplanted (kidney 
subcapsular space) mice were prepared with the following conditions: 1) 8000 IEQ unmodified islets 
(control, n=5) 2) 8000 IEQ unmodified islets with immunosuppressive drugs (control + drug, n=4) 3) 
8000 IEQ PEG nano-shielded islets (artificial ECM + PEG, n=5) 4) 8000 IEQ PEG nano-shielded islets 
with immunosuppressive drugs (artificial ECM + PEG + drug, n=5). To anaesthetize prior to 
transplantation, a mixture of ketamine 80 mg/ml (Yuhan Co., Ltd, Seoul, Korea) and xylazine 16 mg/kg 
(Bayer Healthcare LLC, Seoul, Korea) was injected. The left kidney was exposed by lumber incision 
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and 8000 IEQ islets were delivered into the kidney capsule. Non-fasting blood glucose was monitored 
every day by withdrawing blood from the tail veins of the mice using a portable glucometer (Super 
glucocard II, Arkray, Kyoto, Japan). Transplantation was considered successful if the blood glucose 
level was lower than 200 mg/dl for two consecutive days. If the transplanted animals showed blood 
glucose levels higher than 300 mg/dl for three consecutive days, the transplanted grafts were considered 
as rejected. Body weight was monitored daily for all transplanted recipients.                  
 
2.2.13    Immunosuppressive drug treatment to the recipients 
The effect of a combination of immunosuppressive drugs was evaluated that consists of FK506 
(Prograf®, Astellas Pharmaceuticals, Chicago, IL), Rapamycin (Sigma), MR-1 (anti-CD 154 mAb, 
Bioxcell, West Lebanon, NH), anti-CD19 mAb (Bioxcell, West Lebanon, NH) and Clodrosome® 
(Encapsula NanoScience, Nashvile, TN). Both FK506 and Rapamycin were administered daily at 0.20 
mg/kg. Clodrosome® and MR-1 were administered from the day prior to transplantation at 1.73 mg/kg 
and 0.25 mg/kg, respectively. Clodrosome® was stopped after 7 days, and MR-1 after 15 days of 
transplantation. Anti-CD19 mAb was given at 600 mg/mouse on the days -1, 2 and 5 of transplantation. 
All drugs were diluted in PBS (pH 7.4) and injected intraperitoneally. To demonstrate the synergistic 
effect of nano-shielding and immunosuppressive drugs, the drugs were injected to both groups, 
receiving either unmodified or nano-shielded islets (Figure 2.1).   
 
2.2.14    Statistical analysis 
Size distribution, cell viability, insulin secretion and protein adsorption analysis were stated as 
mean ± SD. Graft survival time was analyzed as median ± SEM. Statistical analysis was carried out 
using the unpaired t-test or ANOVA one-way test. p values less than 0.05 were considered as 
statistically significant.      
 
2.3    Results 
2.3.1    Characterization of artificial ECM grafted islets 
SH-6-arm-PEG-Lipid was synthesized in two steps. Lipid-Mal was first synthesized, which 
was then conjugated to 6-arm-PEG-SH to make SH-6-arm-PEG-Lipid. The conjugation was confirmed 
by the detection of free thiol groups on SH-6-arm-PEG-Lipid with Ellman’s reagent. It was found that 
3.41 ± 0.08 arms among 5.37 ± 0.05 arms of free thiol groups on 6-arm-PEG-SH were conjugated with 
Lipid-mal. Catechol-functionalized gelatin (gelatin-catechol) was characterized by UV spectrometry 
and the catechol peak appeared at 284 nm. The number of catechol moieties was estimated to be 3.63 
± 1.93 for each gelatin-catechol molecule. The synthesis schemes and the interaction of the biomaterials 








































Figure 2.2    Synthesis scheme and structures of biocompatible materials for stabilization and nano-
shielding of porcine islet. (A) SH-6-arm-PEG-Lipid. (B) Gelatin-catechol. (C) 6-arm-PEG-catechol. (D) 
6-arm-PEG-SH. (E) Linear PEG-SH.  (F) Illustration of the conjugated porcine islet surface with 
biomaterials. (G) Catechol-thiol reaction via Michael-type addition, and self-polymerization of 
quinones via radical coupling reactions. 
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The nano-shielding conditions for artificial ECM were optimized by controlling the reaction 
time and the concentrations of FITC-SH-6-arm-PEG-Lipid and FITC-gelatin-catechol (fluorescein 
labeled artificial ECM). Confocal laser scanning microscopy (CLSM) showed that the artificial ECM 
well covered the islet surface (Figure 2.3 A).  
The viability of the artificial ECM-covered islets was evaluated both qualitatively and 
quantitatively by live/dead viability/cytotoxicity assay and CCK-8/DNA assays, respectively. Dead (red) 
cells were barely seen in the artificial ECM-covered islet group obtained by live/dead assay, and this 
was similar to the control group (Figure 2.3 B). The CCK-8/DNA assays demonstrated that the viability 
of the artificial ECM covered-islets was reduced to 81.77 ± 26.03% compared to the viability of the 
control group 100 ± 23.49%, even though the difference was not statistically significant (Figure 2.3 C). 
Glucose-stimulated insulin secretion (GSIS) test was performed to assess the in vitro insulin 
secretion capability of the artificial ECM coated islets against the unmodified islets at different 
concentrations of glucose (Figure. 2.3 D). The artificial ECM was directly attached to the islet cell 
membrane through hydrophobic interaction, which might have interfered with insulin secretion from 
islets. But, similar insulin secretion was observed from the islets of the both groups in response to both 
low and high glucose solutions given. In response to the low glucose (2.8 mM) KRBB solution, the 
insulin secretion from 100 IEQ unmodified and 100 IEQ artificial ECM coated islets were 6.76 ± 4.37 
µg/h and 7.79 ± 5.39 µg/h, respectively. With high glucose (28 mM) KRBB solution, the insulin 
secretion from the unmodified and the artificial ECM coated islets were 10.95 ± 5.98 µg/h and 10.88 ± 
3.82 µg/h, respectively. The stimulation index (SI) indicates no statistical significant difference between 
the groups (Figure 2.3 E). The values were 1.74 ± 0.65 and 1.53 ± 0.55 in unmodified islets and 
artificial ECM coated islets, respectively. This GSIS data suggested that insulin secretion capability of 
islets was not hampered by the artificial ECM. As proven in previous studies, multilayer PEG coating 
onto islet surface apparently did not alter the insulin secretion capability from islets when compared 
with the unmodified islet group [28, 30].        
 
2.3.2    Maintaining islets stability using artificial ECM 
Porcine islet stability according to the artificial ECM was evaluated both qualitatively and 
quantitatively for the duration of one week. Dithizone staining of islets showed well-structured islets 
on the day of coating (day 0) from both of the groups (Figure 2.4 A). However, unmodified islets 
started to dissociate into single cells with time and their initial shapes were not retained, whereas 
artificial ECM coated islets retained its structure with the exception of showing some single cells. The 
size distribution showed size reduction of the unmodified islets from the initial size (day 0) of 127.70 
± 87.03 µm to 36.13 ± 27.88 µm at day 7 (Figure 2.4 B). On the other hand, artificial ECM coated 
islets showed a steady size of islets throughout all the time points. The size on day 0 and day 7 were 







Figure 2.3    Surface coverage, viability and functionality of stabilized porcine islets with artificial 
ECM. (A) Confocal fluorescence images of FITC-linked SH-6-arm-PEG-Lipid as the first layer, and 
FITC-linked gelatin-catechol as a second layer (artificial ECM). (B) Viability assessment by Live/Dead 
assay. (C) The relative viability of control islets and islets coated with SH-6-arm-PEG-Lipid and 
gelatin-catechol (artificial ECM) using CCK-8 assay. (D) The glucose stimulated-insulin secretion 
(GSIS) of control islets and islets coated with artificial ECM at low (2.8 mM, white bar) or high (28 
mM, black bar) glucose solution for 2 h (n=5). (E) Stimulation Index (SI) of control and artificial ECM 









Figure 2.4    Comparison of the morphology and size change of unmodified islets (control) and islet 
coated with SH-6-arm-PEG-Lipid and gelatin-catechol (artificial ECM) after treatment. (A) 
Morphological change of porcine islet on incubation. Scale bar = 100 µm. (B) Size distribution of 





2.3.3    Improved immunoprotection by PEG nano-shielding 
6-arm-PEG-catechol was synthesized by reacting carboxylic groups of 3,4-
dihydroxyhydrocinnamic acid with amine groups of 6-arm-PEG-NH2 for amide bond formation. The 
conjugation was confirmed by UV spectroscopy since catechol gives a peak at 284 nm. The ratio of 
conjugated catechol moieties was quantified as 4.28 ± 0.22 in each 6-arm-PEG-catechol. Artificial 
ECM coated islets were further modified by three layers of PEG derivatives in order to improve 
immunoprotection. The coverage of PEG derivatives was evaluated by grafting FITC labeled 6-arm-
PEG-SH, 6-arm-PEG-catechol and linear PEG-SH at 0.5%, 1% and 0.5% concentrations, respectively, 
on the artificial ECM coated islets. CLSM showed that PEG derivatives completely covered islet 
surfaces (Figure 2.5 A). The viability was not altered after nano-shielding compared to the unmodified 
control islets and this was confirmed by live/dead viability/cytotoxicity kit (Figure 2.5 B).  
 
2.3.4    Protein adsorption on artificial ECM and PEG nano-shielded surfaces  
The protein adsorptions of human serum albumin (HSA), fibronectin and immunoglobulin G 
(IgG) were measured using a BCA protein assay kit for (1) the unmodified (control), (2) artificial ECM 
coated, and (3) both artificial ECM and PEG coated (artificial ECM + PEG) collagen surfaces (Figure 
2.6). The amount of adsorbed protein was the highest (p < 0.001) for the control group (first), compared 
to second and third types of surfaces. In particular, the surface coated with both artificial ECM + PEG 
showed significantly low adsorption of all three kinds of proteins compared to the control group.     
   
2.3.5    Effect of artificial ECM + PEG with immunosuppressive drugs on survival 
prolongation of xenografted porcine islets 
The porcine islets (8000 IEQ) were transplanted into the left kidney capsule of chemically 
induced (STZ) diabetic C57BL/6 mice, followed by monitoring of non-fasting blood glucose (NBG) 
levels (Figure 2.7). To evaluate the nano-shielding effect as well as the immunosuppressive drug 
protocol, islets were transplanted into four groups, as such: (1) unmodified islets (control), (2) 
unmodified islets with immunosuppressive drugs (control + drug), (3) PEG nano-shielded islets 
(artificial ECM + PEG) and (4) PEG nano-shielded islets with immunosuppressive drugs (artificial 
ECM + PEG + drug). A combination of immunosuppressive drugs was administered with the specified 
schedule (Figure 2.1). Unmodified islet recipients with or without immunosuppressive drugs failed to 
maintain their blood glucose level for more than 6 days (Figure 2.7 A, B). The median survival time 
(MST) of the unmodified islets was 2.0 ± 0.5 days, which was increased up to 6.0 ± 1.7 days after 
immunosuppressive drugs were administered. However, this difference was not statistically significant. 
Group (3) of nano-shielded islet recipients showed a survival time for 8.0 ± 1.5 days, which was 














Figure 2.5    (A) Confocal fluorescence images of FITC-linked 6-arm-PEG-SH, 6-arm-PEG-catechol 
and Linear PEG-SH (nano-shielding) on SH-6-arm-PEG-Lipid and gelatin-catechol (artificial ECM) 
grafted islets and (B) Live/Dead cell images of unmodified (control) and artificial ECM + PEG islets. 






















Figure 2.6    Quantitative adsorption of proteins, such as (A) human serum albumin (HSA), (B) 
fibronectin and (C) immunoglobulin G (IgG) on collagen coated glass plate as control, artificial ECM 
and artificial ECM + PEG collagen glass plate. Data were expressed as mean ± SD (n=3). *p < 0.05, 











the combined efforts of artificial ECM and PEG nano-shielding improved islet stability as well as 
immunoprotection. Therefore, without immunosuppressive drug treatment, the islets could maintain the 
blood glucose level for a significantly higher time period. Finally, the survival time of (4) (artificial 
ECM + PEG + drug) group was improved up to 13.0 ±1.8 days, which was highly significant compared 
to the other three groups (Figure 2.7 D, E; p < 0.05). 
 
2.4    Discussion 
Porcine islet xenotransplantation has emerged as an attractive alternative to overcome the 
scarcity of human islets for transplantation. Pig has many promising characteristics, such as similar 
physiology and insulin structural resemblance with humans, with only one amino acid difference [48]. 
However, it is difficult to maintain the intact structure of isolated islets before and after transplantation; 
since the isolated porcine islets are very fragile, they dissociate as single cells rapidly after their isolation 
[49]. There are two types of cell-associations between islet cells themselves and between islets and 
exocrine tissues, such as cell-to-cell and cell-to-matrix associations. Human and rodent pancreases have 
cell-to-cell association between islets, and cell-to-matrix association between islets and exocrine tissue. 
In the case of porcine pancreas, on the other hand, cell-associations between islets themselves and 
between islet and exocrine tissue are mainly cell-to-cell [17]. These observations suggest the underlying 
reason for the dissociation of porcine islets into single cells after their isolation. 
In this study, the aim was to develop surface camouflage of islets using biomaterials that can 
prevent immune reactions in their xenotransplanted status, while maintaining their stability. The 
isolated islets of rodents and non-human primates secret collagen and thereby form the collagen matrix 
on the isolated islets after a one-day culture. Several researches have reported that the collagen matrix 
covering the surface of islets is often used to chemically conjugate biomolecules [32, 38]. However, 
porcine islets are not covered by collagen matrix, and the cell membrane is directly exposed to the 
surface as the isolated porcine islets do not secret collagen matrix. In order to maintain viability and 
functionality of porcine islets, SH-6-arm-PEG-Lipid was synthesized as first layer that is directly 
anchored onto the phospholipids of exposed islet cell membranes via hydrophobic interactions. This 
phospholipid-integration method is known to be a suitable technique in adding biomolecules to the cell 
surface, without damaging cell functionality. Secondly, gelatin-catechol was introduced for second 
layer modification that binds with the thiol group of the first layer, that is, SH-6-arm-PEG-Lipid layer, 
thereby forming artificial ECM. Forming a thin layer of artificial ECM on the islet surface while 
maintaining their viability and functionality reduced islet dissociation into single cells. Moreover, in 
order to prevent immune cell infiltration and recognition, three layers of PEG derivatives were 
chemically grafted on artificial ECM conjugated porcine islets. In the previous study, the 
immunoprotective effect of 6-arm-PEG-catechol was confirmed in a rat islet model. Catechol moieties 
as a surface-independent anchoring molecule anchor onto the surface of rat islet and bind each other to 









Figure 2.7    Non-fasting Blood glucose (NBG) levels after islet transplantation into STZ induced 
C57BL/6 mice. (A) Control islet recipients (n=5). (B) Control islets recipients with drugs therapy (n=4). 
(C) Artificial ECM + PEG islet recipients (n=5). (D) Artificial ECM + PEG with drugs therapy (n=5). 
(E) Graft survival rate of each group. p < 0.05 in control vs artificial ECM + PEG, and p < 0.05 in 







Based on this result, 6-arm-PEG-catechol was applied for nano-shielding of stabilized porcine 
islets with artificial ECM. Finally, linear PEG-SH covered the 4-layer modified islets for preventing 
the reaction between remaining catechol groups and unknown proteins or cells in the body. Previously 
it had been shown that PEG derivatives do not exert harmful effect on islets while keeping islets 
functioning as much as unmodified islets in vitro [50]. PEG nano-shielded islets showed less 
immunological destruction upon culturing with lymphocytes and macrophages during one-week 
incubation time compared to the unmodified islets. The impairment may be caused by the secreted 
cytokines of the immune cells such as IL-2 and TNF-α; cytokine levels were higher for the unmodified 
islet group, and this was reduced by adding immunosuppressive drugs due to the consequent reduction 
in immune cell populations [51].  
Nano-shielding of islet has benefits over micro- or macro-encapsulation, where the diffusion 
barrier is hindered for the permeation of oxygen and nutrients. Alginate encapsulation technology, a 
typical case of encapsulation, shows high performance in preventing immune cell infiltration and 
activation; however, their thick layers hinder the transportation of oxygen and nutrient inside of islet. 
Deficiency of oxygen in the central area of porcine islets induces apoptosis of islet cells. Therefore, the 
thickness of modified layer is important in maintaining cell viability. In addition, thickness of modified 
layer affects the response rate of glucose and secretion of insulin. A thickness above 200 µm is 
considered to be detrimental to diffusive transport of nutrients and metabolites [23, 50]. From the optical 
images, unchanged size and shapes of the shielded islets can be seen compared with the naked islets 
(Figure 2.3 A, B, 2.4 A). Islet viability has been shown both qualitatively and quantitatively to confirm 
that the procedure for nano-shielding didn’t alter viability compared with the unmodified control islets 
(Figure 2.3 B, C and 2.5 B). Moreover, the insulin secretory capability was checked in response to 
glucose stimulation, which is recognized to be the best way of evaluating islet function in vitro (Figure 
2.3 D, E) [52]. Balamurugan et al. reported that pigs have lower serum C-peptide and insulin levels 
compared with non-human primates (NHP) and porcine islets show a poor insulin secretory response 
to glucose stimulation in vitro compared with the NHP islets. On the other hand, (NHP) islets are shown 
to have a quick response to glucose stimulation in vitro and produce high amounts of insulin [53]. 
Holmes et al. demonstrated that the insulin secretion capability of porcine islets is approximately half 
that of human [52]. The measurement of stimulation index for glucose-stimulated insulin secretion 
(GSIS) under static condition is one of the release criteria for clinical islet preparation [54]. Stimulation 
index greater than one (> 1) is considered to be an acceptable value for releasing porcine islets prior to 
transplantation [55]. In contrast, this study showed no statistical significant differences in stimulation 
index between control (unmodified islets) and artificial extracellular matrix modified islets (Figure 2.3 
E). The values were > 1 in both groups which meets the criterion. 
Early graft loss due to the instant-blood mediated inflammatory reaction (IBMIR) is the one of 
the major hurdles for islet transplantation. When the transplanted islets were exposed to the bloodstream 
inflammatory or thrombotic reactions were induced [56]. Platelet aggregation and blood coagulation 
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inducing proteins adhesion onto the islet surface trigger the IBMIR. In this study, it was demonstrated 
that the adhesion levels of human serum albumin, fibronectin, and IgG on the artificial ECM and PEG 
nano-shielded collagen plate were significantly decreased. The surface modified porcine islets 
prevented blood coagulation and inflammation reactions that were triggered by protein adsorption. 
Furthermore, alleviation of complement activation and antibody adhesion to surface of islet delayed the 
immune rejection of transplanted islets.  
Although PEG grafting may prevent immune cell infiltration and activation for a certain time 
period, it cannot completely prevent immune cell activation following transplantation [30, 57]. 
Therefore, several immunosuppressive drugs were added such as FK506, Rapamycin, MR-1, anti-CD19 
mAb and Clodrosome® to this protocol, thereby preventing immune activations responsible for 
xenogeneic rejection. The transplanted islet graft rejection can be classified into three categories – hyper 
acute rejection (HAR), acute rejection and chronic rejection [58]. HAR starts within hours, mediated 
by the pre-existing antibodies against the graft. The principal target for HAR is the Galactos-alpha-1,3-
galactos epitope which is present on the surface of porcine islets [59, 60]. Recipients in the control 
group showed very low survival times for the grafted islet, which indicates HAR. To prevent rejection 
of transplanted grafts in the early stage anti CD-19 mAb was used, which showed improved allograft 
survival by reducing IgM, and IgG alloantibody titers in sensitized animals [61]. Macrophages and 
neutrophils play a major role in rejecting transplanted islet graft during the early inflammatory response 
by secreting IL-1β and TNF-α. These cytokines lead to activation of multiple inflammatory cells, such 
as dendritic cells, CD4+ helper and CD8+ cytotoxic T cells [62-64]. Therefore, depletion of macrophages 
is an effective method in prolonging the survival time of the transplanted graft and this also leads to 
promotion of tolerance. Clodrosome®, a liposomal form of clodronate, showed long survival time by 
depleting macrophages when co-delivered along with the pancreatic islets in rodent models [65]. Low 
doses of FK506 and Rapamycin was also introduced which were used in the ‘Edmonton protocol’. Both 
of the drugs act by inhibiting the activation of T cells, either by inhibiting calcineurin or the secretion 
of IL-2. A critical step for T cell activation includes the binding of CD40 on antigen presenting cells 
(APC) with the CD154 or CD40L on T cells [66]. Using a monoclonal antibody against CD154 this 
mechanism can be blocked. For this purpose, MR1 (anti-CD 154 mAb) was additionally used. This 
immunosuppressive drug regimen could increase the survival time 3-times when unmodified islets were 
transplanted and 1.65-times when nano-shielded islets were transplanted. Nonetheless, the survival time 
was not more than two weeks; no reduction in body weight or death of the transplanted recipients were 
observed during this time period.  
In this study, the primary goal was to stabilize porcine islets using biomaterials so that they can 
maintain their morphology over a long period of time. Coating with artificial ECM reduced dissociation 
of islets into single cells, hence making them more stable after isolation. Later, to reduce 
immunogenicity, three more layers of PEGs were coated and a combination of immunosuppressive 
drugs was administered at different time points. Although more work will be needed to improve the 
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graft survival time by optimizing several factors such as, immunosuppressive drugs, increased number 
of islets or changing nano-shielding materials, etc.. That this study is believed to have a considerable 
impact on the improvement of pig to mouse xenotransplantation models. If this technique combining 
surface stabilization and immune-isolation of porcine islet could be applied in adjunct to an optimized 
immunosuppressive drug regimen, the therapeutic outcome in diabetic patients with xenogeneic porcine 
islets could be effectively improved.   
 
2.5    Conclusion 
A protocol for nano-shielding of porcine islets was established with artificial ECM and PEG 
derivatives for their stabilization and immune-protection. Artificial ECM-immobilized porcine islets 
were robust, which helped PEG nano-shielding of porcine islets without structural damage. In addition, 
it was proved that cocktailed immunosuppressive drug (FK506, Rapamycin, MR-1, anti-CD19 mAb 
and Clodrosome®) therapy was effective in porcine islet xenotransplantation model. These findings 
have immense potential for developing a successful porcine islet transplantation protocol that declines 
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Xenotransplantation of layer-by-layer polyethylene glycol nano-shielded 
non-human primate islets with a specified immunosuppressive drug 
protocol 
 
3.1    Introduction 
T1DM is related with chronic complications and high morbidity in young adults. The advent 
of insulin therapy has improved the life style of T1DM patients by reducing the chronic complications 
associated with T1DM [1]; at the same time, however, the use of insulin also possesses a threefold 
increased risk of hypoglycemia that is potentially life-threatening [2]. Whole organ transplantation 
might be an option that can regulate the blood glucose level (BGL) in the normal range but it carries 
significant risks of morbidity due to high immunogenicity [3]. Alternatively, islet transplantation has 
emerged as an effective approach as pancreas transplantation with lower risk and invasiveness [4]. 
Unfortunately, immune rejection is one of the hurdles for clinical islet transplantation [5]. Several kinds 
of immunosuppressive drug protocols have been developed to overcome this problem [6-9]. The need 
arose, however, to search for more options than immunosuppressive drug protocols to get around 
immunogenicity as it was found that when islet transplant recipients were treated with a cocktail 
immunosuppressive therapy, only 44% of the recipients maintained insulin independence for one year 
after the transplantation [5].  
Since then several immunoisolation techniques have been developed, such as intravascular 
macrocapsulation, extravascular macrocapsulation and microcapsulation, surface modification, etc. 
[10-12]. With regard to encapsulation technology, the intravascular macrocapsulation method has poor 
biocompatibility as it leads to fatal thrombus formation due to direct blood connection of the device 
and requires an intense systemic anticoagulant therapy; on the other hand, the extravascular 
macrocapsulation method, to which the focus of encapsulation has now shifted, can implant islets under 
the kidney capsules or into the peritoneal cavity or into the subcutaneous tissues, while lowering the 
risks [13]. However, the formation of surface fibrosis still remains a hurdle for both micro and macro 
extravascular devices [4]. Up to now, the commonly employed microcapsule using alginate has an 
average diameter of 400-800 µm to encapsulate islets of 50-250 µm in diameter [11, 14, 15]. This large 
size of alginate encapsulated islets is not suitable for intraportal transplantation in clinical trials as it 
limits the diffusion of oxygen and nutrients due to high diffusion barrier [16-18]. Diffusion barrier of 
more than 200 µm in thickness potentially harms islet viability by hindering the oxygen and nutrient 
transport [4].  
PEG has been used extensively for making foreign materials biocompatible [19, 20]. Unlike 
alginate encapsulation, PEG molecules are resistant to osmotic stress. Very recently, approaches have 
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been made to improve the mechanical stability of alginate capsules by adding PEG [21, 22]. By doing 
so, an alginate capsule with 800 µm diameter could be reduced up to 500 µm and the transplanted 
volume could be minimized comparatively. Surface modification of islets using Layer-by-Layer (LbL) 
PEGs range in the size of nanometers, hence the term ‘nano-shielding’ of islets was coined. Islet nano-
shielding can eliminate problems associated with the above-mentioned encapsulation techniques 
regarding the diffusion barrier. In addition, the coated thin layer on islet surface reduces the volume of 
islets per unit, making it feasible for islets to be transplanted via the portal vein [23-26]. Lee et al. 
demonstrated that nano-shielding covers islet surface antigens while maintaining viability and insulin 
secretory capability [25]. Nano-shielding protects islets from the deleterious effects of immune cell 
secreted cytokines in vitro [27]. When allotransplanted, nano-shielded islets show stable blood glucose 
level over one-year post-transplantation treated with a lower than the clinical level dose of cyclosporine 
A. Immunohistochemical investigations showed that nano-shielding makes transplanted grafts 
unrecognizable to the recipient immune system, and thus reduces immune infiltration into the grafts 
[28-30]. Studies on rat-to-mouse xenotransplantation also demonstrated superior outcomes of this 
system on islets using different immunosuppressive drug combinations [26, 31, 32]. Recently, porcine 
islets were encapsulated with a combination of artificial extracellular matrix (A. ECM) and LbL PEG 
(A. ECM + PEG, Chapter 2). It was assumed that artificial ECM would make the porcine islet structure 
robust while nano-shielding would reduce islet immunogenicity [33]. Although the median survival 
time (13.0 ± 1.8 days with immunosuppressive drugs) was not considerably high in xenotransplanted 
C57BL/6 mice, the difference was statistically significant compared with naked islets. Improved 
survival time allowed us to use the same PEG system for the current work. Non-human primate (NHP) 
islets do not undergo physical destruction after isolation as much as porcine islets, thus encapsulation 
with A. ECM was unnecessary. Hence, in the current study, the immunogenicity of NHP islets was 
reduced in xenorecipients by using the nano-meter thick three-layer PEGylation system to encapsulate 
NHP islets by employing the conventional LbL approach. Along with the nano-shielded islets, a 
glucocorticoid free immunosuppressive drug protocol was used consisting of the following: tacrolimus 
(TAC), sirolimus (SRL), anti-CD154 (MR1), and anti-LFA-1 monoclonal antibodies to study in a 
xenorecipient. TAC and SRL, in combination with a T cell inhibitor, were used in the Edmonton 
protocol, and MR1 is known to inhibit the activation of CD4+ T cells by blocking the CD40-CD154 
interaction, resulting in the prolongation of skin, islets, and renal allograft survival in non-human 
primates (NHP) models. Leukocyte function-associated antigen-1 (LFA-1) is a β2 integrin. Anti-LFA-
1 mAb reduces adhesion, activation and trafficking of leukocytes. Production of islet specific antibody 
requires interaction among T cells, B cells and dendritic cells. They form cluster within 1 h of in vitro 
culture, and anti-LFA-1 reduces this clustering [34]. Short-term blockage of LFA-1 monoclonal 
antibody results in a long-term islet allo- and xenograft survival and induction of tolerance [35-39]. 
This study is the first step towards applying the nano-shielding technology in human islets. 
Although there have been currently several successful reports about human-to-human islet 
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transplantation, the immune rejection of transplanted islets is still an important issue to resolve [5]. To 
evaluate the application of nano-shielding system to human islets, in this study, the NHP model was 
selected as the most similar model to the human physiology [40]. Since the physiology of pancreatic 
islet is different according to different animal models, it is important to evaluate the therapeutic efficacy 
of the new technology in the NHP model before applying them to human islets. However, not many 
studies have been conducted yet on NHP islets to evaluate its coating efficiency with PEG and its 
success as immune barrier in vivo. Validating nano-shielding on NHP islets an insight can be achieved 
about how this system might work on human islets. Here, the thickness of nano-shielding technology 
using three layers of PEGs was studied and checked for the feasibility on NHP islets. Furthermore, 
using a glucocorticoid free immunosuppressive drug protocol, the survival time of PEG nano-shielded 
islets (referred to as ‘PEG’ on figures) was investigated in a xenograft model.  
 
3.2    Materials and methods 
3.2.1    Animals  
Cynomolgus monkeys (male, 2 years old, weighing 3-5 kg) were used as islet donors. Inbred 
C57BL/6 mice and BALB/c nude mice (male, 7–8 weeks old) were used as recipients. Cynomolgus 
monkeys (Macaca fascicularis) were supplied by Orient Bio Co. Ltd. (Seongnam, Korea). All monkeys 
were screened and found to be negative for herpes B virus, measles, cynomolgus cytomegalovirus, 
tuberculosis, simian retrovirus, simian T cell leukemia virus, simian immunodeficiency virus, and 
simian varicella virus by Zoologix Inc. (Chatsworth, CA). Cynomolgus monkeys were kept in separate 
cages. Water was supplied ad libitum and biscuits were given two times daily (Certified Primate Diet 
5048*, LabDiet, St Louis, MO). Fresh fruits, vegetables, and nuts were given twice a day. Various toys, 
as well as music, and visual entertainment (DVDs) were provided as part of an enrichment program. 
The procedures were conducted according to the guidelines of Institutional Animal Care and Use 
Committee of Orient Bio Laboratories.  
 
3.2.2    Diabetic modeling  
Diabetes of C57BL/6 and BALB/c nude mice recipients were induced by intraperitoneally 
injecting 180 mg/kg and 220 mg/kg of streptozotocin (STZ, Sigma), respectively. The BGL was 
monitored after STZ injection to find diabetic recipients. Mice having BGL over 350 mg/dl for 2 
repeated days were selected as recipients. Institute of Laboratory Animals Resources of Seoul National 
University approved all the surgical and experimental procedures for the recipients.  
 
3.2.3    Isolation of pancreatic islets 
The pancreas was dissected from the donor and placed in histidine-tryptophan-ketoglutarate 
solution (HTK, Dr Franz Köhler Chemie GmbH, Germany) at 4 ºC. It was then distended by 3-4 ml of 
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cold Liberase MTF C/T solution (Roche, Indianapolis, IN) per gram of pancreas. The modified Ricordi 
method was utilized to perform islet isolation. The distended pancreas was placed and digested in a 
Ricordi chamber (BioRep Technologies Inc., Miami, FL) at 37ºC. Throughout the digestion procedure, 
the chamber was gently shaken. The state of digestion was assessed by collecting samples from the 
digestion chamber at different time points; the samples were observed under a microscope by dithizone 
staining (DTZ; Sigma, St. Louis, MO). Immediately after observing free islets, the enzyme reaction was 
arrested by circulating phase II solution (Dilution solution, Corning, NY). Digested cells were collected 
into 250 ml conical tubes along with washing solution and preserved in the HTK solution for 1 h before 
purification. Islet purification technique was based on density gradient centrifugation using COBE 2991 
(Gambro BCT, Lakewood, CO). Optiprep (Axis-Shield PoC AS, Oslo, Norway) was mixed with the 
HTK solution to make different gradients. Purified islets were counted and cultured in the CMRL 1066 
medium (Mediatech, Inc., Corning) supplemented with 10% fetal bovine serum at 37°C in a humidified 
5% CO2 incubator.  
 
3.2.4    Synthesis of SH-6-arm-PEG-NHS 
SH-6-arm-PEG-NHS was synthesized according to previously reported protocol [33]. Briefly, 
6-arm-PEG-SH (1000 mg; MW 15 kDa, SunBio, Seoul, Korea) was dissolved in N,N-
dimethylformamide (DMF, Sigma). 3-Maleimidobenzoic acid N-hydroxysuccinimide ester (50.28 mg; 
MBS, Sigma) was also dissolved in DMF and added to the solution (Figure 3.1 A). Both of the reactants 
were mixed in a round bottom flask and the reaction was run overnight under nitrogen atmosphere in 
an ice bath. Unreacted MBS was purified by precipitating in distilled water. The purified reactant was 
filtered and freeze dried to obtain SH-6-arm-PEG-NHS. FITC labeled SH-6-arm-PEG-NHS was 
synthesized by reacting MBS with pre-synthesized SH-6-arm-PEG-FITC followed by precipitation in 
water and freeze drying.   
 
3.2.5    Synthesis of 6-arm-PEG-catechol 
To synthesize 6-arm-PEG-catechol, the optimized protocol reported previously was followed 
[33]. Shortly, 3, 4-dihydroxyhydrocinnamic acid (145.74 mg; DHCA, Sigma) was dissolved in DMF 
and poured into a round bottom flask (Figure 3.1 B). N, N’-dicyclohexylcarbodiimide (330.73 mg; 
DCC, Sigma), N-hydroxysuccinimide (184.78 mg; NHS, Sigma), and 6-arm-PEG-NH2 (1000 mg; MW 
15 kDa, SunBio) were dissolved in DMF and added to the flask sequentially. The reaction was 
continued overnight under nitrogen environment in ice bath. Next day, the unreacted residues were 
purified by precipitation in cold diethyl ether (Sigma) and freeze dried to obtain 6-arm-PEG-catechol. 
FITC labeled 6-arm-PEG-catechol was synthesized by reacting 6-arm-PEG-catechol (200 mg) with 
NHS-Fluorescein (19 mg, Pierce Biotechnology, Rockford, IL) in DMF overnight followed by dialysis 
and freeze drying.  
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3.2.6    Synthesis of FITC labeled linear PEG-SH 
mPEG-SH (linear PEG-SH, MW 5 kDa, Figure 3.1 C) was purchased from Laysan Bio, Inc. 
(AL). FITC labeled linear PEG-SH was synthesized by reacting NH2-linear PEG-SH (200 mg; MW 5 
kDa) with NHS-fluorescein (19 mg) in DMF overnight in an ice bath under nitrogen atmosphere. Next 
day, the reactant was purified by dialysis using a 2 kDa MWCO dialysis membrane followed by freeze 
drying to yield FITC-linear PEG-SH. 
 
3.2.7    AFM imaging of nano-shielded surface 
AFM imaging (XE-100 AFM, Park Systems Inc., Santa Clara, CA) was employed to assess 
surface alteration upon nano-shielding with collagen coated glass plates (control) and PEG nano-
shielded collagen coated glass plates (PEG surface). For the first layer of nano-shielding, 1.5 mg SH-
6-arm-PEG-NHS was dissolved in 300 µl Hank’s balanced salt solution (HBSS, pH 8, Sigma), and 
poured onto the collagen coated glass plates and incubated for 1 h. Unreacted SH-6-arm-PEG-NHS was 
washed out by rinsing the plates twice with HBSS (pH 7.4). 3 mg of 6-arm-PEG-catechol and 1.5 mg 
of linear PEG-SH were similarly dissolved in 300 µl HBSS (pH 8) and added onto the collagen plates, 
followed by 1 h incubation and washing between each layer. The plates were dried before obtaining 
AFM images. The images were analyzed using a XEP Program Software (Park Systems Inc.).    
 
3.2.8    Protein adsorption on nano-shielded surface  
Micro-bicinchoninic acid (m-BCA) protein assay (Pierce Chemical Co., Rockford, IL) kit was 
utilized to quantify the amount of proteins adsorbed on the nano-shielded surface [41]. Collagen coated 
glass plates were used as control and PEG nano-shielding was performed on the collagen surface (PEG 
surface) as mentioned above. Each individual protein, namely, human serum albumin (HSA, Sigma), 
human fibronectin (Sigma) and human serum immunoglobulin G (IgG, Sigma), was prepared by 
dissolving it in PBS at 100 µg/ml concentration. Control and PEG surfaces were filled with PBS and 
left for 1 h to hydrate. The proteins were added onto the plates and incubated for 2 hours at 37 ºC for 
protein adsorption to take place. Afterwards, unbound proteins were rinsed out with PBS. The plates 
were sonicated in 5 ml of 1% w/v of sodium dodecyl sulfate (SDS, Amresco Inc., Cochran road solon, 
OH) for 1 h to extract the adsorbed proteins. 50 µl of each eluted protein was placed in a 96-well plate. 
A microplate reader was used to measure the absorbance at 526 nm. A value based on a calibration 
curve was obtained with bovine serum albumin standard.  
 
3.2.9    Nano-shielding of islets  
NHP Islets were cultured for three days after isolation at 37°C under humidified atmosphere 
containing 5% CO2. For the first layer of nano-shielding, islets were washed with HBSS (pH 7.4) and 
incubated 1 h in the HBSS (pH 8.0) containing 0.5% w/v SH-6-arm-PEG-NHS. N-hydroxysuccinimide 
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(NHS) groups bind with amine groups located on the islet surface collagen and form the amide bond. 
The second and third layers were formed by dissolving 1% w/v 6-arm-PEG-catechol and 0.5% w/v 
linear PEG-SH in HBSS. Similarly, as before, islets were washed twice by HBSS (pH 7.4) before each 
layer of nano-shielding to remove residual PEG. Finally, islets were washed with CMRL 1066 medium 
(supplemented with 10% FBS) and prepared for further experiments.  
Nano-shielding on islets was examined using FITC-labeled PEG molecules. The islets were 
incubated in HBSS containing FITC-SH-6-arm-PEG-NHS, FITC-6-arm-PEG-catechol, and FITC-
linear PEG-SH at three different concentrations of 0.5%, 1%, and 0.5% w/v, respectively, for 1 h at 
37°C. Islets were washed with HBSS after each layer of nano-shielding. The fluorescence intensity of 
FITC-labeled PEGs was observed using a laser scanning confocal microscope (Carl Zeiss LSM710, 
Germany). 
 
3.2.10    Cell viability assay 
Islet viability was monitored right after nano-shielding to check the detrimental effect of this 
system. Qualitative viability was checked by Live/Dead viability and cytotoxicity kit assay (Molecular 
Probes, Eugene, OR). After isolation NHP islets were cultured in CMRL 1066 medium (Mediatech, 
Inc., Corning, NY) supplemented with 10% FBS at 37°C in a 5% CO2 incubator for three days, followed 
by nano-shielding with three layers of PEG (SH-6-arm-PEG-NHS 0.5%, 6-arm-PEG-catechol 1% and 
linear PEG-SH 0.5%, 1 h for each layer). 100 IEQ nano-shielded islets (PEG) were washed without 
delay and suspended in 1 ml HBSS. 2 µl of 50 µM calcein AM and 4 µl of 2 mM ethidium homodimer 
(EthD-1) were added to the cell suspension and incubated for 15 min at room temperature. Naked islets 
were used as control group. Living cells are stained green fluorescent by the intracellular esterase 
activity which converts non-fluorescent calcein AM to intensely fluorescent calcein. Dead cells are 
stained red fluorescence by the entrance of EthD-1 into the cell by passing through the broken cell 
membrane and binding to nucleic acids, eventually resulting in a highly enhanced red fluorescence.      
The viability of the nano-shielded islets was quantitatively analyzed by a cell counting kit-8 
(CCK-8, Dojindo Molecular Technologies Inc, MD) as well. 100 IEQ of naked islets (control) and 
nano-shielded islets (PEG) were placed in 96 wells, suspending in 100 µl CMRL 1066 medium 
(supplemented with 10% FBS) separately. 10 µl of WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium, monosodium salt] was added to each well and 
incubated for 4 h. Live islets convert WST-8 by their metabolic activity to produce water soluble orange 
colored formazan which was determined by reading the absorbance at 450 nm using a UV microplate 
reader. The data obtained from CCK-8 was normalized by the DNA content of islets in each well by 




3.2.11    Glucose-stimulated insulin secretion (GSIS) assay 
The functionality of nano-shielded islets was confirmed by GSIS assay. 100 IEQ islets from 
both naked (control) and nano-shielded (PEG) islet groups were suspended in Krebs-Ringer bicarbonate 
buffer (KRBB; pH 7.4) containing low (2.8 mM) glucose and placed in Millicell inserts (100 IEQ 
islets/insert; Millipore corp., Billerica, MA) of a 24-well plate. Islets were pre-incubated at 37°C for 1 
h under humidified atmosphere containing 5% CO2. The medium was exchanged with the same buffer 
and incubated for 2 h followed by further incubation for the same duration in high glucose KRBB 
solution (28 mM) to measure glucose-stimulated insulin secretion at low and high glucose concentration, 
respectively. The secreted amount of insulin was quantified by Mercodia human insulin ELISA kit 
(Mercodia, Upsala, Sweden). The stimulation Index (SI) was calculated by dividing the concentration 
of secreted insulin at high glucose KRBB solution by that of the low glucose solution. 
 
3.2.12    Nano-shielded islet xenotransplantation 
To evaluate the therapeutic potential of the nano-shielding and the synergistic effects with the 
immunosuppressive drug protocol, four groups of mice (n=4) were prepared as below: 1) 4000 IEQ 
naked islets (control), 2) 4000 IEQ nano-shielded islets (PEG), 3) naked islets with immunosuppressive 
drugs (control + drugs), and 4) 4000 IEQ nano-shielded islets with immunosuppressive drugs (PEG + 
drugs). 
Before transplantation, the recipients were anesthetized by intraperitoneal injection of a mixture 
of ketamine 80 mg/kg (Yuhan Co., Ltd, Seoul, Korea) and xylazene 16 mg/kg (Bayer Healthcare LLC, 
Seoul, Korea). A lumbar incision was made to expose the left kidney. Naked islets (control and control 
+ drugs) and nano-shielded islets (PEG and PEG + drugs) were transplanted into the left kidney capsule. 
After transplantation, the body weight and BGL were measured daily using a glucometer (Super 
glucocard II, Arkray, Kyoto, Japan). The transplanted islets were considered as graft rejection if the 
BGL persisted elevated than 350 mg/dl for three days straight.  
 
3.2.13    Immunosuppressive drug protocol  
The immunosuppressive drugs were administered intraperitoneally at different time points to 
the recipients, which received both control and nano-shielded islets, as follows: 0.20 mg/kg of TAC 
(Astellas Pharmaceuticals, Chicago, IL) daily after transplantation, 0.20 mg/kg of SRL (Sigma) up to 
14 days of transplantation, 0.20 mg/mouse of anti-LFA-1 (Bioxcell, West Lebanon, NH) at -1, 0, 1, 7 
and 14 days of transplantation and 0.25 mg/mouse of MR1 (anti-CD-154 mAb, Bioxcell, West Lebanon, 





3.2.14    Intraperitoneal glucose tolerance test 
Intraperitoneal glucose tolerance test (IPGTT) was performed on the control + drugs (n=2) and 
PEG + drugs (n=4) treated recipients at 150th day of transplantation or right after rejection (control + 
drugs, n=2) to assess the glucose responsiveness of the transplanted islets. Two more groups of animals 
were also employed as STZ induced diabetic mice (n=3) and normal mice (n=3). All groups of animals 
were kept fasting overnight. Next morning, they were administered 20% glucose (Sigma) solution at a 
dose of 2 g/kg into the peritoneal cavity. BGL was measured at 0, 5, 10, 15, 20, 30, 45, 60, 90 and 120 
min.  
 
3.2.15    Immunohistochemistry 
The left kidney containing transplanted graft was retrieved, fixed in 10% formalin for 2 days 
and embedded in paraffin to make sections at 4 µm. The sections were deparaffinized by heating in a 
dry oven, washing in xylene, and rehydrating again by dipping into serially graded alcohol. Antigen 
retrieval was done by heating the slides in 10 mM citrate buffer (pH 6.0, Sigma) in a microwave for 5 
min. It was then cooled down to room temperature for 20 min. The slides were immersed in 3% H2O2 
(Sigma) for 15 min to neutralize citric acid followed by washing in PBS. The slides were incubated 
overnight at 4°C with anti-insulin (1:50, Abcam Inc., Cambridge, MA), anti-glucagon (1:50; Abcam 
Inc., Cambridge, MA), anti-CD31 (1:50; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-CD11b+ 
(1:10; eBioscience, San Diego, CA), anti-CD20+ (1:40; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA), anti-CD4+ (1:100; Abcam Inc., Cambridge, MA), and anti-CD8a+ (1:25; BioLegend, San Diego, 
CA) in a humidified chamber. The slides were brought back to the room temperature, washed and 
observed with a peroxidase labeled polymer conjugated to goat anti-mouse immunoglobulins in Tris–
HCl buffer (Envision plus System-HRP labeled polyer; Dako, Glostrup, Denmark) and incubated for 2 
h at room temperature. The slides were incubated with liquid 3, 30-diaminbenzidine (Dako) for 15 min 
to develop chromogen. Counterstaining was done with Mayer hematoxylin. The negative control slides 
were treated similarly except for the incubation with primary antibodies. The slides were dehydrated 
gradually by dipping serially into 70%, 80%, 90%, and 100% alcohol. Finally, tissue slides were fixed 
using mounting medium (Dako) with glass coverslips. 
 
3.2.16    Quantification of insulin, C-peptide and IL-1β concentrations in serum 
At 150th day of transplantation, transplanted animals were anesthetized by diethyl ether (Sigma). 
Blood was collected by retro-orbital sinus puncturing. The whole blood was left at room temperature 
for 30 min to form a clot. The clot was removed by centrifugation at 2000 g for 10 min in a refrigerated 
centrifuge. Serum was collected as supernatant; insulin (Mercodia human insulin ELISA, Mercodia), 
C-peptide (Mercodia human C-peptide ELISA, Mercodia), and a pro-inflammatory cytokine, IL-1β 
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(Mouse IL-1 β quantikine ELISA, R&D Systems, Minneapolis, MN) concentrations were quantified 
according to the manufacturer’s instructions.  
 
3.2.17    Statistical analysis 
Protein adsorption, islet viability, insulin secretion, stimulation index, IPGTT, insulin, C-
peptide, and IL-1β cytokine concentrations were expressed as mean ± SD. The survival time was 
expressed as median ± SEM. Statistical analysis was performed by unpaired t-test or ANOVA one-way 
test. P values less than 0.05 were considered as statistically significant. 
 
3.3    Results 
3.3.1    Synthesis and characterization of PEGs  
Synthesis procedure and nano-shielding of islets with three layers of PEGs were shown in 
Figure 3.1. In SH-6-arm-PEG-NHS, the incorporation of NHS groups to the PEG was confirmed by 
1H NMR spectra and quantified by Ellman’s reagent (Pierce Biotechnology, IL). The results showed 
that 3.41 ± 0.08 arms of 6-arm-PEG-SH were incorporated with NHS (Figure 3.1 A). The number of 
catechol moieties on 6-arm-PEG-catechol was evaluated by UV spectroscopy, which showed a peak at 
284 nm. 4.28 ± 0.22 catechol molecules were bound to each of the 6-arm-PEG-NH2 to form a molecule 
of 6-arm-PEG-catechol (Figure 3.1 B). 
 
3.3.2    Nano-shielding reduced protein adsorption 
AFM images were evaluated for collagen surface (control, Figure. 3.2 A) and nano-shielded 
collagen surface (PEG surface, Figure 3.2 B) that were used to mimic islet surfaces and nano-shielded 
islet surfaces, respectively. The AFM images revealed that nano-shielding had an average thickness of 
0.727 nm. Nano-shielding significantly reduced (p < 0.001) protein adhesion when checked in vitro 
(Figure. 3.2 C). Apparently, adsorption of human serum albumin (HSA), fibronectin, and 
immunoglobulin G (IgG) was significantly reduced on the PEG surfaces in all three cases compared to 
the control. 
 
3.3.3    Nano-shielding of islets  
Islet yield after the PEG nano-shielding procedure was 74 ± 2.6%. Confocal microscopy 
allowed us to evaluate the gross uniformity and distribution of the three-layers of PEG formed on the 
islet surface using FITC-labeled PEGs (Figure 3.3 A, B). The two-dimensional image of islets 
confirmed the uniform coverage of nano-shielding throughout the islet surface. 
Islet viability was assessed after nano-shielding. The results of Live/Dead assay and 
CCK8/DNA assay showed that the nano-shielded did not alter the viability of islets as shown in Figure 









Figure 3.1    Synthesis schemes and encapsulation of islets with three-layers of PEG. Synthesis of (A) 
SH-6-arm-PEG-NHS, and (B) 6-arm-PEG-catechol. (C) Chemical structure of linear PEG-SH. (D) 
Assembly of PEG layers onto islet surface by (E) forming amide bond between SH-6-arm-PEG-NHS 
and amines on islet surface collagen. (F) The catechol groups on 6-arm-PEG-catechol (second layer) 
are oxidized to quinones in alkaline condition (pH 8.0) which react with thiol groups of SH-6-arm-
PEG-NHS (first layer) and linear PEG-SH (third layer). The activated quinones also react with each 




















Figure 3.2    In vitro characterization of the PEG surface. The thickness of three-layer PEG nano-
shielding was assessed by AFM imaging (4 µm x 4 µm). Two-dimensional images of (A) collagen 
surface (control), and (B) nano-shielded collagen surface (PEG surface). The images were shown with 
the height profile along the line. (C) Adsorptions of proteins, such as human serum albumin (HSA), 


















Figure 3.3    In vitro characterization of nano-shielded islets (PEG). (A) Confocal laser scanning 
microscopic images of nano-shielding with FITC-labeled PEGs (FITC-SH-6-arm-PEG-NHS, 0.5%; 
FITC-6-arm-PEG-catechol, 1%; FITC-linear PEG-SH, 0.5%). (B) Fluorescent intensity of the merged 
image. (C) Live/Dead viability/cytotoxicity kit, and (D) cell counting kit-8 (CCK-8/DNA, n=5) assays 
reveled non-cytotoxicity of nano-shielding on islets. (E) Functionality of the nano-shielded islets was 
checked compared with the naked islets (control) by glucose-stimulated insulin secretion (GSIS) test at 





In vitro islet functionality was evaluated by insulin secretion from the control and nano-shielded 
islets, respectively, in response to a low (2.8 mM) and a high (28 mM) glucose concentrations (Figure 
3.3 E). The results, which were not significantly different in insulin secretion between the control and 
the nano-shielded islets, were the following: the insulin secretion from the control islets was 129.64 ± 
11.41 mU/L and from the nano-shielded islets was 145.12 ± 44.57 mU/L, at the high glucose 
concentration. The stimulation index was 1.67 ± 0.32 for the control islets and 2.52 ± 0.76 for the nano-
shielded islets (Figure. 3.3 F).  
 
3.3.4    Xenotransplantation of nano-shielded NHP islets in mice  
As of the time of this study there was no case of NHP islet xenotransplantation in C57BL/6 
mouse model. The number of islets for SD rat-to-C57BL/6 mouse xenotransplantation ranges from 300-
500 IEQ. Therefore, for the optimization of dose, different quantities of naked NHP islets, such as, 500 
IEQ (n=4), 1000 IEQ (n=3), 2000 IEQ (n=3), and 4000 IEQ (n=4) were transplanted into the kidney 
subcapsular space of immunosuppressed diabetic nude mice (Figure 3.4). The median survival time 
(MST) of 500 IEQ and 1000 IEQ transplanted islet recipients were 5 ± 0.25 days and 8 ± 1.67 days, 
respectively. Recipients transplanted with 2000 IEQ islets were monitored for 60 days post-
transplantation. One of the mice was rejected on the 20th day of transplantation and the remaining two 
showed fluctuating blood glucose level all over. The final group, which was transplanted with 4000 
IEQ islets, showed a stable blood glucose level with no rejection during the monitored time period of 
108 days. Therefore, 4000 IEQ was chosen as optimized islet number to be transplanted into C57BL/6 
mice and to evaluate the immunoprotective effect of nano-shielding with the specified 
immunosuppressive drug protocol. The nano-shielded islets were transplanted into the kidney 
subcapsular space of diabetic C57BL/6 mice, followed by observing non-fasting BGL once a day 
(Figure 3.5). The following four groups of mice (n=4 in each group) were transplanted: naked islets 
(control, Figure. 3.5 B), nano-shielded islets (PEG, Figure 3.5 C), naked islets with 
immunosuppressive drugs (control + drugs, Figure. 3.5 D), and nano-shielded islets with 
immunosuppressive drugs (PEG + drugs, Figure. 3.5 E). The rejection of graft occurred in all the 
recipients of the control group within 10 days of transplantation, where the MST was 5.5 ± 1.4 days 
(Figure 3.5 F, Table 3.1). Nano-shielded islets showed a significant increase in survival time for 26 ± 
5.21 days (p < 0.05 vs control). The MST was increased up to 77.5 ± 42 days when the control islets 
were transplanted with the immunosuppressive drugs (control + drugs), where graft rejection occurred 
in two of the four recipients within 5 days of transplantation. Third recipient showed fluctuated BGL 
throughout 150 days but never crossed the rejection limit (>350 mg/dl for three consecutive days) while 
the last one had steady BGL all over. The BGL of PEG + drugs group was measured for 150 days until 
the termination point of the in vivo experiment; none of this group showed graft rejection during this 
time period. A steady BGL with an increase in body weight (Figure 3.6) was achieved in all four 











Figure 3.4    Non-fasting blood glucose (NBG) level after transplanting (A) 500 IEQ (n=4), (B) 1000 
IEQ (n=3), (C) 2000 IEQ (n=3), and (D) 4000 IEQ (n=4) naked islets into kidney subcapsular space of 













Figure 3.5    Non-fasting blood glucose (NBG) level after 4000 IEQ of islets transplanted into kidney 
subcapsular space of diabetic C57BL/6 mice. (A) Immunosuppressive drug protocol was applied as 
follows: 0.20 mg/kg of TAC daily after transplantation, 0.20 mg/kg of SRL up to 14 days of 
transplantation, 0.20 mg/mouse of anti-LFA-1 at -1, 0, 1, 7 and 14 days of transplantation and 0.25 
mg/mouse of MR1 at -1, 0, 1, 3, 5, 7 days and weekly thereafter. NBG level of (B) naked islets (control, 
n=4), (C) nano-shielded islets (PEG, n=4), (D) naked islets with immunosuppressive drugs (control + 
drugs, n=4), and (E) nano-shielded islets with immunosuppressive drugs (PEG + drugs, n=4) treated 














Figure 3.6    Body weight after transplanting 4000 IEQ islets into diabetic C57BL/6 mice. (A) Naked 
islets (control) and (B) nano-shielded islets (PEG) without immunosuppressive drugs, (C) naked islets 
























Table 3.1    Survival outcomes of the transplanted islets 
 
Groups Graft survival (days) 
Median survival time 
(MST ± SEM) 
Control 2, 5, 6, 10 5.5 ± 1.65 
PEG 8, 25, 27, 32 25 ± 5.21* 
Control + drugs 4, 5, 150, 150 >77.5 ± 42 
PEG + drugs 150, 150, 150, 150 >150** 
 














Intraperitoneal glucose tolerance test (IPGTT) assessed glucose sensitivity of the recipients of 
control + drugs and PEG + drugs in comparison with diabetic and normal C57BL/6 mice (Figure 3.7). 
After an overnight of fasting, all groups of animals were administered with a high concentration of 
glucose solution. Diabetic animals showed BGL exceeding 500 mg/dl within 5 min and were 
maintained over 2 h. Control + drugs treated animals had BGL around 400 mg/dl throughout. On the 
other hand, animals from the normal mice group and the PEG + drugs recipients showed reduced BGL 
during the experiment period. 
 
3.3.5    The combined effort of nano-shielding and immunosuppressive drugs on 
immunoprotection  
Recipients from all transplanted groups were sacrificed to investigate the functionality of the 
transplanted grafts and immunomodulatory effects of nano-shielding in combination with 
immunosuppressive drugs on the 150th day of transplantation (control + drugs, n=2 and PEG + drugs, 
n=4) or right after rejection (control, n=4 and control + drugs, n=2). A detailed view of islet secreted 
hormones and activated immune cells were revealed by immunohistochemical staining. A profound 
staining of insulin and glucagon was found in the PEG + drugs group, whereas the control showed 
almost no staining (Figure 3.8 A). Additionally, immune cell staining of CD20+, CD11b+, CD8a+, and 
CD4+ markers were the highest for the control group, although the PEG + drugs group stained a small 
amount of CD20+ and CD11b+ (Figure 3.8 B).  
Enzyme-linked immunosorbent assay (ELISA) was employed to measure insulin, C-peptide, 
and a pro-inflammatory cytokine interleukin-1β (IL-1β) concentration in the serum (Figure 3.8 C). 
Both insulin and C-peptide concentrations of PEG + drugs group were the highest when compared with 
those of control and control + drugs groups. The difference was significant (p < 0.05) for C-peptide 
concentrations between control (29.17 ± 5.89 pmol/L) vs. control + drugs (185.83 ± 48.32 pmol/L) and 
control (29.17 ± 5.89 pmol/L) vs. PEG + drugs (206.11 ± 52.10 pmol/L). On the other hand, the control 
group showed significantly higher (p < 0.05) concentration of the pro-inflammatory cytokine IL-1β 
(28.94 ± 9.72 pg/ml) than that of the PEG + drugs (0.27 ± 0.21 pg/ml) group. 
 
3.4    Discussion 
A major problem regarding islet encapsulation is the increased volume of encapsulated islets 
due to the thickness of the capsule itself. For example, the predominantly used encapsulation system, 
alginate encapsulation, increases the size of a single islet by several times, thus limiting choice of 
transplant route for clinical study [42]. Additionally, high diffusion barrier reduces islet viability and 
insulin sensitivity to glucose [4]. To address these issues, a thin coating system was sought to develop 
















Figure 3.7    The intraperitoneal glucose tolerance test (IPGTT). Diabetic mice (●, n=3), normal mice 
(■, n=3), PEG + drugs treated recipients (▲, n=4), and control + drugs treated recipients (▼, n=4). *p 


















Figure 3.8    Immunohistochemical analysis of the transplanted grafts. (A) H&E, insulin, glucagon, 
CD31, and (B) immune cells, such as, CD20+, CD11b+, CD8a+, and CD4+ staining. Black arrows point 
at the corresponding staining. (C) Insulin, C-peptide, and pro-inflammatory cytokine IL-1β 
concentrations were measured by enzyme-linked immunosorbent assay (ELISA) from the serum of all 
three recipient groups. Scale bar, 50 µm. *p < 0.05. 
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In this study, NHP islets were nano-shielded with a three layer of PEG system covalently 
grafted on islet surface in a layer-by-layer fashion. It was demonstrated that nano-shielded islets, 
administered along with an appropriate immunosuppressive drug protocol, can significantly achieve 
higher graft survival time than that of the naked islets. The first layer of the nano-shielding was formed 
by the chemical conjugation of SH-6-arm-PEG-NHS on the islet surface. Islets are naturally covered 
by a collagen layer which is almost entirely disrupted by the enzymatic digestion during isolation. This 
layer of collagen is replaced by a new one in several days of culture [43]. The N-hydroxysuccinimide 
(NHS) groups of SH-6-arm-PEG-NHS were reacted with the primary amines located on the collagen 
matrix, thereby forming a stable amide bond. The second layer was formed by the chemical conjugation 
of 6-arm-PEG-catechols on top of the first layer. A catechol, a side chain of 3, 4-dihydroxy-L-
phenylalanine (DOPA), is oxidized to quinone in alkaline condition (pH 8.0). The quinone groups of 
the 6-arm-PEG-catechol were then reacted with thiol groups of the first layer (SH-6-arm-PEG-NHS). 
Also, the activated quinones were reacted with other catechols or quinones of the 6-arm-PEG-catechol, 
thereby forming a multi-layered 6-arm-PEG-catechol [44, 45]. Finally, the third layer was formed with 
linear PEG-SH on the second layer by chemical reactions between the unreacted catechols of the second 
layer and the thiol groups of linear PEG-SH [46, 47].   
Islet encapsulation materials must fulfill two criteria: they must isolate islets from immune 
invasion and must not interfere with the diffusion of oxygen, nutrients, glucose and insulin [48]. 
Currently, alginate encapsulation has been the most famous immunoisolation technique [4]. Alginate 
encapsulation showed good viability and insulin secretory functionality in vitro as well as promising 
immunoisolation effects in rats [49, 50]. Nonetheless, alginate encapsulation cannot solve the diffusion 
barrier problem, since it increases the volume of islets by several folds of the actual volume of islets. 
As a result, clinical outcome was also poor in humans [42, 51]. It was thus necessary to develop 
encapsulation materials that are as thin as possible so that islet surfaces can be coated while ensuring 
greater efficiency in masking surface antigens. Nano-shielding by three-layers of PEGs can fulfill both 
of these goals. AFM imaging showed that the nano-shielding ranges less than one nano-meter in 
thickness, yet it completely eliminated the detrimental diffusion barrier. This nano-thickness of coating 
reduced protein adsorption on a collagen surface more significantly than on an uncoated collagen 
surface in vitro, confirming PEG compounds’ well-known property of decreasing nonspecific protein 
binding on its surface [52, 53]. The encapsulation system can hamper the diffusive transport of oxygen, 
nutrients and metabolites into the cell, resulting in the loss of cellular viability [54]. Also, it should be 
noted that neither cell encapsulation system nor materials used for it should alter cellular viability [55, 
56]. In this nano-shielding system, no degradation of viability in islets was observed. Moreover, insulin 
secretory capability, evaluated by GSIS, proved the intact function of islets upon nano-shielding. 
Contrastively, several conventional microencapsulation formulations showed delayed and impaired 
insulin secretion from islets due to high diffusion barrier [10, 57]. 
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After confirming in vitro parameters, nano-shielded as well as naked NHP islets were 
transplanted into the kidney subcapsular space of diabetic C57BL/6 mice. Kidney subcapsular space 
has several benefits as a route of transplantation over liver. The transplanted islets are accumulated in 
a specific place and can be removed easily for laboratory assessments. When transplanted into the liver, 
the islets are dispersed throughout the organ and it is hard to locate them at any exact place, making it 
difficult for further studies. An immunosuppressive drug protocol was administered to both groups of 
recipients. All the recipients of the PEG + drugs group maintained BGL below the normal range for 
150 days with 100% survival rate, compared with 50% of control + drug and 0% of control islet 
recipients. Tomei et al. reported that islets, when a conformal coating was applied with PEG hydrogel 
(coating thickness: a few tens of micrometers), maintained euglycemia over 100 days in syngeneic 
diabetic mice [21]. However, in case of xenotransplantation study or to enroll into clinical trials, islets 
encapsulated with PEGs would not sustain a long-term effect without simultaneous administration of 
immunosuppressive drugs [26, 32, 33]. Neither immunosuppressive drugs nor encapsulation 
technology alone can maintain a complete survival rate of transplanted graft, rather a combination of 
both is required. IPGTT showed well functional nano-shielded islets after 150 days of transplantation. 
Data shows that in the PEG + drugs recipients, BGL was raised immediately after glucose 
administration but lowered below the normal range within 2 h, whereas, the control + drugs recipients 
failed to maintain normoglycemia during this time period. Normal mice showed slightly higher BGL 
than the nano-shielded NHP islet recipients that proves different metabolic parameter for blood glucose 
in different species reported by Graham et al. [58]. Insulin secretory capacity in NHP-to-NHP function 
at much higher level than that in pig-to-NHP and human-to-human; for instance, the median fasting 
BGL in cynomolgus monkey (57 mg/dl) is lower than in pigs (99 mg/dl) and humans (95 mg/dl) [58, 
59]. In contrast, median fasting BGL in normal C57BL/6 mouse and in NHP-to-C57BL/6 mouse 
recipient were found at 76 mg/dl and, 28.5 mg/dl, respectively. 
Recipient immune reaction is known to be more aggressive to xenograft than to allograft, and 
results in rapid immune rejection due to the presence of preformed antibodies [60]. Moreover, 
xenogeneic T cell responses also do not allow long-term xenograft acceptance [61]. However, using the 
selected immunosuppressive drug protocol, the nano-shielded graft function was able to maintain up to 
5 months without observing any fluctuations in the BGL in the xenograft model. Immunohistochemistry 
with serum insulin, C-peptide and cytokine analysis revealed complete destruction of the naked islets 
by increased invasion of immune cells. Administration of the immunosuppressive drugs increased 
survival of naked islets, showing higher staining of insulin and glucagon with reduced immune cell 
infiltration in the transplanted grafts. On the other hand, PEG + drugs recipients exhibited the highest 
staining of insulin, glucagon and a few staining of immune cells. Healthy serum insulin and C-peptide 
levels were also observed with null IL-1b concentration in this group. The pro-inflammatory cytokine 
IL-1 activates T cells that result in the increased production of IL-2 and IL-2 receptor (IL-2R). Inhibition 
of T cells or selective prevention of IL-2/IL-2R interaction prolongs graft survival time [62, 63]. In a 
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previous study, it was demonstrated that healthy concentrations of insulin in serum can be attained from 
transplanted islets by lowering the secretion of IL-1β and tumor necrosis factor-α (TNF-α) 
concentration using appropriate immunosuppressive drugs [64]. SRL and TAC have been proven for 
their T cell inhibitory efficacy, and used as maintenance treatment in clinical transplantations. Both 
drugs, along with daclizumab, a humanized monoclonal antibody that inhibits the activation of T cells, 
are included in the ‘Edmonton protocol,’ which is still being developed and tested with modifications. 
In this study, instead of daclizumab, the combination of LFA-1 and MR-1 was used. A study 
demonstrated that a short-term administration of a combination of anti-LFA-1 and MR-1 antibodies 
induced tolerance and led up to 97.5% survival rate of xenotransplanted porcine islets in mice when 
monitored up to 150 days post-transplantation [65]. Also, a combined use of MR-1 and TAC with PEG 
nano-shielded islets demonstrated synergistic effects of immunoprotection. Jeong et al. showed a 100% 
survival rate of PEG nano-shielded rat islets, which were administered combined with TAC and MR-1 
and monitored for 50 days in mouse recipients. In contrast, MST of nano-shielded islets was only 21 ± 
1.9 days when TAC alone was used [32].  
Early graft loss is significantly higher in islet transplantation than in pancreas transplantation 
[66]. Significant inflammation has been observed at the transplanted site, characterized by the activation 
of complement and platelets, infiltration of leukocytes, and increased levels of pro-inflammatory 
cytokines, causing 60% graft destruction within 3 days post-transplantation [67-70]. To solve this 
problem, a recent study used drug agents, such as Cobra venom factor (CVF) and anti-TNF-α mAb in 
addition to anti-CD154 mAb, SRL, and anti-thymocyte globulin (ATG) as maintenance therapy [71]. 
The nano-shielding of islets cuts down the number of drugs used to reduce the initial loss. Nano-
shielding with PEG to the islet surface creates a barrier to prevent molecular recognition between cell 
surface receptors and soluble ligands. PEG nano-shielded islets cultured with cytokines for 7 days 
showed delayed damage compared to naked islets [27]. The PEG nano-shielded islets have shown 
reduced activation of splenocytes in co-culture [72, 73]. Tissue factors are the primary regulator of 
blood coagulation cascade, which is expressed by and released from β and α cells of islets [74, 75]. 
Islets transplanted into the liver release tissue factors, ultimately leading to blood coagulation [66]. It is 
imaginable that tissue factors on islet surface also get masked by the nano-shielding.   
In a previous study, it was shown that islet nano-shielding with PEG substantially reduced the 
dose of cyclosporine A below the clinical dose in rat-to-rat allotransplantation model [30, 76], hence 
reducing side effects and toxicity associated with immunosuppressive drugs. However, as an initial 
study on NHP islets, only establishing the LbL PEG nano-shielding technique was emphasized with a 
generalized dose of the glucocorticoid free immunosuppressive drug protocol. The future works will 
include changing of anchoring moieties on PEG molecules to nano-shield freshly isolated islets that 
lack collagen layer, changing of nano-shielding composition to get around inflammatory reactions 
(IBMIR), and nano-shielded NHP islet allotransplantation studies.  
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3.5    Conclusion 
In this study, PEG nano-shielded NHP islets were validated and transplanted along with an 
immunosuppressive drug protocol in a xenorecipient. Islet nano-shielded with the three-layer of PEGs 
showed less plasma protein adsorption on the collagen surface with unchanged viability and 
functionality In vitro. The diffusion barrier, owing to the nano-thin coating applied, was virtually absent, 
which improved the feasibility of clinical transplantation. Finally, the presence of accompanied 
glucocorticoid free immunosuppressive drug protocol increased the survival time of the nano-shielded 
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Effects of transplanted islets nano-shielded with hyperbranched 
polyethylene glycol and heparin on microenvironment reconstruction and 
glucose control 
 
4.1    Introduction 
Islet transplantation is a preferred treatment option in terms of invasiveness and 
immunogenicity over whole pancreas transplantation for treating T1DM [1]. However, it employs a 
suboptimal isolation technique and uses enzymes to digest extracellular matrix components of pancreas, 
all of which disrupts the islet microenvironment and results in inferior engraftment efficiency [2, 3]. 
Enzyme digestion includes several critical steps that involve factors such as digestion time, 
concentration of the enzyme, and temperature, and a small variation of these steps may result in poor 
isolation yield [1, 2]. For instance, a shorter digestion time and an improper collagenase composition 
would yield impure islets mixed with exocrine cells. On the other hand, a longer digestion time would 
increase the exposure of islets to the enzymes, resulting in low islet integrity due to disrupted cell-to-
cell adhesion and cell-to-matrix interaction [1, 2].  
Islets are miniature organs having numerous vasculature intracellularly [4]. The capillaries are 
essential for transporting glucose, nutrients and oxygen into the core of the islets, and for distributing 
insulin out of the islets into the blood stream [5]. Enzyme digestion, which is responsible for rupturing 
the blood vessels, therefore results in poor islet viability after transplantation. Several reports have 
shown, however, that islets regrow their vasculature after transplantation [6, 7], and attempts have been 
made to promote islets to regrow their vasculature prior to transplantation by VEGF gene delivery or 
co-encapsulating VEGF protein with islets [8, 9]. Besides causing poor islet viability, enzyme digestion 
poses another problem, the loss of peri-islet basal membrane, which induces islet apoptosis [10, 11]. To 
overcome this problem, the function and viability of ß-cells in the islet had to be enhanced by re-
establishing cell-to-matrix relationship before transplantation. This was done by using collagen and 
fibronectin in islet culture, which accelerated insulin release and reduced apoptosis [12]. However, the 
complete regrowth of vascular basal membrane before transplantation in vitro has been barely 
demonstrated, indicating that the process might be time consuming. This also contradicts the Edmonton 
protocol which proposed that the cold ischemic time should be reduced before transplantation [13].  
The peri-islet basal membrane, which helps cells to migrate, differentiate, and survive, is also 
found to act as a barrier against leukocyte infiltration [14], as indicated by higher levels of leukocytes 
found at the ruptured peri-islet basal membrane along with a loss of insulin positive cells during the 
progression of insulitis [15]. One of the ideas proposed by the Edmonton protocol was to transplant 
freshly isolated islets to minimize cold ischemia induced injury [13]. However, freshly isolated islets 
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might have a greater chance of immune rejection due to the loss of peri-islet basal membrane. The use 
of glucocorticoid free immunosuppressive drug protocol, also proposed in the Edmonton protocol, 
advanced the transplant outcome associated with immunogenicity, although it did not yield an 
impressive success rate in a long-term [13, 16]. A great amount of research has been conducted in 
pursuit of islet immunoprotection that can be applied at the precarious initial stage of transplantation 
without using immunosuppressive drugs. 
In the previous study, it was demonstrated that immunoisolated NHP islets with PEG 
employing layer-by-layer (LbL) nano-shielding method prolonged survival time in a mouse model 
when compared with naked islets (Chapter 3). The addition of a glucocorticoid free immunosuppressive 
drug protocol synergistically improved the survival rate up to 100% for 150 days with no rejection, in 
contrast to the 50% survival rate of naked islets [17]. Here, the nano-shielding efficiency was further 
improved by incorporating heparin into the LbL composition. It was hypothesized that LbL nano-
shielding with PEG and heparin will have a potential in reducing both IBMIR and immunogenesis.  
In this study, islet microenvironment was investigated in regulating BGL in the context of 
vascular basal membrane, cell-to-matrix relationship, and cell-to-cell interaction in a NHP-to-mouse 
xenotransplantation model. NHPs are a model of interest in preclinical studies as they are the 
phylogenetically and immunologically closest species to humans and can provide an understanding 
about human islets [18]. Here, a polymeric nano-shielding system composed of PEG and heparin was 
proposed to protect islets from the host’s innate and adaptive immune activation during the typically 
vulnerable early stage of transplantation. Nano-shielding is non-toxic to islets, can be done within a 
brief time duration and immediately after isolation without prolonging the cold ischemic time.  
 
4.2    Materials and methods 
4.2.1    Animals 
Two-year old male cynomolgus monkeys (Macaca fascicularis) were used as islet donors. 
Monkeys were supplied and maintained by Orient Bio Co. Ltd. (Seongnam, Korea). The guidelines of 
Institutional Animal Care and the Use Committee of Orient Bio Laboratories were followed to maintain 
the lifestyles and food habits of the animals. Eight-week old male C57BL/6 mice were used as recipients. 
They were induced diabetic by a single intraperitoneal injection of streptozotocin (STZ, Sigma, St. 
Louis, MO) and were considered as recipients when their blood glucose level became over 350 mg/dl 
for three consecutive days. All surgical procedures on the recipients were approved by the guidelines 
from the Institute of Laboratory Animals Resources of Seoul National University.  
 
4.2.2    Isolation of pancreatic islets 
The pancreas was removed from cynomolgus monkey and inflated with 3-4 ml of Liberase 
MTF C/T solution (Roche, Indianapolis, IN) per gram of pancreas. The swollen pancreas was chopped 
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and placed into a Ricordi chamber (BioRep Technologies Inc., Miami, FL). Temperature was raised to 
37 ºC and the chamber was gently shaken to start the digestion procedure. The samples were collected, 
stained by dithizone (DTZ; Sigma) and observed under a light microscope at different times throughout 
the digestion procedure to assess the state of digestion. The digestion was stopped by mixing phase II 
solution (Dilution solution, Corning, NY) with the digested tissue. Cells were collected and purified 
using a density gradient solution, Optiprep (Axis-Shield PoC AS, Oslo, Norway), in COBE 2991 
(Gambro BCT, Lakewood, CO). Finally, islets were washed twice with a culture medium CMRL 1066 
(Mediatech, Inc., Corning) supplemented with 10% fetal bovine serum (FBS, Atlas biologicals, Inc., 
CO) in a refrigerated centrifuge at 1400 RPM for 3 minutes and incubated at 37°C in a humidified CO2 
incubator. 
 
4.2.3    Synthesis of PEGs and heparin 
SH-6-arm-PEG-Lipid was synthesized using the two-step synthesis method as described 
previously [19]. Briefly, first, 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE, Avanti Polar 
Lipids, Inc., ALABASTER, AL) was added into a round bottom flask and dissolved in chloroform. 
Next, triethylamine (Sigma) and 3-maleimidobenzoic acid N-hydroxysuccinimide ester (MBS, Sigma) 
were sequentially added to the solution and sat overnight in an ice bath under nitrogen atmosphere. The 
product was freeze-dried to obtain Lipid-Mal. Then 6-arm-PEG-SH (SunBio, Korea) was reacted with 
Lipid-Mal in chloroform overnight under the same condition as the first step. Lastly, the reactant was 
dialyzed (MWCO 2 kDa, Spectra Por. SPECTRUM® LABORATORIES Inc. CA) and freeze-dried to 
obtain SH-6-arm-PEG-Lipid.  
6-arm-PEG-catechol was synthesized following the previously reported protocol [17]. Briefly, 
first, 3, 4-dihydroxyhydrocinnamic acid was dissolved in N, N-dimethylformamide (DMF, Sigma) and 
poured into a round bottom flask. Next, the following materials, N, N’-dicyclohexylcarbodiimide (DCC, 
Sigma), N-hydroxysuccinimide (NHS, Sigma), and 6-arm-PEG-NH2 (MW 15 kDa, SunBio) were also 
dissolved, respectively, in DMF and added to the flask. Finally, the reaction was continued overnight 
in an ice bath, and the products were purified by precipitation using cold diethyl ether (Sigma), followed 
by freeze drying.  
Heparin-SH was synthesized by reacting unfractionated heparin (Sigma) with 3-amino-1-
propanethiol hydrochloride (APH, Sigma). Unconjugated APH was precipitated out using cold ethanol 
and heparin-SH was obtained followed by freeze drying.  
Fluorescein isothiocyanate (FITC) was tagged to SH-6-arm-PEG-Lipid and heparin-SH by 
reacting them with Fluorescein-5-maleimide (Thermo Fisher Scientific, MA). FITC tagged 6-arm-PEG-
catechol was synthesized by reacting NHS-fluorescein (Thermo Fisher Scientific) with the previously 
synthesized 6-arm-PEG-catechol. All three materials were purified from the unreacted FITC by dialysis 
using a 2 kDa MWCO membrane (Spectra Por. Spectrum® Laboratories Inc.). 
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4.2.4    Islet nano-shielding and xenotransplantation 
After isolation, islets were cultured for 24 h before nano-shielding. Islets were washed twice 
with Hank’s balanced salt solution (HBSS, Sigma) and incubated for 1 h with 1% w/v of SH-6-arm-
PEG-Lipid, 2% w/v of SH-6-arm-PEG-catechol, and 2% w/v of heparin-SH dissolved in HBSS (pH 8), 
respectively. Islet coverage was evaluated by nano-shielding with FITC tagged materials at the same 
concentrations and duration as the corresponding untagged materials. Confocal laser scanning 
microscopy (CLSM, Carl Zeiss LSM710, Germany) was employed to detect the fluorescence intensity 
of FITC-tagged PEGs and heparin on islet surface. The resulting nano-shielded islets are referred to as 
PEG-Hep islet. 
The therapeutic potential of the PEG-Hep islets was observed by transplanting 4000 IEQ NHP 
islets into the kidney subcapsular space of C57BL/6 mice (n=8). The islet number was optimized at 
4000 IEQ/mouse after comparing blood glucose profiles of 500 IEQ, 1000 IEQ, 2000 IEQ and 4000 
IEQ transplanted recipients (Chapter 3) [17]. Body weight and blood glucose level (BGL) were 
measured daily using a glucometer (Super glucocard II, Arkray, Kyoto, Japan) until the animals were 
sacrificed. A previously reported in-house immunosuppressive drug protocol was applied to the 
recipients to prolong the survival time of the transplanted grafts until the animals were sacrificed 
(Chapter 3) [17]. The protocol involved administration of the following: tacrolimus (TAC, 0.20 mg/kg, 
Astellas Pharmaceuticals, Chicago, IL) daily after transplantation, sirolimus (SRL, 0.20 mg/kg, Sigma) 
until 14 days of transplantation, anti-LFA-1 antibody (0.20 mg/mouse, Bioxcell, West Lebanon, NH) 
at -1, 0, 1, 7 and 14 days of transplantation, and anti-CD 154 antibody (MR-1, 0.25 mg/mouse, Bioxcell) 
at -1, 0, 1, 3, 5, 7 days and weekly thereafter transplantation. Four recipients were sacrificed at 1st week 
and another four at 4th week of transplantation. The left kidney containing the transplanted graft was 
retrieved for the whole mount staining and immunohistochemical analysis.  
 
4.2.5    Whole-mount staining 
The extent of angiogenesis in the transplanted grafts was investigated at two different time 
points, at 1 week and 4 weeks of transplantation. First, transplanted sites were cut into small pieces of 
2 mm x 2 mm using a scalpel. These pieces were fixed in methanol containing 25% DMSO for 24 h at 
4 ºC, and washed with sterile PBS three times (30 min each time), followed by incubation in 5% BSA 
for 3 h for blocking. Then the resulting samples were incubated overnight in a blocking buffer (5% 
BSA in TBST) containing primary antibodies, anti-insulin (1:50, Abcam Inc., Cambridge, MA), and 
PE labeled anti-CD31 (1:50; Santa Cruz Biotechnology Inc., Santa Cruz, CA). The samples were then 
washed three times with TBST, and incubated with Alexa Fluor® 488 labeled goat anti-chicken antibody 
in blocking buffer. After washing for 3 h, the samples were stained with hoechst dye to stain the nucleus 
blue. Finally, the samples were fixed in the mounting medium and sealed with Pertex® (Medite, 
Germany) to prevent drying out. The entire washing and incubation process were carried out under 
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gentle agitation at 4ºC. CLSM images were taken to reveal the three-dimensional structure of the 
capillary networks surrounding the islets. The regions of interest (ROI) were drawn around the islets 
(n=5) and the average of total fluorescence intensity was calculated using ImageJ software (National 
Institutes of Health).  
 
4.2.6    Immunohistochemistry  
Immunohistochemical (IHC) analysis were performed using the standard protocol [31]. 
Antibodies used to stain transplanted sites were anti-insulin (1:1000; Novus biologicals, CO), anti-
collagen vi (Abcam Inc., Cambridge, MA), anti-integrin α1 (Abcam Inc.), and anti-connexin 36 (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA). All antibodies were diluted at the ratio of 1:100 unless 
mentioned otherwise. Mayer hematoxylin was used to counterstain the slides. The stained areas were 
quantified immunohisotochemically from the light microscope images at 200x magnification using 
ImageJ software. Insulin and collagen vi positive areas were quantified per field (n=5), and integrin α1 
and connexin 36 (Cx36) positive areas were quantified from 10 islets per mouse in each group. 
 
4.2.7    Cell viability assay 
Islet viability was assessed after PEG-Hep nano-shielding and complement activation study to 
quantify the viable cell number. For Live/Dead® viability/cytotoxicity kit assay (Molecular probes, Inc., 
OR), islets were first washed and suspended in 500 µl HBSS. Calcein AM and ethidium homodimer 
were then added to the cell suspension and incubated for 15 min, followed by washing three-times with 
HBSS. Islets examined under an Eclipse TS100 microscope (Nikon, Japan) revealed that dead cells 
were stained with red fluorescence and live cells with green fluorescence.  
Qualitative viability was determined by cell counting kit-8 assay (CCK-8, Dojindo Molecular 
Technologies, Inc., MD). 100 IEQ islets suspended in CMRL 1066 medium were incubated with WST-
8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium 
salt] at 37°C for 4 h under humidified atmosphere containing 5% CO2. Absorbance was observed at 
450 nm using a UV microplate reader. For normalization, the obtained values from the CCK-8 assay 
were divided by the values obtained from the DNA contents (Quanti-iTTM Picogreen® dsDNA reagent 
and kits, Molecular probes) of the islets in each well.  
 
4.2.8    Glucose-stimulated insulin secretion assay 
Glucose-stimulated insulin secretion (GSIS) assay consisted of culturing 100 IEQ islets in 1 ml 
of Krebs-Ringer bicarbonate buffer (KRBB; pH 7.4) with low (2.8 mM) glucose and high glucose (28 
mM) for 2 h, respectively. At a pre-determined time point, low and high glucose solutions were 
collected and checked for the concentration of secreted insulin using a human insulin ELISA kit 
(Mercodia, Upsala, Sweden). The stimulation index was determined by dividing the value of insulin 
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secreted in the high glucose solution by that secreted in the low glucose solution. 
 
4.2.9    Complement activation 
Blood was drawn from a cynomolgus monkey and allowed to clot for 20 minutes at room 
temperature. The serum was separated by centrifuging the blood at 2000 g for 10 minutes in a 
refrigerated centrifuge. Collected serum, or the supernatant, was filtered through a 0.22 µm syringe 
filter and used freshly for the complement activation assay. 100 IEQ islets from both control (naked 
islets) and PEG-Hep groups were cultured with 50% serum in CMRL 1066 medium. After one day, 
islet morphology was observed using an optical microscope (Eclipse TS100). The cell culture 
supernatant was collected to measure C3a concentration (monkey complement component 3a ELISA 
kit, Elabscience, MD). To assess the concentration of insulin released (human insulin ELISA kit, 
Mercodia, Sweden) and viability (CCK-8 and Live/Dead® viability/cytotoxicity kit assays), islets 
cultured in 50% serum in CMRL 1066 medium were compared with the islets that had been cultured 
only in the normal cell culture medium.    
 
4.2.10    Immune cell activation 
Spleen was dissected from cynomolgus monkeys, washed twice with HBSS and put in a cell 
strainer (70 µm, BD Biosciences, MA). The spleen was sliced into small pieces and tamped with a 
plunger from a 3-ml syringe against the strainer. HBSS was added to the strainer and single splenocytes 
were released through the pores of the cell strainer. The splenocytes were loaded into a 15-ml conical 
tube and treated with RBC lysis buffer (Sigma) for 3 minutes. Isolated splenocytes (1x107) were 
cultured with 300 IEQ islets (control and PEG-Hep) in 300 µl of CMRL 1066 medium supplemented 
with 10% FBS in a 48-well plate (Corning, NY) for 2 days. Cell number was counted using an optical 
microscope. Supernatant was collected from the cell suspension by centrifugation at 1400 RPM for 3 
minutes to assess pro-inflammatory cytokines, such as, interleukin-1 beta (monkey IL-1ß platinum 
ELISA, Bioscience, Austria) and tumor necrosis factor-alpha (monkey TNF-α, Elabscience).  
 
4.2.11    Statistical analysis 
Data were expressed as mean ± SEM. Statistical analysis was carried out by unpaired t-test or 
ANOVA one-way test. The results were considered significant when p values were less than 0.05.  
 
4.3    Results 
4.3.1    Loss of islet microenvironment during isolation delays engraftment after 
transplantation   
Islet isolation caused the basement membrane collagen in islets to rupture (Figure 4.1 A), 
leading to the loss of islets’ native microenvironment. IHC staining of the transplanted grafts showed 
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hampered insulin production after one week of transplantation (Figure 4.1 B). However, the 
transplanted islet restored its insulin production capability within a month. Insulin staining after 4 weeks 
of transplantation showed a significant increment (p < 0.01) in the insulin positive area at the 
transplanted site. 
It was anticipated that the islet vascular BM might have a direct correlation with insulin 
production and secretion. To confirm that, the whole mount immunofluorescence staining of the 
transplanted grafts was performed to stain blood vessel endothelial cells (CD31) at the transplanted site 
(Figure 4.2 A). Confocal laser scanning microscopy (CLSM) generated a three-dimensional view of 
the blood vessels in the transplanted microenvironment. Blood vascular endothelial cell staining was 
significantly lower after one week than at four weeks (p < 0.05). The sprouting of blood vessels was 
observed inside and around the transplanted islets after four weeks. The optical imaging of IHC staining 
with collagen VI showed growth of a thin layer of collagen encasing each individual islet after four 
weeks; in contrast, the microenvironment at one week showed less and scattered staining of collagen 
VI around the islets (p < 0.0001, Figure 4.2 B). A strikingly lower staining of integrin α1 was observed 
in grafts at one week than in those at four weeks (p < 0.0002, Figure 4.2 B). A gap junction protein, 
connexin 36 (Cx36), was stained to determine whether intercellular junctions were ruptured during the 
isolation process (Figure 4.2 B). The results showed no difference in the stained Cx36 at one or four 
weeks, consequently suggesting that only cell surface components, such as, receptors and vascular BM 
were ruptured during islet isolation while intercellular junctions were not hampered. Taken together, 
these data reveal a reciprocal relation between islet vascular BM, transcellular integrins, and insulin 
production in the transplanted microenvironment. Although islets lose their basement membrane matrix 
during the process of enzyme digestion, they regrow their components and recreate the 
microenvironment within four weeks when transplanted into the kidney subcapsular space. The results 
thus show that the regeneration of the microenvironment allowed transplanted grafts to promote insulin 
production and secretion. 
 
4.3.2    LbL PEG-Hep nano-shielding of islets  
The LbL PEG-Hep nano-shielding was formed on islet surface as described previously (Figure 
4.3) [17, 19]. The yield after PEG-Hep nano-shielding was 73 ± 3.1%. CLSM imaging was utilized to 
determine the optimum coverage concentrations for individual layers of fluorescence-tagged polymers 
(Figure 4.4-4-6). It demonstrated the uniformity and localization of the materials coated on the islet 
surface at the finally chosen concentrations for each layer. The core of the islet was not penetrated by 
the materials (Figure 4.7 A). As a result, the viability of the islets confirmed the non-cytotoxicity of 
the materials (Figure 4.7 B). The relative viability assessed by CCK-8 assay after nano-shielding was 














Figure 4.1    Characterization of islet surface collagen after isolation and correlated insulin expression 
after transplantation. (A) Immunocytochemistry (ICC) of islets stained for collagen VI revealed 
disrupted peri-islet basement membrane (BM) after isolation. (B) Immunohistochemical (IHC) staining 
of insulin to check for islet functionality after 1 and 4 weeks of transplantation; quantification of stained 















Figure 4.2    Immunohistochemical investigation of the transplanted grafts after 1 and 4 weeks of 
transplantation. (A) Comparison of angiogenesis in the transplanted grafts by whole mount staining. 
Samples were stained for insulin (green), blood vessel endothelial cells (red), and nuclei (blue). (B) 
IHC staining for collagen VI, integrin α1, and connexin 36 (Cx36), and quantification of the stained 







Figure 4.3    Synthesis of (A) SH-6-arm-PEG-Lipid, (B) 6-arm-PEG-catechol, and (C) heparin-SH. (D-
F) Layer-by-layer nano-shielding of islets with the materials. To form the first layer, the lipid moieties 
of SH-6-arm-PEG-Lipid anchor to the lipid bilayer of cell membrane by forming hydrophobic 
interaction. In alkaline condition (pH 8) the catechol groups of 6-arm-PEG-catechol (second layer) react 
with the thiol groups of SH-6-arm-PEG-Lipid (first layer) and heparin-SH (third layer) through Michael 





Figure 4.4    Simultaneous evaluation of coverage and viability for the SH-6-arm-PEG-Lipid (first 
layer) and 6-arm-PEG-catechol (second layer) to determine the optimum concentrations. To check for 
coverage of the first layer, islets were nano-shielded with 0.5%, 1%, 2%, and 4% w/v of FITC labeled 
SH-6-arm-PEG-Lipid. For second layer, 1%, 2%, and 4% w/v of FITC-labeled 6-arm-PEG-catechol 
were used with the above-mentioned concentrations of SH-6-arm-PEG-Lipid. Viability was checked 












Figure 4.5    Simultaneous evaluation of coverage and viability for the 6-arm-PEG-catechol (second 
layer) and heparin-SH (third layer). Islets covered with 1% w/v of SH-6-arm-PEG-Lipid + 1% or 2% 
w/v of 6-arm-PEG-catechol were encapsulated with three concentrations of FITC-labeled heparin-SH, 

























Figure 4.6    (A) Relative viability, and (B) glucose-stimulated insulin secretion test (GSIS) at different 























Figure 4.7    Characterization of PEG-Hep islets. (A) Confocal laser scanning microscopic images of 
FITC-labeled PEG-Hep (SH-6-arm-PEG-Lipid, 1%; 6-arm-PEG-catechol, 2%; FITC-Heparin-SH, 
2%). Viability checked for PEG-Hep islets in contrast to naked (control) islets by (B) live/dead 
viability/cytotoxicity, and (C) cell counting kit-8 (CCK-8/DNA, n=5) assays. (D) Glucose stimulated 
insulin secretion (GSIS) test at a low (□, 2.8 mM), and a high (■, 28 mM) glucose solution for 2 h (n=5). 








Statistically, however, there was no difference between the groups. Glucose stimulated insulin secretion 
(GSIS) assay was performed to confirm functionality (Figure 4.7 D). The stimulation index of control 
islets and PEG-Hep islets were 1.48 ± 0.23 and 1.63 ± 0.26, respectively, with no statistical differences 
between them (Figure 4.7 E). 
 
4.3.3    PEG-Hep nano-shielding inactivates the innate and adaptive immune systems 
To assess the immunomodulatory effect of PEG-Hep nano-shielding, both innate and adaptive 
immune responses were tested. For the complement activation study, islets were cultured with 50% 
monkey serum (Figure 4.8). Control islets showed distorted morphology when observed under a 
microscope (Figure 4.8 A). To confirm whether the morphological change of islets was caused by the 
activated complements, C3a level was quantified from the culture supernatant. A significantly higher 
level of C3a (p < 0.05 vs PEG-Hep) was found in the control group (Figure 4.8 B); in contrast, islets 
nano-shielded with PEG-Hep had reduced levels of C3a, and morphological distortion was not observed. 
The higher level of complement activation reduced insulin secretory capability of the control islets 
down to 6,380 ± 491 mU/L/day compared with the PEG-Hep islets at 15,173 ± 1608 mU/L/day (p < 
0.001, Figure 4.8 C). PEG-Hep islets in 50% serum showed a similar insulin secretion profile with the 
islets cultured in the normal cell culture medium. Viability was critically reduced for the control islets 
by the complement activity, as demonstrated by live/dead viability/cytotoxicity and CCK-8 assays 
(Figure 4.8 D, E). Viability for control islets and PEG-Hep islets were 52 ± 23% and 78 ± 35% (p < 
0.01), respectively, when compared with the control islets cultured in the normal cell culture medium 
(100 ± 5.02%, Figure 4.8 E).  
Adaptive immune response was evaluated by co-culturing islets with splenocytes, where the 
number of naked islets was reduced by half (53.04 ± 1.76%, Figure 4.9 A). Contrastively, PEG-Hep 
islets retained their number up to 91.67 ± 2.58% (p < 0.0002 vs control + splenocyte). To find out why 
this islet damage occurred, pro-inflammatory cytokine levels were quantified in the cell culture 
supernatant (Figure 4.9 B, C). Both IL-1ß (p < 0.05) and TNF- α (p < 0.005) concentrations were 
significantly higher in the control group than in the PEG-Hep group.  
 
4.3.4    PEG-Hep islets are functional in vivo 
PEG-Hep nano-shielded NHP islets were transplanted in the kidney subcapsular space of 
diabetic C57BL/6 mice (n=8, Figure 4.10 A). To investigate the transplanted microenvironment of 
hyperglycemia (1 week) and normoglycemia (4 weeks), recipients were sacrificed at 1 week (n=4) and 
4 weeks (n=4) of transplantation. For the recipients sacrificed at 4th week, normoglycemia was restored 
at 13 ± 1.68 day (mean ± SEM) post-transplantation and BGL was maintained below 200 mg/dl until 
the day of sacrifice. A stable BGL with an increase in body weight (data not shown) at 3rd and 4th week 











Figure 4.8    Protection of PEG-Hep islets from the cytotoxic effects of activated complements. (A) 
Morphological change of control islets observed by optical imaging when cultured in 50% monkey 
serum for 24 h. (B) C3a concentration (n=5), (C) insulin content (n=5) and viability checked by (D) 
live/dead viability/cytotoxicity, and (E) cell counting kit-8 (CCK-8/DNA, n=5) assays for the control 
and PEG-Hep islets cultured in normal cell culture medium and 50% monkey serum. *p < 0.05, **p < 
























Figure 4.9    Effects of adaptive immunity when islets (control and PEG-Hep) were co-cultured with 
splenocytes for 48 hours. (A) Reduction of islet number (n=3) by the immune cells. Quantification of 
secreted cytokines, (B) IL-1ß, and (C) TNF-α in the co-culture supernatant (n=5). *p < 0.05, **p < 























Figure 4.10    (A) Non-fasting blood glucose (NBG) level of the transplanted recipients. Four recipients 
were sacrificed after one week (■) and the rest four after four weeks (●) of transplantation for graft 
microenvironment analysis. (B) H&E staining of the transplanted grafts. (C) Illustration for the re-









In the previous study, the survival time for LbL PEG nano-shielded NHP islets in C57BL/6 
mice was found to be 26 ± 5.21 days without the application of any immunosuppressive drug protocol 
(Chapter 3) [17]. In the current study, to promote graft survival time up to 4 weeks, an 
immunosuppressive drug protocol was administered to the transplant recipients. Hematoxylin and eosin 
(H&E) staining demonstrated the stable engraftment of islets at the transplanted site with intact 
morphology and no lymphocyte infiltration (Figure 4.10 B).  
 
4.4    Discussion 
It has been showed that a high BGL in the first few days of transplantation is associated with 
the loss of islet vascular BM and cell-to-matrix interaction (Figure 4.10 C). In this work, the whole 
mount staining of islets in the hyperglycemic condition (at 1 week post-transplantation) revealed a lack 
of vascular network in the transplanted graft. This lack of vascular BM and cell surface integrins caused 
the transplanted grafts to remain in defenseless condition for about 2-3 weeks. When the vascular 
network is disrupted, as in this case, islets survive on the diffusion of oxygen and nutrients from the 
surrounding tissue and nearby blood vessels [20]. In the highly vascular organs, as in the liver, 
transplanted islets find sufficient bathing with nutrition by diffusion, but islets transplanted to the kidney 
subcapsular space are deprived of this privilege. The subcapsular space in the kidney has a 
comparatively lower blood supply than that in the liver, and its microenvironment is not oxygen rich 
[21]. Therefore, a high diffusion barrier hampers blood glucose regulation in the recipients until the 
grafts regrow their own vascular networks. After transplantation, islets regrow their vasculatures by 
secreting vascular endothelial growth factors (VEGF) and its receptors to promote vascularization from 
the surrounding tissues [22]. VEGF-A knockdown islets possess lower vascular networks and therefore 
show defective ß-cell functions, such as, insulin transcription, insulin content and insulin secretion [23]. 
However, the reformation of vascular network leads to simultaneous regrowth of collagen, and together 
they shape the vascular BM within the transplanted graft. In this work, the regrowth of integrin α1 was 
also observed in the graft during the reformation of the vascular BM. It indicates that the vascular BM 
with the cell surface receptors and integrins worked co-operatively to promote insulin expression and 
regulate BGL.  
Intracellular gap junctions play another important function in insulin secretion. Cx36 gap 
junctions strongly attach ß-cells within islets and help insulin oscillation synchronization between the 
adjacent ß-cells by way of electrical coupling [24]. Cx36 knocked out mice have also shown reduced 
insulin secretion by glucose stimulation [25]. In this work, however, Cx36 was found at similar levels 
in the initial and later stages of transplantation, proving that enzyme digestion only affects extracellular 
components, such as, vascular BM or surface receptors, but not intracellular Cx36 gap junctions.  
Following the investigation on islet microenvironment, it was found that islets remain in 
vulnerable condition for the first few days of transplantation since their native microenvironment is 
disrupted. However, while the disrupted microenvironment is being restored, islets have to survive 
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against the inflammatory reactions (IBMIR) and immune activation of the host body. As a result, the 
early graft loss is one of the major obstacles in clinical studies [26]. Islets transplanted through the 
portal vein initiates IBMIR, which is characterized by complement activation, blood coagulation, and 
platelet activation. In the next study, it will be shown that nano-shielding with PEG-Hep reduces the 
propagation of IBMIR in NHP allorecipients (Chapter 5). In the present study, it is argueed that this 
system has a potential to reduce both innate and adaptive immune systems. In the complement activation 
study, naked islets showed a morphological distortion with the loss of viability and insulin content 
(Figure 4.8). This was because a central step in the complement activation involves the cleavage of C3, 
which causes the release of C3a and C5a, and a high concentration of C3a surrounding islets. 
Consequently, lymphocytes generate a variety of inflammatory reactions [27]. PEG-Hep nano-shielding 
reduced complement activation, and resulted in the retention of islet potentials. Furthermore, PEG-Hep 
islets co-cultured with splenocytes generated less pro-inflammatory cytokines, IL-1ß and TNF-α than 
the control islets, leading to significantly lower islet damage (Figure 4.9). Importantly, the nano-
shielding system itself did not cause any injury to the cells and the cell functionality remained 
unchanged, verifying the non-cytotoxicity of the materials (Figure 4.7).  
The BGL of the diabetic recipients was not altered immediately albeit with a sufficient number 
of PEG-Hep islets. High BGL persisted for 2-3 weeks until the vascular BM and cell-to-matrix 
interactions were regenerated. Afterwards, a stable BGL was observed until sacrifice (4th week). A 
specified immunosuppressive drug protocol was applied merely to maintain the graft survival up to four 
weeks. In the previous study, a similar profile of BGL was observed, which was slightly below the 
normal range for a mouse model with a three-layer PEG nano-shielded on islets using the similar drug 
protocol [17]. The number of transplanted islets for this study was 4000 IEQ per recipient, which was 
roughly 10 times higher than that for the rat-to-mouse model [28, 29]. Below this transplanted islet 
number, normoglycemia was not achieved in mouse recipients [17]. Therefore, 4000 IEQ was chosen 
as an optimum dose for this xenotransplantation study. One explanation for the subnormal BGL could 
be a different metabolic parameter of blood glucose in different species [30]. A median fasting BGL 
was observed in a C57BL/6 mouse at 76 mg/dl, whereas, NHP-to-C57BL/6 mouse recipients 
demonstrated at 28.5 mg/dl [17]. However, the recipients were fit with an increase in body weight 
indicating a decent graft function. Histological analysis also revealed healthy engrafted islets at the 
transplanted site with no lymphocyte infiltration. 
 
4.5    Conclusion 
This study summarizes the microenvironment of NHP islets after transplantation, and the 
regulation of BGL in relation with vascular BM and cell-to-matrix interaction. It has been showed that 
islets remain in delicate condition in the first few days of transplantation when they need extra support 
for survival from immunogenic attack. The PEG-Hep nano-shielding provided such support to the islets 
by hindering innate and adaptive immune activation whilst islets regrow their microenvironment. The 
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nano-shielding procedure is simple and short. Therefore, in clinical settings, this process can be applied 
as an immunoisolation technique simultaneously with current immunosuppressive drug protocols to 
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Allotransplantation of polymeric nano-shielded islets with polyethylene 
glycol and heparin in a non-human primate model 
 
5.1    Introduction 
Although islet transplantation is a desirable treatment option that improves the general quality 
of life for T1DM patients, post-transplant insulin-independence lasting more than 24 months is often as 
low as 24%, making its clinical efficacy non-ideal [1]. The following obstacles must be overcome in 
the current clinical setting to achieve a successful clinical outcome: a suboptimal islet isolation 
technique that prevents a consistent and effective maximal islet yield [2-4], the IBMIR which 
immediately leads to islet loss after intraportal transplantation [5], diabetogenic side effects caused by 
the immunosuppressive drugs [6, 7], and an absence of effective biomarkers for the early detection of 
graft rejection. Nevertheless, islet transplantation is less invasive and is associated with lower surgical 
morbidity compared to pancreatic transplantation, making it a favorable treatment option for T1DM 
patients [8].  
Various immunosuppressive regimen combinations have been used for islet transplantation to 
improve graft survival, including co-stimulatory pathway blockade and steroid-free regimens to 
eliminate diabetogenic drugs [9-13]. Research efforts have also been made to avoid direct contact 
between islets and recipient blood or to evade immune reactions against the islet graft; these include 
islet encapsulation and alternative transplantation sites [14-16]. However, all immunosuppressant drug 
types are associated with adverse effects. Encapsulation techniques may lead to islet loss, and 
alternative transplantation sites are not applicable in the clinical setting.  
Here, using surface modification technique, islets were encapsulated with polymers, including 
PEG and heparin. This encapsulation procedure is referred to as ‘nano-shielding’ because of the nano-
thickness of the capsule around the islets. Islet nano-shielding with polymers via chemical modification 
is an immunoisolation method in which the diffusion barrier is eliminated while protecting the islets 
from the host immune response. When compared with alginate encapsulation method, nano-shielding 
improves islet viability by reducing diffusion barrier and makes it feasible for transplantation via the 
portal vain in clinical applications [17-20]. PEG is a standard reagent that renders islets non-
immunogenic for transplantation studies [23]. When shielded with PEG, islets demonstrate higher 
survival rates than unmodified islets in rodents [24]. Additional surface modifications to the outermost 
layer with unfractionated heparin (PEG-Hep) may attenuate the IBMIR that occurs during intraportal 
islet transplantation [25, 26]. Unfractionated heparin is a potent thrombin inhibitor and reduces platelet 
and complement activation [23]. 
PEG nano-shielded islets clearly demonstrate prolonged survival times in recipients compared 
with unmodified islets (Chapter 2-4) [20, 27].  However, longer survival times require that recipients 
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also receive immunosuppressive drugs [20, 24, 26]. The joint administration of islets whose surfaces 
are modified with both PEG and heparin, and immunosuppressive drugs demonstrates synergy and has 
significantly improved transplantation outcomes in numerous allo- and xeno-recipients [24, 26, 27]. 
Various immunosuppressive regimen combinations have been used in islet transplantation studies to 
improve graft survival, including steroid-free regimens, co-stimulatory pathway blockade and the 
elimination of diabetogenic drugs [9-13]. However, further evaluation of the efficacy of polymeric 
nano-shielded islet transplantation in non-human primate (NHP) models is necessary to pursue clinical 
trials in human patients. 
NHP model was adapted in this study because they resemble humans phylogenetically and 
immunologically. Diabetic cynomolgus monkeys were transplanted with PEG and PEG-Hep nano-
shielded islets via the portal vein. Graft survival was prolonged by depleting T cells and B cells using 
a rabbit anti-thymocyte globulin antibody and an anti-CD20 monoclonal antibody, respectively, to 
induce immunosuppression. Additionally, anti-inflammatory agents, including etanercept (a tumor 
necrosis factor (TNF) inhibitor) and anakinra (an interleukin (IL) 1 receptor antagonist), were 
administered. Tacrolimus (FK506) and mycophenolate mofetil (MMF) were given as maintenance 
immunosuppression, following the standard regimen used in the local clinical setting. It was 
hypothesized that the application of this combinatorial strategy comprising polymeric nano-shielding 
and immunosuppression would prolong graft survival in the T1DM NHP model (Figure 5.1). 
 
5.2    Materials and methods 
5.2.1    Non-human primate model 
All cynomolgus monkeys (Macaca fascicularis) were supplied by Orient Bio Co. Ltd. 
(Seongnam, Korea). They were screened and found to be negative for tuberculosis, herpes B virus, 
simian T cell leukemia virus, simian retrovirus, simian immunodeficiency virus, measles, cynomolgus 
cytomegalovirus, and simian varicella virus by Zoologix (Chatsworth, CA, USA). Subjects were 
maintained in separate cages. Water was supplied ad libitum, and biscuits were provided twice daily 
(Certified Primate Diet 5048*, LabDiet, St Louis, MO, USA). Fresh fruits, vegetables, and nuts were 
also provided twice daily. Various toys, music and visual entertainment were provided as part of an 
enrichment program. Subjects were maintained at 25 ± 2°C and 40-60% humidity with 1-5 mmHg 
positive pressure air conditioning and a 12-h 300 lux illuminance alternation cycle. System maintenance 
and animal care were performed according to the standard operating protocol at Orient Bio. All animal 






5.2.2    Induction and management of diabetes mellitus 
Subtotal pancreatectomies and splenectomies were performed to induce diabetes mellitus and 
to procure islets. No food or drink was provided 12 h prior to surgery. After intramuscular injections 
with 10 mg/kg ketamine, subjects were intubated with 4.0 to 4.5 Fr endotracheal tubes, and general 
anesthesia was induced with 3-5% isoflurane. Subjects were maintained under anesthesia with 1-2% 
isoflurane, nitrous oxide and oxygen. Prophylactic intravenous antibiotics (20 mg/kg cefazolin sodium) 
were administered at the time of the skin incision, and 60 mg/kg streptozotocin (STZ, Sigma, St. Louis, 
MO, USA) was intravenously administered immediately after the subtotal pancreatectomy and 
splenectomy. Islets were isolated from resected pancreatic specimens and transplanted into other 
diabetes-induced animals. Analgesics were administered for 3 days after surgery with 3 daily injections 
of 2 mg/kg tramadol or 0.5 mg/kg ketorolac. Feeding was initiated the following day, beginning with 
water as part of a gradual return to the regular diet. All subjects were able to tolerate food during the 
postoperative period. 
T1DM diagnosis was made when all three of the following criteria were satisfied: (1) sustained 
hyperglycemia (blood glucose level >250 mg/dl), (2) fasting NHP C-peptide level below 0.5 ng/ml or 
less than one-third of the pre-induction level, and (3) the absence of a stimulated C-peptide response in 
the intravenous glucose tolerance test (IVGTT). Serum C-peptide was measured with a 
radioimmunoassay kit that was developed for human plasma (C-peptide IRMA kit; IMMUNOTHECH, 
Beckman Coulter, Prague, Czech Republic), which exhibits a 90% cross-reactivity with cynomolgus 
monkeys. IVGTT was performed after 12 h of fasting. After sedation with ketamine, three blood 
samples were drawn for C-peptide and blood glucose measurements, and 0.5 g/kg dextrose was 
intravenously administered. Blood samples were drawn at 1, 3, 5, 7 and 10 min. Blood samples were 
also drawn at 15, 20, 25, 30 and 60 min to measure the glucose disappearance rate. The acute C-peptide 
response (ACR) was calculated as the difference between the mean C-peptide level after glucose 
infusion and the baseline C-peptide. The glucose disappearance rate (KG%/min) was calculated as the 
slope of the decline in the log-transformed blood glucose value between 10 and 30 min [62].  
Once T1DM was successfully induced, blood glucose levels were checked 3 to 4 times per day 
and maintained below 200 mg/dl with insulin (glargine: Lantus®; Sanofi-Aventis, Bridgewater, NJ, 
USA and glulisine: Apidra®, Sanofi-Aventis). Body weight measurements and physical examinations 
were performed at regular intervals. The following blood hematological parameters were also regularly 
checked: white blood cell counts (WBCs) (by performing differential counts), hemoglobin (Hb), 
hematocrit and platelet counts, and levels of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, blood urea nitrogen (BUN), 
creatinine, albumin, globulin, sodium, potassium, chloride, calcium, inorganic phosphorus, cholesterol, 
triglyceride, amylase and c-reactive protein. 
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5.2.3    Islet isolation and functional assay  
The pancreas was dissected and placed in histidine-tryptophan-ketoglutarate solution 
(Custodiol HTK, Köhler Chemie GmbH, Bensheim, Germany) solution at 4°C. After transferring to a 
clean bench, the pancreas was distended with 3-4 ml of a cold Liberase MTF C/T solution (Roche, 
Indianapolis, IN) per gram of pancreas. Islet isolation was performed according to a modified Ricordi 
method. The distended pancreas was placed into an isolation chamber, whose temperature was raised 
to 37°C using a peristaltic pump. During digestion, the isolation chamber was gently shaken, and serial 
samples were observed by light microscopy after dithizone staining (DTZ, Sigma, St. Louis, MO) when 
the temperature in the chamber reached 37°C. The enzymes were inactivated when free circulating islets 
were observed in the phase II solution (Dilution solution, Corning, NY) by microscopy. The digested 
cells were collected into 200-ml conical tubes with washing solution. The collected cells were preserved 
for 1 h in HTK solution before purification. Islets were purified using a continuous density gradient 
consisting of HTK solution and iodixanol (OptiprepTM, Axis-Shield PoCAS, Oslo, Norway) in a 
COBE 2991 cell processor (COBE BCT, Lakewood, CO). After purification, islets were counted and 
cultured in CMRL1066 medium (Corning, NY) with 10% FBS at 37°C in a 5% CO2 incubator. Aliquots 
(0.5 ml) were collected before and after purification and prior to 72-h culture. The islet quantity was 
determined by calculating the islet equivalents number (IEQ), which involved obtaining the number of 
islets that were an average size of 150 mm after staining with DTZ. The ratio of IEQ to the number of 
islet cells was calculated as the isolation index. 
 
5.2.4    Synthesis of PEGs and heparin  
The 6-arm-PEG-NHS was synthesized by reacting 6-arm-PEG-SH (SunBio, Korea) with 3-
maleimidobenzoic acid N-hydroxysuccinimide ester (MBS, Sigma) in dimethylformamide (DMF, 
Sigma). The reactant was purified via precipitation in distilled water. FITC-labeled 6-arm-PEG-NHS 
was obtained by reacting MBS with previously synthesized FITC-6-arm-PEG-SH. 6-arm-PEG-catechol 
was synthesized by sequentially adding 3,4-dihydroxyhydrocinnamic acid (DHCA, Sigma), N, N’-
dicyclohexylcarbodiimide (DCC, Sigma), N-hydroxysuccinimide ester (NHS, Sigma), and 6-arm-PEG-
NH2 (SunBio) into the reaction flask for dissolution in DMF. The reaction was carried out overnight, 
followed by precipitation in cold diethyl ether. FITC labeling was performed by reacting 6-arm-PEG-
catechol with NHS-fluorescein (Thermo Fisher Scientific, MA), followed by dialysis for purification. 
Thiol groups were incorporated into the unfractionated heparin by reacting heparin (Sigma) with 3-
amino-1-propanethiol hydrochloride (APH, Sigma) in water at pH 5. Purification was performed by 
precipitating in ethanol. FITC-labeled heparin-SH was synthesized by reacting fluorescein-5-maleimide 
(Thermo Fisher Scientific) with heparin-SH and purifying by dialysis. NHS-fluorescein (Thermo Fisher 
Scientific) was reacted with NH2-linear PEG-SH (Laysan Bio, Inc., AL) to synthesize FITC-labeled 
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linear PEG-SH, followed by dialysis purification. All reactions were performed overnight under a 
nitrogen atmosphere in ice baths. The purified reactants were freeze-dried to obtain the final products. 
 
5.2.5    Nano-shielding of islets with PEGs and heparin 
Three days after isolation, the islets were washed with HBSS (pH 7.4). Islets were divided into 
two groups and prepared for surface modifications as follows: (1) islets with three PEG layers, referred 
to as PEG islets, and (2) islets with two PEG layers and one heparin layer, referred to as PEG-Hep islets. 
To form the first shielding layer, islets were incubated in 6-arm-PEG-NHS dissolved in HBSS (pH 8) 
at 37ºC in a humidified atmosphere that contained 5% CO2. After 1 h, islets were washed twice with 
HBSS (pH 7.4) to remove residual PEG. The second layer was similarly shielded with 6-arm-PEG-
catechol. The third layer was formed with linear-PEG-SH or heparin-SH for the PEG and PEG-Hep 
nano-shielding, respectively. The optimal material concentration for each layer was determined after 
assessing the islet surface coverage by each material and the islet viability at each concentration. Islets 
that were covered with different concentrations of FITC-tagged materials were visualized by confocal 
laser scanning microscopy (CLSM, Carl Zeiss LSM710). The optimum concentrations were determined 
to be 0.5% w/v 6-arm-PEG-NHS, 1% w/v 6-arm-PEG-catechol, 0.5% w/v linear-PEG-SH and 0.5% 
w/v heparin-SH. 
 
5.2.6    Viability and functionality of PEG-Hep islets  
Qualitative islet viability was assessed with a live/dead viability and cytotoxicity assay kit 
(Molecular Probes, Eugene, OR). Immediately following the polymeric nano-shielding procedure, islets 
from the control (unmodified islets), PEG, and PEG-Hep groups were incubated in 2 µl of 50 µM 
calcein AM and 4 µl of 2 mM ethidium homodimer (EthD-1) for 15 min. Islets were washed, and the 
fluorescence intensities of calcein in the live cells (green) and EthD-1 in the dead cells (red) were 
examined. Islet viability was quantitatively verified using a cell counting kit-8 assay (CCK-8, Dojindo 
Molecular Technologies). One hundred IEQ islets from each group were placed into 96-well plates (n 
= 5 for each group), and 10 µl of WST-8 solution was added to the cell suspension. After incubating 
for 4 h, UV absorbances were measured at 450 nm to quantify the formazan produced by live islet 
metabolic activity. CCK-8 assay-based values were normalized to the islet DNA quantity in each well 
using the Quanti-iTTM Picogreen® dsDNA kit (Invitrogen). Islet functionality was assessed by 
incubating control, PEG, and PEG-Hep islets in high (28 mM) and low (2.8 mM) glucose solutions for 
2 h. The secreted insulin concentration upon glucose stimulation was measured using a human insulin 
ELISA kit (Mercodia, Uppsala, Sweden). The insulin concentrations at the high glucose level were 




5.2.7    Surface characterization and platelet adhesion on PEG-Hep nano-shielded 
surfaces in vitro 
 Collagen glass plates were hydrated with PBS for 1 h at room temperature. Then, 0.5% w/v 6-
arm-PEG-NHS, 1% w/v 6-arm-PEG-catechol, and 0.5% w/v linear PEG-SH or 0.5% w/v heparin-SH 
were separately dissolved in HBSS (pH 8) and sequentially added to previously hydrated collagen glass 
plates for 1 h with rinsing between each round of material application. The surface roughness and 
thickness upon grafting were evaluated by AFM imaging (XE-100 AFM) of the dry and wet (additional 
1-h incubation in PBS prior to AFM imaging) states. Platelet-rich plasma (PRP) was obtained from the 
cynomolgus monkeys, and 3.8x108 platelets/µl were added to the collagen (control, n = 5) and PEG-
Hep nano-shielded collagen (PEG-Hep surface, n = 5) surfaces for 1 h. This was followed by rinsing, 
fixing, dehydration and freeze-drying. Activated platelets were imaged with a Field-Emission Scanning 
Electron Microscope (Sigma, Carl Zeiss). Quantification was performed based on 30 representative 
areas from 5 samples. 
 
5.2.8    Complement activity on PEG-Hep islet 
Serum was collected from the whole blood of each cynomolgus monkey. One hundred IEQ 
islets from the unmodified (control) and PEG-Hep groups were cultured in 50% serum in CMRL 1066 
medium (Corning) for 1 day. Islet morphology was observed by phase-contrast microscopy (Nikon), 
and viability was quantified with the CCK-8 assay. The C3a concentration was measured from the cell 
culture supernatant using a Monkey C3a ELISA kit (Elabscinece). Islets were washed and incubated 
for one additional day in CMRL 1066 to check the released insulin concentration in the cell culture 
supernatant using a human insulin ELISA kit (Mercodia). 
 
5.2.9    Immune cell activity on PEG-Hep islet 
The spleen from cynomolgus monkey is dissected, chopped, and put in a 70 µm cell strainer 
(BD Biosciences, MA). A syringe plunger is used to tamper the spleen against the strainer. Collected 
splenocytes were treated with RBC lysis buffer (Sigma) for 3 minutes and washed with HBSS. Islets 
from control and PEG-Hep groups were cultured with 1x107 splenocytes in CMRL 1066 medium 
(Corning) for 2 days. Islet number was counted by phase-contrast microscopy (Nikon). Interleukin-1 
beta concentration was measured from the cell culture supernatant using an ELISA kit (monkey IL-1ß 
platinum ELISA, eBioscience, Austria). 
 
5.2.10    Activated Partial Thrombosis Time (APTT) assay 
Activated partial thrombosis time (APTT) is a useful assay to monitor the anticoagulant activity 
of heparin. This assay was utilized to determine the concentration of heparin that was coated onto the 
islet surface. Plasma was derived from the whole blood of each cynomolgus monkey. One thousand 
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IEQ of PEG-Hep islets were mixed with 50 µl of plasma and incubated for 1 min at 37ºC. Fifty 
microliters of APTT reagent (HemosIL) was added to the plasma and incubated for 4 min. Fifty 
microliters of 0.025 mol/l calcium chloride was then added, and the time required for clot formation 
was measured. A standard curve was constructed with different concentrations of heparin in the plasma. 
The unknown concentration of heparin that was shielded on the islet surface was calculated based on 
the values obtained from the standard curve.  
 
5.2.11    Islet transplantation and perioperative management 
Seventeen cynomolgus monkeys underwent allo-islet transplantations as follows: (1) two 
subjects received uncoated islets (control), (2) five subjects received PEG nano-shielded islets with 
specified immunosuppressive drugs, and (3) ten subjects received PEG-Hep nano-shielded islets with 
specified immunosuppressive drugs, of which five recipients also received rituximab (PEG-Hep + 
Rituximab). There were no age or body weight differences between the three groups. Transplanted islets 
were administered at 10,000 – 20,000 IEQ/kg in the control and PEG groups and 9,000-15,600 IEQ/kg 
in the PEG-Hep group (Table 5.1). 
Under general anesthesia, a tunneled implantable venous access port was inserted via the right 
internal jugular vein. Drugs and fluids were delivered through this access line, which was also used to 
induce immunosuppression with immunosuppressive agents. With a central venous line in place, 5 
mg/kg rabbit anti-thymocyte globulin (rATG, Genzyme, Cambridge, MA) was administered in 
combination with 20 mg/kg hydrocortisone over 5 min and 2 mg of pheniramine to prevent 
hypersensitivity reactions against rATG. All subjects received rATG 4 times over 12-h intervals up to 
a cumulative dose of 20 mg/kg to induce immunosuppression. Five recipients in the PEG-Hep group 
additionally received 375 mg/m2 injections of the rituximab anti-CD20 monoclonal antibody 
(MabThera, Roche Pharma, Schweiz). A laparotomy was performed, and the portal vein was isolated. 
An 18-gauge angiocatheter was inserted into the portal vein. Islets mixed with 75 IU/kg heparin were 
slowly infused through the angiocatheter into the portal vein over 10 min. After the islet infusion, the 
angiocatheter was drawn, and the puncture hole was closed using 6-0 prolene sutures. The laparotomy 
was closed, and the subject was returned to its cage after fully awakening from anesthesia. 
After islet infusion, 1 mg/kg enoxaparin was subcutaneously administered for 7 days. 
Etanercept (TNF inhibitor) was administered on the day of transplant (day 0), day 3 and day 6. 
Subcutaneous injections of anakinra (IL-1 receptor antagonist) were administered daily from day 0 to 
day 7. The immunosuppression maintenance regimen included orally administered tacrolimus with a 
target trough level of 5-10 µg/ml and orally administered mycophenolate mofetil (MMF) with a target 
trough level of 1-3 µg/ml (Figure 5.1). 
Tramadol was used to control surgical site pain for 3 days after transplantation. Cefazolin was 
administered as a prophylactic antibiotic. For prophylaxis against CMV reactivation, 5 mg/kg 
ganciclovir was administered for 2 weeks. CMV antigenemia was also routinely monitored during this 
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period. Appetite, urination, defecation and physical activity were closely monitored. Blood was drawn 
two times per week for two weeks and once per week thereafter for hematologic and serum chemistry 
tests (2 ml), lymphocyte subset analyses (2 ml), tacrolimus, mycophenolic acid drug levels (1.4 ml) and 






































Table 5.1    Summary of experiments, including islet dose, induction agents and survival times 
 










Control 1 41 M 4.0 10000 ATG 56 
Control 2 50 M 4.2 10000 ATG 27 
Control 3 51 M 4.6 20000 ATG 93 
Control 4 44 M 3.5 20000 ATG 98 
PEG 
PEG 1 79 F 2.9 10000 ATG 49 
PEG 2 78 F 3.4 10000 ATG 98 
PEG 3 57 M 5.4 10000 ATG 90 
PEG 4 89 M 6.1 10000 ATG 35 
PEG 5 33 F 3 10000 ATG 48 
PEG-Hep 
PEG-Hep 1 60 M 4.2 10000 ATG 74 
PEG-Hep 2 58 M 4.1 13600 ATG 172 
PEG-Hep 3 57 M 3.7 13500 ATG 97 
PEG-Hep 4 67 M 4.6 10500 ATG 151 
PEG-Hep 5 58 M 4.5 12500 ATG 44 
PEG-Hep 6 62 M 4.5 9000 ATG + Rituximab 138 
PEG-Hep 7 73 M 4.7 12670 ATG + Rituximab 131 
PEG-Hep 8 59 M 3.5 13000 ATG + Rituximab 123 
PEG-Hep 9 55 M 3.0 15600 ATG + Rituximab 116 
















Figure 5.1    Systemic immunosuppressant and anti-inflammatory agent regimens. Diabetes was 
induced one month prior to transplantation, and 5 mg/kg rATG was administered daily for 4 days 
beginning from the day of the transplant. Etanercept was administered 3 times (transplant day and post-
transplant days 3 and 6). Anakinra was administered daily for 7 days beginning from the day of the 
transplant. Single doses of rituximab were administered to PEG-Hep 5- PEG-Hep 10. Tacrolimus and 












 5.2.12    Flow cytometric analysis 
For flow cytometric analyses, the following monoclonal antibodies from BD Pharmingen™ 
(San Diego, CA, USA), which cross-reacted with NHPs, were used: FITC anti-CD20 (clone: 2H7), PE 
anti-CD56 (clone: MY31), PE anti-CD28 (clone: CD28.2), PE anti-CD10 (clone: HI10a), PerCP-cy5.5 
anti-CD4 (clone: L200), PerCP-cy5.5 anti-CD7 (clone: M-T701), PE-cy7 anti-CD3 (clone: SP34-2), 
PE-cy7 anti-CD20 (clone: 2H7), PE-cy7 anti-CD14 (clone: M5E2), APC anti-CD95 (clone:DX2), APC 
anti-CD14 (clone: M5E2), APC anti-CD34 (clone:563), and APC-H7 anti-CD8 (clone: SK1). V450 
anti-CD27 (clone: M-T271), V450 anti-CD16 (clone: 3G8) and BV510 anti-NHP-CD45 (clone: D058-
1283) were purchased from BD Biosciences (San Jose, CA, USA). FITC anti-CD38 (clone AT-1) was 
purchased from Stemcell Technologies. 
T lymphocyte subsets in macaque peripheral blood were analyzed based on singlet and live 
lymphocyte light scatter profiles and surface expression of NHP-CD45, CD3, CD4 and CD8. CD4+ 
helper T cells and CD8+ cytotoxic T cells were divided into two major subsets, naïve and memory cells, 
using the cell surface expression of CD28 and CD95 to differentiate naïve (CD28+CD95-), central 
memory (CD28+CD95+) and effector memory (CD28-CD95+) T cell subpopulations. B cell subsets were 
analyzed in cynomolgus monkeys based on CD20 expression as the definitive B cell marker because 
commercial CD19 monoclonal antibodies were only weakly cross reactive with macaque B 
lymphocytes. B cell subsets were classified into naïve (CD20+CD27-) and memory (CD20+CD27+) B 
cells using CD27. Natural killer cells were characterized as CD3- and CD56+.  
Peripheral whole blood cells were stained with relevant antibody mixtures as described above 
for 25 min at room temperature. Prior to flow cytometry, blood was treated with FACS Lysing Solution 
(BD Biosciences, San Jose CA) to lyse red blood cells for 15 min. 
 
5.2.13    Histology 
Liver biopsies were obtained by open laparotomy 1 month after transplantation. Liver 
specimens were obtained in the form of wedge resections of segments 2 or 3. The samples were fixed 
in 10% formalin, embedded in paraffin, sliced into 4-µm-thick sections and stained with hematoxylin 
and eosin (H&E). For insulin and glucagon immunostaining, the sections were separately incubated 
with anti-insulin and anti-glucagon antibodies (Dako, Carpinteria, CA), followed by incubation with 
PE- and FITC-labeled secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for red and 
green staining, respectively. Slides were then counterstained with DAPI. Immune cell invasion was 
assessed by incubating the slides with anti-CD3 (Dako) and anti-CD20 (Dako) antibodies, followed by 
incubation with an anti-rabbit-HRP-labeled polymer for 2 h at room temperature. Slides were incubated 
with 3, 30-diaminobenzidine (Dako) for 15 min, counterstained with hematoxylin, and fixed using 
mounting medium (Dako). Images from the histologic slides were examined to quantify the degree of 
immune cell infiltration into the transplanted islet graft. Using the Aperio positive pixel V0 algorithm, 
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the range of insulin-stained islets was identified, and the degrees of CD3+ T cell and CD20+ B cell 
infiltration were quantified. 
 
5.2.14    Statistical Analysis 
The relative cell viability, insulin secretion, stimulation index, platelet count, and C3a 
concentration are presented as the mean ± SD. Graft survival was defined as the time from 
transplantation to the time of graft failure or censored at the date of the last follow-up. Graft survival 
probabilities were estimated using the Kaplan-Meier method and compared between groups using the 
log-rank test. The generalized estimating equation method was used for group comparisons of 
longitudinal trends up to 13 weeks after transplantation for absolute numbers of CD4 and CD8 EM T 
cells. The two-sided Wilcoxon signed-rank sum test was used to compare CD3 T cell and CD20 B cell 
liver infiltration levels between the PEG and PEG-Hep groups. p values < 0.05 were considered 
statistically significant. Statistical analyses were carried out using SAS version 9.4 (SAS Institute, Cary, 
NC) and IBM SPSS version 23.0 (SPSS, Chicago, IL). 
 
5.3    Results 
5.3.1    Islet nano-shielding with PEG and heparin 
The 6-arm-PEG-NHS and 6-arm-PEG-catechol were synthesized by incorporating the N-
hydroxysuccinimide (NHS) ester and catechol functional groups into 6-arm-PEG-SH and 6-arm-PEG-
NH2, respectively. The conjugations were confirmed by 1H NMR and UV spectroscopy (Figure 5.2). 
Thiol incorporation into heparin was confirmed by 1H NMR and with Ellman’s reagent (Pierce 
Biotechnology). When cultured with islets, the NHS esters of 6-arm-PEG-NHS acted as the anchoring 
moiety and formed stable amide bonds with primary amines on the islet surface collagen. 6-arm-PEG-
catechol formed as a second layer, and linear PEG-SH or heparin-SH formed as the third layer for PEG 
and PEG-Hep, respectively, via Michael-type addition (Figure 5.3 E). The roughness of this nano-
shielding was evaluated by performing AFM imaging in both the dry and wet states (Figure 5.3 F-H). 
The root mean square of the roughness of the PEG-Hep surface in the dry state was 3.145 nm, which 
was reduced to 1.201 nm in the wet state due to the flexible nature of PEG. The final concentrations 
were optimized for the PEGs and heparin by comparing islet coverage and viability at different 
concentrations (Figure 5.4). To assess coverage, FITC-labeled materials were used. Visualizing the 
coverage through CLSM, the final concentrations were determined to be 0.5% w/v 6-arm-PEG-NHS, 
1% w/v 6-arm-PEG-catechol, and 0.5% w/v linear PEG-SH or 0.5% w/v heparin-SH (Figure 5.5 A). 
Islet viability and glucose-stimulated insulin secretion (GSIS) were preserved during the coating 
procedure at these concentrations (Figure 5.5 B-E). Islet coverage, surface thickness, viability and the 
GSIS of the PEG nano-shielded islets were confirmed in previous study (Chapter 3). The APTT assay 
was used to measure the heparin concentration on the PEG-Hep islets. The concentration of heparin 
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coated onto the islet surface was estimated to be 0.8 U/ml for 10,000 IEQ of islets. Numerous activated 
platelets were observed on the collagen surface (control), which was used to mimic naturally occurring 
islet surface collagen. However, when PEG-Hep was used to nano-shield the surface, platelet activation 
was significantly reduced (Figure 5.5 F). The number of activated platelets on the PEG-Hep surface 
was 1.69% relative to the control (p < 0.001, Figure 5.5 G). To investigate the effects of PEG-Hep 
nano-shielding on complement activation, unshielded (control) islets and PEG-Hep islets were cultured 
in 50% monkey serum (Figure 5.5 H). After a 1-d culture period, a significantly higher level of C3a (p 
< 0.01) was observed in the control group (0.27 ng/ml) than that of the PEG-Hep group (0.18 ng/ml). 
C3a is a product of complement activation, and PEG-Hep nano-shielding clearly demonstrated a 
reduction in complement activation. Consequently, PEG-Hep nano-shielding preserved islet viability 
and insulin secretory capacity (Figure 5.5 I, J). Viability was reduced to 40.02% for the control islets 
and 82.20% for PEG-Hep when cultured in 50% monkey serum, while it remained at 100% and 
101.08%, respectively, when cultured in normal cell culture medium (CMRL1066 medium with 10% 
FBS). Higher viability led to higher insulin content in PEG-Hep nano-shielded islets relative to the 
control islets (PEG-Hep: 64,989 ± 72.68 mU/l vs control: 24,954 ± 1984 mU/l, p < 0.001). 
Immunoprotective effects of PEG-Hep were further checked by co-culturing islets with splenocytes. 
During the culture period, splenocytes cultured with control islets (6.89 ± 0.71 U/ml) secreted 
significantly higher (p < 0.05) level of IL-1β than that of the PEG-Hep (4.41 ± 0.35 U/ml). Consequently, 
only 44.29 ± 2.47% control islets were survived compared with the PEG-Hep nano-shielded islets 
(Figure 5.5 K, L).  
 
5.3.2    Islet allograft survival and outcome 
Exogenous insulin (Lantus®, Sanofi US, NJ) was administered after islet transplantation when 
the recipient’s morning blood glucose exceeded 200 mg/dl for three consecutive days. Islet graft 
survival was defined in terms of C-peptide release and graft failure was said to have occurred on the 
day serum C-peptide went below 0.5 ng/ml. 
In the control group, control 1 and control 2 had been injected insulin on post-transplant day 9 
and day 2 after transplantation of 10,000 IEQ/kg islets. Control 3 and control 4 received 20,000 IEQ/kg 
islets and required insulin on post-transplant day 37 and 40 for glucose control (Figure 5.6 A-D) The 
C-peptide levels fell below 0.5 ng/ml at 26 and 56 days in control 1 and control 2, respectively. C-
peptide positive survival of subjects that received 20,000 IEQ/kg islet transplants (control 3 and control 
4) were 93 and 98 days, respectively (Figure 5.7 A-D). In the PEG group, subjects received insulin at 
post-transplant 9.4 day (mean) following transplantation of 10,000 IEQ/Kg islets (Figure 5.6 E-I). 


















Figure 5.3    Synthesis schematics, polymeric nano-shielding on the islet surface, and surface 
characterization of the PEG-Hep surface. Synthesis of (A) SH-6-arm-PEG-NHS, (B) 6-arm-PEG-
catechol, and (C) heparin-SH. (D) Chemical structure of linear PEG-SH. (E) Formation of PEG or PEG-
Hep nano-shielding on islet surface. AFM imaging (4 µm x 4 µm) of (F) collagen surface (control), (G) 
PEG-Hep surface in the dry state, and (H) PEG-Hep surface in the wet state after incubating the PEG-






Figure 5.4    CLSM images of PEG-Hep nano-shielded islets that were tagged with FITC-labeled PEGs 
and heparin, and their viability per analysis with a live/dead viability/cytotoxicity assay kit. Optical 
(top), merge (middle), and live/dead (bottom) images of islets treated with (A) SH-6-arm-PEG-NHS at 
0.25%, 0.5%, 1% and 2% w/v; (B) SH-6-arm-PEG-NHS at 0.5% w/v as the first layer and 6-arm-PEG-
catechol at 0.25%, 0.5%, 1% and 2% w/v as the second layer; (C) SH-6-arm-PEG-NHS at 0.5% w/v as 
the first layer, 6-arm-PEG-catechol at 1% w/v as the second layer, and heparin-SH at 0.25%, 0.5%, 1% 

































Figure 5.5    Characterization and the effects of PEG-Hep nano-shielding on IBMIR reduction in vitro. 
(A) CLSM images of PEG-Hep islets; intensity profile along the line. Scale bar: 100 µm. (B) Qualitative 
viability assessment of unshielded (control) and PEG-Hep islets, performed using a live/dead 
viability/cytotoxicity assay kit. Scale bar: 100 µm. (C) The relative viabilities of the control and PEG-
Hep islets quantified using cell counting kit-8 (CCK-8/DNA, n = 5) assay. (D) The glucose-stimulated 
insulin secretion test performed to compare the functionality of PEG-Hep with that of control islets in 
a low (□, 2.8 mM) and a high (■, 28 mM) glucose Krebs-Ringer bicarbonate buffer solution (n = 5). (E) 
Stimulation index for glucose stimulation (n = 5). (F) Platelet adhesion on the collagen (control) and 
PEG-Hep nano-shielded collagen surfaces. Scale bar: 10 µm. (G) Reduction in adhered platelets on the 
PEG-Hep surface compared with the control surface (*** p < 0.001). (H-J) Islet damage through 
complement activation. (H) C3a generated while islets were cultured in 50% monkey serum. The higher 
C3a concentration in the control group (* p < 0.05) resulted in reduced (I) viability and (J) insulin 
secretory capability compared with those of the PEG-Hep group (** p < 0.01). (K, L) Islet co-culture 
with splenocyte. (K) Concentration of secreted IL-1ß from the splenocytes cultured with control and 
PEG-Hep islets (* p < 0.05). (L) Control islets were more damaged by immune cell activity, in contrast 
to the PEG-Hep (** p < 0.01). 
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In the PEG-Hep group, islets ranging from 10,000 to 15,600 IEQ/kg body weight were 
transplanted (Table 5.1). PEG-Hep 1 did not require insulin for 2 months following transplantation and 
showed stable blood glucose with detectable C-peptide levels (Figure 5.6 J). The one-month post-
transplant IVGTT for this subject showed an acute C-peptide response that was similar to that of the 
normal subjects, implying successful engraftment of transplanted islets into the recipient (data not 
shown). The liver biopsy showed histologic evidence of transplanted islets in the recipient’s liver. 
Insulin- and glucagon-positive islets were detected in the liver by histology, and there was no evidence 
of CD3 and CD20 infiltration (Figure 5.8 C). PEG-Hep 2 was insulin-free for 17 days following 
transplantation. However, a minimal insulin dose (<1 IU/kg/d) was required from post-transplant days 
18 to 30. C-peptide remained detectable throughout the post-transplant period, and the insulin dose was 
eventually reduced (Figure 5.6 K, Figure 5.7 K). The one-month post-transplant liver biopsy showed 
islets that had engrafted into the recipient’s liver (Figure 5.8 C). Insulin was required for PEG-Hep 3 
on post-transplant day 11, while C-peptide levels were detectable until day 77 (over 0.5 ng/ml) (Figure 
5.6 L, Figure 5.7 L). PEG-Hep 4 remained insulin-free for 71 days after transplantation, and the serum 
C-peptide levels remained above 2 ng/ml throughout that time (Figure 5.6 M, Figure 5.7 M). PEG-
Hep 5 maintained a stable post-transplant blood glucose level without insulin with C-peptide above 2 
ng/ml but was found dead on post-transplant day 44 (Figure 5.6 N, Figure 5.7 N). The autopsy revealed 
a large amount of food in the stomach and main bronchi, and asphyxia was confirmed as the cause of 
death. The liver biopsy that was performed at autopsy showed islets engrafted in the liver (Figure 5.8 
C). 
PEG-Hep 6-10 received rituximab in addition to ATG to induce immunosuppression. PEG-Hep 
6 began using insulin on post-transplant day 58, and the serum C-peptide levels remained above 2 ng/ml 
throughout the post-transplant period (Figure 5.6 O, Figure 5.7 O). PEG-Hep 7, 8 and 9 began using 
insulin on post-transplant days 51, 43, and 36, respectively, and their serum C-peptide levels remained 
above 1 ng/ml (Figure 5.6 P, Q, R, Figure 5.7 P, Q, R). PEG-Hep 10 maintained stable blood glucose 
levels for 1 month but was sacrificed due to a catheter-related S. aureus infection (Figure 5.6 S, Figure 
5.7 S). 
Figure 5.8 A shows the C-peptide positive graft survival curves for each subject group. The 
subjects in the PEG-Hep group demonstrated superior graft survival compared to the control and PEG 
groups (p < 0.05). The mean C-peptide positive graft survival time was 68.5 days for the control group, 
64 days for the PEG group, and 108 days for the PEG-Hep group.  
IVGTT was performed 1 month after transplantation for each group. In the PEG-Hep group, a 
partial response to IVGTT was observed with 0.68%/min mean KG and an acute C-peptide response of 
0.18. The control and PEG groups lacked responses to IVGTT, showing 0.59%/min and 0.95%/min 






Figure 5.6    Blood glucose level (■, mg/dl) of the allogenic islet transplanted cynomolgus monkeys. 
Administration of exogenous insulin (|, IU/kg/d) was initiated on post-transplant days 9 and 2 in (A) 
Control 1 and (B) Control 2, respectively. (C) Control 3 and (D) control 4 required insulin injections 
from post-transplant days 37 and 40, respectively. (E-I) All subjects in the PEG group became insulin 
dependent within 3 weeks of transplantation. (J) PEG-Hep 1 and (K) PEG-Hep 2 did not require insulin 
until 3 months post-transplant. (L) PEG-Hep 3 became insulin dependent on post-transplant day 11 and 
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showed similar blood glucose levels to those of subjects in the control or PEG groups. (M) PEG-Hep 4 
exhibited a severe blood glucose fluctuation and began using insulin on post-transplant day 71. (N) 
PEG-Hep 5 did not require insulin until 44 days post-transplant but was sacrificed due to asphyxia. 
Rituximab was added to the regimen for (O-S) PEG-Hep 6 to PEG-Hep 10. (O-R) PEG-Hep 6, 7, 8, 
and 9 became insulin dependent on post-transplant days 58, 51, 43 and 36, respectively. (S) PEG-Hep 



































Figure 5.7    C-peptide level (■, ng/ml) of the allogenic islet transplanted cynomolgus monkeys. (A) 
Control 1 and (B) control 2 had detectable C-peptide levels above 0.5 ng/ml until post-transplant days 
56 and 27. (C) Control 3 and (D) control 4 had detectable C-peptide until post-transplant days 93 and 
98. (E-I) Animals in the PEG group had C-peptide positive graft survival for 35 to 98 days. (J-N) PEG-
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Hep 1 to PEG-Hep 5 had detectable C-peptide levels above 0.5 ng/ml for 44 to 172 days. (O-S) PEG-
Hep 6 to PEG-Hep 10 had additional induction immunosuppression with Rituximab and had detectable 









































Figure 5.8    Survival rate, metabolic parameters and representative histologic sections of the recipients. 
(A) C-peptide positive graft survival comparison between the control, PEG and PEG-Hep groups. The 
mean islet survival was significantly longer in the PEG-Hep group (p < 0.05). (B) Comparison of 
IVGTTglu (left) and IVGTTc-pep (right) 1 month post-transplantation. The data show a 0.59%/min 
glucose disappearance rate in the control group, and KG 0.95%/min and KG 0.68%/min rates in the 
PEG and PEG-Hep groups, respectively (partial response). An acute C-peptide response was not 
observed in any group. However, the C-peptide levels were above 2 ng/ml in the PEG-Hep group. (C) 
Representative histologic sections of liver biopsy specimens one month after islet transplantation. 
Numerous islets were evident in the liver sections from PEG-Hep 1, 2 and 5. CD3+ T cells or CD20+ B 
cells were nearly absent around the insulin- and glucagon-stained islets. Scale bar: 100 µm. 
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Islets were identified in the 1-month post-transplant liver biopsies of 6 of 10 subjects in the 
PEG-Hep group. As shown in Figure 5.8 C, islets that stained positive for insulin and glucagon by 
immunohistochemistry were observed. A dearth of immune cell infiltration was observed by CD3 and 
CD20 staining.  
 
5.3.3    Lymphocyte subset analysis in the peripheral blood and in the liver  
WBCs and absolute neutrophil counts (ANCs) were not significantly different between the 
three groups until 3 months after transplantation (Figure 5.9 A, B). However, the post-transplant 
absolute lymphocyte count (ALC) showed a tendency to increase in the control and PEG groups, while 
the ALC for the PEG-Hep group remained low relative to the control and PEG groups (Figure 5.9 C). 
In the control group, CD3+ T cells and CD20+ B cells began increasing on post-transplant day 35 
(Figure 5.9 D, E). On post-transplant day 42, the rate of increase accelerated despite continued 
immunosuppression. The lymphocyte subset that increased primarily comprised total CD3+ T cells, 
particularly CD4+ effector memory (EM) T cells and CD8+ EM cells. In the PEG group, a T cell increase 
was observed at 3 weeks post-transplant and returned to pre-transplant levels by day 56. The T cells 
primarily comprised CD4+ EM T cells and CD8+ EM cells, as observed in the control group (Figure 
5.9 G, J).  
In the PEG-Hep group, ANCs remained similar to pre-transplant levels, while the ALC was 
suppressed until 3 months post-transplant. CD4+ T cells were suppressed until 3 months post-transplant, 
and CD4+ EM cells were not observed in the peripheral blood for 3 months post-transplant. In the PEG-
Hep group, CD8+ T cells increased and returned to pre-transplant levels between post-transplant days 
70 and 90. A subset analysis of these cells revealed the majority to be CD8+ EM cells (Figure 5.9 C, 
G, J). 
Immune cell infiltration was also observed in liver biopsy specimens. As shown in Figure 5.10 
A, extensive CD3+ T cell and CD20+ B cell infiltration was present around the islets of the PEG group. 
Quantitative measurements of immune cell infiltration revealed a lower degree of CD20+ B cell 
infiltration (p = 0.07) and significantly less infiltration by CD3+ T cells in the PEG-Hep group (Figure 
5.10 B, *p < 0.001).  
 
5.4    Discussion  
Islet transplantation is a clinically effective treatment modality for T1DM patients. Since the 
introduction of the Edmonton protocol, two key concepts have been emphasized in this field: the 
application of glucocorticoid-free immunosuppressive therapy and the transplantation of a sufficient 
number of freshly prepared islets from two or more donors [1, 9, 28, 29]. However, donor pancreas for 
islet transplantation is not abundantly available. Thus, numerous research efforts have been made to 































Figure 5.10    Lymphocyte analysis in liver histology. (A) CD3 T cell staining (brown) shows moderate 
infiltration around the islets in the PEG group. CD3 T cell staining was evident in small areas for the 
PEG-Hep group, with most islets showing no infiltration. (B) Comparison of CD3 T cell and CD20 B 
cell infiltration in the livers between the PEG and PEG-Hep groups. CD3 T cell staining was markedly 













Several studies have examined islet-friendly immunosuppression in allo-islet transplantation. 
Most notably, steroid-free immunosuppressive therapy restored endogenous insulin production in islet 
transplant recipients, but it was not sufficient to achieve and sustain insulin independence reproducibly 
[1]. Thus, preclinical studies to assess compounds targeting the CD28 pathway, such as hCTLA4Ig and 
CD154 antibodies, have been conducted [10, 13, 30, 31]. Additionally, the use of FTY720 as a non-
diabetogenic immunosuppressive regimen to replace calcineurin inhibitors has been suggested for 
preclinical studies [12, 13, 30]. Liu et al. reported improved islet allograft survival in non-human 
primates undergoing B cell depletion using rituximab [32].  
A variety of medical therapies, in combination with T cell depletion therapy have aimed to 
reduce the inflammatory response and protect islet allografts from apoptosis by blocking alpha-1 
antitrypsin [33] and administering GLP-receptor agonists [34], blocking TNF-α, and anti-IL-1β [34, 
35]. There have also been reports of improved islet engraftment following the intraportal co-
transplantation of mesenchymal stem cells and islet allografts [36]. However, research on 
immunosuppressive therapy targeting co-stimulatory pathways and co-transplantation of mesenchymal 
stem cells with islets has not progressed beyond the preclinical stage.  
Several attempts have been made to evade the immunologic barrier that is associated with the 
intraportal route of islet transplantation. One study showed a prolonged allograft survival time for islets 
that were transplanted into a pre-vascularized subcutaneous site without immunosuppressive treatment 
[37]. Another study achieved partial functionality in a baboon eye when islets were transplanted into 
the anterior chamber [37, 38]. A bioartificial pancreas has also been tested in rodents [39]. However, 
these alternative methods are not suitable for clinical application because their efficacies and donor 
supply are limited.  
Immunoisolation of islets using biocompatible polymers may lower the need for 
immunosuppressive drugs [40]. Four decades earlier, a technology to immunoisolate islets using 
alginate matrix was reported by Lim and Sun et al. [41]. Alginate-encapsulated porcine islets 
xenotransplanted in the peritoneal cavity of humans maintained HbA1c < 7% with reduced 
hypoglycemic events for over 600 days without any anti-rejection drugs [42]. Alginate encapsulation 
ranges in a diameter between 600 µm to 1000 µm, which causes a high diffusion barrier for oxygen and 
nutrients to pass into the core of islets [43]. After transplanting this bulk volume of cells into the 
peritoneal cavity, the cells fall and aggregate in the lower abdomen, worsening the diffusion transport 
[43]. Moreover, as a polymer, alginate is subjected to swelling and rupture due to the osmotic pressure 
at the transplanted site. Therefore, recent approaches have been made to reduce the size of the capsule, 
increase flexibility and biocompatibility by incorporating PEG and chitosan with alginate [43, 44]. PEG 
is resistant to osmotic stress and has long been used as a biocompatible material [45, 46]. When islet 
surface was modified with PEG, the surface antigens were effectively covered without having any 
cytotoxic effects on the cells [47]. Allotransplanted PEGylated islets maintained insulin independence 
for over a year with low doses of cyclosporine A in a rat model. Histologic analysis revealed no 
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lymphocyte infiltration into the PEGylated islets [48-50]. Studies on rat-to-mouse, porcine-to-mouse 
and NHP-to-mouse xenotransplantation studies using PEGylated islets undoubtedly demonstrated 
better outcome in survival rate compared with naked islets [20, 26, 27]. To improve the surface 
modification efficiency, incorporation of heparin with PEG also showed significant (p < 0.01) 
improvement on survival in a rat allotransplantation study, which simultaneously reduced immune 
activation and IBMIR [26]. In addition, the surface modification with several layers of polymers did 
not increase the size of the islets more than nano-meter in range [27]. This makes the surface 
modification process an attractive choice over micro-encapsulation for clinical transplantation of islets 
via the portal vein. Unfortunately, transplantation with surface modified islets using biocompatible 
polymers is far behind clinical trial. Thus, this primate study was conducted as a final step before 
clinical application of PEG and PEG-Hep nano-shielded islets.  
This study failed to increase islet survival in PEG nano-shielded islet transplanted recipients. 
Therefore, PEG-Hep nano-shielding was focused to reduce IBMIR and immune activation. IBMIR and 
immunogenesis have an interdependent relationship. IBMIR involves blood coagulation, platelet 
activation, complement activation, release of cytokines and chemokines [51]. In case of intraportal islet 
transplantation, direct contact between transplanted grafts and blood stream initiates coagulation 
triggered by the tissue factors expressed on the islet surface. With a covalent chemical interaction 
between the islet surface collagen and the polymers, a completely covered islet surface was achieved 
accompanied by unchanged viability and functionality relative to the unmodified islets (Figure 5.5 A-
E). It can be anticipated that surface modification with the three-layer of polymers might mask islet 
surface tissue factors. APTT assay measurements indicated that heparin concentration on islet surface 
was within the recommended therapeutic dose of heparin for patients with venous thromboembolisms 
or unstable angina [52]. Platelets, which adhere to specific surfaces that express extracellular matrix 
components, such as collagen and laminin, are a key factor in thrombus formation [53]. Islets are 
naturally covered with a layer of collagen on its surface, therefore, platelet adhesion leads to platelet 
aggregation around the transplanted cells. PEG-Hep nano-shielding masks the islet surface collagen, 
thus, a significant reduction in adherent platelets was observed in the in vitro study. Complement, a 
component of the innate immune system, plays multiple roles in the propagation of IBMIR. It recruits 
phagocytes to the transplantation site, participates in B cell and T cell activation, and provokes 
inflammation, among other functions [55]. Heparin affects the complement system by lowering the 
requirements to initiate C3 activation [23]. PEG-Hep and control islets were cultured in 50% monkey 
serum to assess complement activation. Significantly low C3a concentrations were detected in the PEG-
Hep group, which exhibited high viability and insulin secretion capability relative to the control group. 
By lowering the propagation of the factors involved in IBMIR, PEG-Hep nano-shielding had reduced 
adaptive immunity demonstrated in the co-culture with splenocytes. However, a low level of IL-1β was 
found in the PEG-Hep group that indicates the shielding cannot completely eliminate immune activation 
but to a significant extent.  
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In this study, diabetes modeling and islet transplantation was performed. 10,000-20,000 IEQ/kg 
islets were isolated and transplanted from a single subtotal pancreatectomy specimen, which was lower 
than the 15,000-30,000 IEQ/kg islets transplanted in previous studies [32, 60]. This may explain why 
three of the subjects (PEG-Hep 3, PEG-Hep 8, PEG-Hep 9) were unable to sustain long-term insulin 
independence. Furthermore, the one-month post-transplant IVGTT showed incomplete responses to 
glucose administration and partial acute C-peptide responses in the PEG-Hep groups (Figure 5.8 B). 
These results may be related to the lower number of islets that were transplanted in this study. However, 
the graft survival time for the PEG-Hep group was superior to the control and PEG group. Moreover, 
superior graft survival was seen in the PEG-Hep group after addition of subjects receiving 20,000 
IEQ/kg islets in the control group.  
Liu et al. reported that the use of anti-CD20 antibody to promote islet survival [32]. Rituximab 
was administered to 5 monkeys in the PEG-Hep group (Table 5.1). However, the effects of rituximab 
on graft survival were not evident in the results (statistical analysis not shown). This may be due to the 
removal of the spleen and pancreas from the NHPs in all subject groups during the diabetes modeling 
step [32]. We routinely removed the spleen with the pancreas to perform a meticulous subtotal 
pancreatectomy that preserved the pancreatic capsule during islet procurement. Nevertheless, rituximab 
injection led to B cell suppression for more than 3 months compared to NHPs that did not receive 
rituximab, even with spleen removal. Future studies should investigate this further by preserving the 
spleens in the recipient animals. 
 
5.5    Conclusion 
This study uses an NHP model to demonstrate the feasibility of transplanting PEG-Hep nano-
shielded islets in combination with a tailored immunosuppressive regimen to reduce complications 
associated with IBMIR and immunogenicity (Figure 5.11). One advantage of PEG-Hep nano-shielding 
on islet surface modification is its ability to be used in combination with most established 
immunosuppressive regimens. This is the first report to demonstrate the effectiveness of PEG-Hep 
modified islets in the allotransplanted T1DM NHP model. This method is believed to have translational 
potential for clinical trials to improve islet graft survival outcomes. Future studies should focus on 
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Islet nano-shielding with a combination of tannic acid, polyethylene glycol 
and heparin for improved immune protection  
 
6.1    Introduction 
Islet nano-shielding with multi-layer polymers is a promising approach to circumvent immune 
recognition after transplantation while preserving islet’s ability to maintain euglycemia. In previous 
studies, it has been demonstrated that islet nano-shielding in a layer-by-layer (LbL) fashion with PEG 
or a combination of PEG and heparin is non-toxic and maintained islet functionality both in vitro and 
in vivo (Chapter 2-5). Although nano-shielding with PEG or PEG-Hep protect islets by reducing 
immune activation and inflammatory reactions, they don’t have protective effects against the free-
radicals generated by the already activated immune cells. LbL assembly has long been used in studies 
to modify islet surface by depositing water soluble polymers which forms nano-thin coatings of 
desirable thickness and composition [1, 2]. Current LbL system involves positive and negatively 
charged polymers to form electrostatic bond for the assembly. However, the major disadvantage of this 
system is cytotoxicity of the polycationic compounds [3]. To get over this problem, covalent bond 
formation or hydrophobic interactions were employed previously to deposit PEG onto islet surface 
(Chapter 2-5) [4, 5]. In this regard, hydrogen bonded LbL approach is a new approach and proposes 
new opportunities for cytocompatible coating strategies [6, 7]. The LbL assembly driven by hydrogen 
bond allows inclusion of polymers carrying no charge [8]. Hydrogen bonded multilayer films based on 
tannic acid (TA) has been proven to be stable in physiologic conditions [8]. TA is a natural polyphenol 
which is known for its antioxidant properties [9, 10]. TA scavenges free-radicals and inhibits oxidation 
provoked free-radicals [11]. Most inflammatory processes are induced by reactive oxygen species (ROS) 
which is associated with oxidative stress [12, 13]. Activation of macrophages and T cells by the 
oxidative stress results in production of pro-inflammatory cytokines and leads to inflammation and 
immune activation [14]. Conventional antioxidant agents are injected directly into tissue, therefore, not 
many studies have been done on immobilizing active compound on islet surface [8, 11, 15]. Dissipating 
locally generated ROS prevents the maturation of effector T cells, IFN-gamma, and other pro-
inflammatory Th1 cytokines [16-19]. Hence, study to evaluate the role of TA on immune modulation 
for islet nano-shielding was highly demanded.  
In this chapter, LbL nano-shielding systems composed of TA, PEG and heparin were designed. 
In the previous chapters, it has been proved that nano-shielding with PEG and heparin has 
immunoprotective effects against both cellular and humoral immune systems. Here, the aim is to find 
out the effects of TA in conjugation with PEG and heparin on improving graft function by reducing 
cytotoxic effects of free radicals besides cellular, and humoral immunity. 
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6.2    Materials and methods 
6.2.1    Animals 
Sprague–Dawley (SD) rats (male, 8 weeks old) were used as islet donors and inbred C57BL/6 
mice (male, 7–8 weeks old) were used as recipients. They were purchased from Orient Bio Inc. 
(Seongnam, Republic of Korea) and were housed under a specific pathogen-free condition at our 
institution. T1DM was induced chemically in the recipient C57BL/6 mice by a single intraperitoneal 
injection of 180 mg/kg of streptozocin (STZ; Sigma, St. Louis, MO). Mice with the blood glucose level 
of over 350 mg/dl for two consecutive days were selected as diabetic recipients for transplantation. All 
experimental and surgical procedures were conducted by following the guidelines of the Institute of 
Laboratory Animal Resources, Seoul National University (IACUC no. SNU-070822-5).  
 
6.2.2    Isolation of pancreatic islets 
Pancreatic islets were isolated from the pancreases of outbred male SD rats. Briefly, SD rats 
were anaesthetized with intraperitoneal injection of ketamine (90 mg/kg) and xylazine (10 mg/kg) 
mixture, and their pancreases were exposed by laparotomy. The common bile duct was ligated, 
cannulated with a 25-gauge-needle, and then injected with 10 ml of Hank’s balanced salt solution 
(HBSS; Sigma) containing 0.8 mg/ml Collagenase P (Roche, Indianapolis, IN). Distended pancreases 
were removed and incubated at 37°C for 20 min. Islets were then purified by centrifuging in the solution 
of discontinuous Histopaque (Sigma) density gradient at 2,400 rpm for 18 min. Isolated islets were 
cultured for 1 day in RPMI-1640 (Sigma) containing 10% fetal bovine serum (FBS; Sigma) at 37°C in 
a humidified atmosphere of 5% CO2.  
 
6.2.3    Synthesis of PEG and heparin 
TA was purchased from Sigma. 6-arm-PEG-catechol was synthesized following the previously 
reported protocol [5]. Briefly, first, 3, 4-dihydroxyhydrocinnamic acid was dissolved in N, N-
dimethylformamide (DMF, Sigma) and poured into a round bottom flask. Next, the following materials, 
N, N’-dicyclohexylcarbodiimide (DCC, Sigma), N-hydroxysuccinimide (NHS, Sigma), and 6-arm-
PEG-NH2 (MW 15 kDa, SunBio) were also dissolved, respectively, in DMF and added to the flask. 
Finally, the reaction was continued overnight in an ice bath, and the products were purified by 
precipitation using cold diethyl ether (Sigma), followed by freeze drying.  
Heparin-SH was synthesized by reacting unfractionated heparin (Sigma) with 3-Amino-1-
propanethiol hydrochloride (APH, Sigma). Unconjugated APH was precipitated out using cold ethanol 
and heparin-SH was obtained followed by freeze drying.  
FITC tagged 6-arm-PEG-catechol was synthesized by reacting NHS-fluorescein (Thermo 
Fisher Scientific) with the previously synthesized 6-arm-PEG-catechol. Fluorescein isothiocyanate 
(FITC) was tagged to heparin-SH by reacting them with Fluorescein-5-maleimide (Thermo Fisher 
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Scientific, MA). Both materials were purified from the unreacted FITC by dialysis using a 2 kDa 
MWCO membrane (Spectra Por. Spectrum® Laboratories Inc.). FITC labeled BSA (Thermo Fisher 
Scientific Korea Ltd., Korea) was used to tag TA shielded on islet surface.  
 
6.2.4    LbL islet nano-shielding with TA, PEG and heparin 
After isolation, islets were cultured for 24 h and nano-shielded with a three-layer (TA-PEG-
Hep) or a five-layer of materials ((TA-PEG)2- Hep)). For TA-PEG-Hep, islets were washed twice with 
Hank’s balanced salt solution (HBSS, Sigma) and incubated for 3 min each with 0.04% w/v of TA, 1% 
w/v of 6-arm-PEG-catechol, and 1 h with 0.5% w/v of heparin-SH, respectively (Figure 6.1 B). For the 
(TA-PEG)2-Hep, a bi-layer of TA and PEG was formed by incubating islets sequentially with TA, 6-
arm-PEG-catechol, TA, and 6-arm-PEG-catechol (Figure 6.1 C). The fifth and final layer was formed 
with heparin-SH. The concentrations and time periods were same for the corresponding materials in 
both layers and were optimized from previous studies (Chapter 3, 4) [5, 8]. 
To check islet coverage with TA, islets nano-shielded with TA was incubated with FITC 
labeled BSA at 1 mg/ml concentration for 15 minutes. Islet coverage of PEG and heparin was evaluated 
by using FITC tagged materials at the same concentrations and duration as the corresponding untagged 
materials. Confocal laser scanning microscopy (CLSM, Carl Zeiss LSM710, Germany) was employed 
to detect the fluorescence intensity of FITC-tagged PEGs and heparin on islet surface.  
 
6.2.5    Cell viability assay 
Islet viability was assessed both qualitatively and quantitatively after nano-shielding. For 
Live/Dead® viability/cytotoxicity kit assay (Molecular probes, Inc., OR), islets were first washed and 
suspended in 500 µl HBSS. Calcein AM and ethidium homodimer were added to the cell suspension 
and incubated for 15 min, followed by washing three-times with HBSS. Islets examined under an 
Eclipse TS100 microscope (Nikon, Japan) revealed that dead cells were stained with red fluorescence 
and live cells with green fluorescence.  
Qualitative viability was determined by cell counting kit-8 assay (CCK-8, Dojindo Molecular 
Technologies, Inc., MD). 100 IEQ islets suspended in CMRL 1066 medium were incubated with WST-
8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium 
salt] at 37°C for 4 h under humidified atmosphere containing 5% CO2. Absorbance was observed at 
450 nm using a UV microplate reader. For normalization, the obtained values from the CCK-8 assay 
were divided by the values obtained from the DNA contents (Quanti-iTTM Picogreen® dsDNA reagent 


















Figure 6.1    (A) Chemical structure of tannic acid (TA), and formation of hydrogen bonds between 
islet surface collagen and TA. LbL nano-shielding with (B) TA-PEG-Hep, and (C) (TA-PEG)2Hep on 














6.2.6    Glucose-stimulated insulin secretion assay 
Glucose-stimulated insulin secretion (GSIS) assay consisted of culturing 100 IEQ islets in 1 ml 
of Krebs-Ringer bicarbonate buffer (KRBB; pH 7.4) with a low (2.8 mM) glucose and a high glucose 
(28 mM) concentrations for 2 h, respectively. Low and high glucose solutions were collected and 
checked for the concentration of secreted insulin using a human insulin ELISA kit (Mercodia, Upsala, 
Sweden). The stimulation index was determined by dividing the value of insulin secreted in the high 
glucose solution by that secreted in the low glucose solution. 
 
6.2.7    Migration assay  
Millicell® hanging cell culture inserts (3 um pore size, 24-well plate) were coated with rat tail 
collagen I (Corning, NY). The inserts were further coated with TA-PEG-Hep as described above. 
Spleen was dissected from SD rats, washed twice with HBSS and put in a cell strainer (70 µm, BD 
Biosciences, MA). The spleen was sliced into small pieces and tamped with a plunger from a 3-ml 
syringe against the strainer. HBSS was added to the strainer and single splenocytes were released 
through the pores of the cell strainer. The splenocytes were loaded into a 15-ml conical tube and treated 
with RBC lysis buffer (Sigma) for 3 minutes, washed in a refrigerated centrifuge at 1400 RPM for 3 
min. Isolated splenocytes (5x104) were cultured in collagen coated (control) or TA-PEG-Hep nano-
shielded collagen inserts for 24 h and counted with trypan blue staining.  
 
6.2.8    Xenotransplantation  
The therapeutic potential of TA-PEG-Hep and (TA-PEG)2Hep islets was observed by 
transplanting 500 IEQ SD rat islets into the kidney subcapsular space of C57BL/6 mice (n=8-9 per 
group). Body weight and blood glucose level (BGL) were measured daily using a glucometer (Super 
glucocard II, Arkray, Kyoto, Japan) until the animals were sacrificed. Intraperitoneal glucose tolerance 
test (IPGTT) was performed on the animals after overnight fasting followed by an intraperitoneal 
injection with 20% glucose (Sigma) solution.  
 
6.2.9    Immunohistochemistry  
Immunohistochemical (IHC) analysis were performed using the standard protocol [20]. Anti-
insulin (1:1000; Novus biologicals, CO) antibody was diluted at the ratio of 1:1000. Mayer hematoxylin 
was used to counterstain the slides. The stained areas were captured using a light microscope at 200x 
magnification. 
 
6.2.10    Quantification of insulin and C-peptide concentrations in serum 
After the transplanted animals were rejected (blood glucose level over 350 mg/dl for 3 
consecutive days), they were anesthetized by diethyl ether (Sigma) and blood was withdrawn by retro-
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orbital sinus puncturing. The whole blood was left at room temperature for 30 min and centrifuged at 
2000 g for 10 min. Serum was collected as supernatant; insulin (Mercodia rat insulin ELISA, Mercodia, 
Sweden), and C-peptide (Mercodia rat C-peptide ELISA) concentrations were quantified according to 
the manufacturer’s instructions.  
 
6.2.11    Statistical analysis 
Data were expressed as mean ± SEM. Statistical analysis was carried out by unpaired t-test or 
ANOVA one-way test. The results were considered significant when p values were less than 0.05.  
 
6.3    Results 
6.3.1    Islet nano-shielding with TA, PEG and heparin 
The coverage for each layer of the TA-PEG-Hep, and (TA-PEG)2Hep on islet surface was 
evaluated using confocal microscopy (Figure 6.2). The two-dimensional images of islets confirmed 
uniform coverage of the materials throughout the surface.  
Islet viability after nano-shielding was quantified by CCK8/DNA assay that showed relative 
viability at 92% and 85% of the TA-PEG-Hep and (TA-PEG)2Hep groups, respectively, compared with 
the naked control islets (Figure 6.3 B).  
In vitro islet functionality evaluated by measuring secreted insulin from the islets in response 
to a low (2.8 mM) and a high (28 mM) glucose concentrations show similar insulin secretion in the 
nano-shielded islets compared with that of control islets (Figure 6.3 C).  
 
6.3.2    Xenotransplantation of the nano-shielded islets 
The LbL nano-shielded islets were transplanted into the kidney subcapsular space of diabetic 
C57BL/6 mice, followed by observing non-fasting BGL once a day (Figure 6.4). The following three 
groups of mice were transplanted: naked islets (control, n=9; Figure 6.4 B), TA-PEG-Hep islets (n=8, 
Figure 6.4 C), and (TA-PEG)2Hep islets (n=8, Figure 6.4 D). The rejection of the grafts occurred in 
all the recipients of the control group within 10 days of transplantation, where the mean survival time 
was 8 ± 0.69 days (mean ± SEM). TA-PEG-Hep islets showed an increase in survival time for 13.50 ± 
2.13 days. However, the survival time was unchanged for (TA-PEG)2Hep group compared with the 
control (Figure 6.4 E). 
Intraperitoneal glucose tolerance test (IPGTT) assessed glucose sensitivity of the recipients in 
comparison with diabetic and normal C57BL/6 mice (Figure 6.4 F). After an overnight of fasting, all 
groups of animals were administered with a high concentration of glucose solution. Diabetic animals 
showed BGL exceeding 500 mg/dl within 5 min and were maintained over 2 h. Control recipients 
showed a similar blood glucose profile as the diabetic animals. On the other hand, the BGL of the 












Figure 6.2    Confocal laser scanning microscopic images of islets nano-shielded with TA, PEG, and 


















Figure 6.3    (A) Live/Dead viability/cytotoxicity kit, and (B) cell counting kit-8 (CCK-8/DNA, n=5) 
assays of nano-shielded islets. (C) Functionality of the nano-shielded islets was checked by glucose-
stimulated insulin secretion (GSIS) test at a low (□, 2.8 mM), and a high (■, 28 mM) glucose solution 
















Figure 6.4    (A) Islets were isolated from SD rats and transplanted (500 IEQ) into the kidney 
subcapsular space of diabetic C57BL/6 mouse. Non-fasting blood glucose level (NBG) of (B) naked 
(control, n=9), (C) TA-PEG-Hep (n=8), and (D) (TA-PEG)2Hep (n=8) islet recipients. (E) Graft 
survival rate of each group. (F) Intraperitoneal glucose tolerance test (IPGTT) after overnight fasting 
of diabetic mice (n = 3), normal mice (n = 3), naked islet recipients (control, n = 9), TA-PEG-Hep 







Recipients from all transplanted groups were sacrificed right after rejection to investigate the 
functionality of the transplanted grafts. Enzyme-linked immunosorbent assay (ELISA) was employed 
to measure C-peptide, and insulin concentrations in the serum (Figure 6.5 A, B). A Profoundly higher 
level of C-peptide was found in both TA-PEG-Hep (271 ± 27 pmol/L), and (TA-PEG)2Hep (478 ± 123 
pmol/L) groups compared with the control (158 ± 40 pmol/L, *p < 0.05). Insulin level was also greater 
in TA-PEG-Hep (0.242 ± 0.006 µg/L), and (TA-PEG)2Hep (0.610 ± 0.235 µg/L) than that of the control 
(0.226 ± 0.004 µg/L), but failed to achieve any significant difference among groups. 
 
6.3.3    TA-PEG-Hep nano-shielding decreases immune cell migration in vitro 
To verify the attenuated level of immune cell activation, a migration assay was performed with 
splenocytes from C57BL/6 mouse on well inserts (Figure 6.6). The well inserts were coated with rat 
tail collagen to mimic the surface of rat islets. The ability of immune cells to migrate from the top of 
the inserts to the bottom chamber was assessed after 24 hours. TA-PEG-Hep modified collagen inserts 
showed decreased number of migrated splenocytes than the unshielded collagen inserts by 1.67-fold.  
 
6.4    Discussion 
Islet nano-shielding with TA, PEG and heparin have a good coverage on islet surface for each 
individual layer. Cell shielding materials might cause loss of viability and functionality by interfering 
with the diffusive transport of oxygen, and nutrients [21]. Therefore, careful selection of material 
composition and thickness are very important. A gradual reduction in viability was observed with an 
increment of the layer number in the LbL composition. Functionality checked by GSIS was similar 
among the groups proving an absence of diffusion barrier.  
Nano-shielded islets, when transplanted in the kidney subcapsular space of C57BL/6 mice, did 
not compromise the functionality in vivo. Survival time in (TA-PEG)2Hep was similar to the control 
islets, whereas, it was improved in TA-PEG-Hep. It was anticipated that the five-layer system, (TA-
PEG)2Hep, would have a higher shielding effect on islets from the immune invasions than that of the 
three-layer system (TA-PEG-Hep). GSIS also showed similar insulin secretion upon glucose 
stimulation between the groups. Thus, the lower survival rate in (TA-PEG)2Hep could only be explained 
by the reduced viability of islets observed during the shielding procedure. IPGTT showed improved 
glucose tolerance for both of the nano-shielded groups compared with the naked islets. C-peptide and 
insulin quantity in the serum and in the transplanted grafts were also higher in the nano-shielded islets 















Figure 6.5    (A) C-peptide, and (B) insulin concentrations were measured by enzyme-linked 
immunosorbent assay (ELISA) from the serum of all three recipient groups. (C) Hematoxylin and eosin 






















Figure 6.6    Migration of immune cells is reduced in TA-PEG-Hep nano-shielded collagen well inserts. 
(A, B) Millicell® hanging cell culture insert (3 µm pore size, 24-well plate) were coated with rat tail 
collagen I, and the three-layer (TA-PEG-Hep) nano-shielding was formed on the collagen layer. 
Isolated splenocytes (5x104) were incubated in the inserts for 24 h and counted with trypan blue staining. 













Analyzing the in vivo results, TA-PEG-Hep was sorted as the better system in respect to 
preserving islet viability and improved survival time. In vitro migration assay was conducted using well 
inserts to verify the extent of immune infiltration in contact to the TA-PEG-Hep. Therefore, an in vitro 
system similar to the rat islet xenograft was created by coating well inserts with rat collagen. When 
nano-shielded with TA-PEG-Hep, lower number of migrated splenocytes was observed compared with 
the control group.  
The results suggest, although the nano-shielding improved the outcome of transplanted islets 
compared with naked islets, it was not considerable enough for clinical applications. In previous studies, 
it was shown that neither nano-shielding nor immunosuppressive drug protocol alone could sustain a 
long-term functionality of the transplanted islets in recipient body; rather a combined effort of both is 
required (Chapter 2-5) [4, 5]. Consequently, in the future studies, two more groups will be included 
transplanted with naked, and TA-PEG-Hep nano-shielded islets administered with an 
immunosuppressive drug protocol. The future works will also include measuring the exact thickness of 
the shielding systems, modulation of free-radicals (reactive oxygen and nitrogen species), and extent of 
activation of immune cells by the TA-PEG-Hep nano-shielding. 
 
6.5    Conclusion 
It is clear that for a successful islet transplantation there is an awful need for developing 
immunoisolation system to induce tolerance and improve graft survival. Although this study is currently 
ongoing, from the existing data it can be said that the combination of TA, PEG and heparin nano-
shielding system has the potential to meet the criteria of a close to perfect nano-shielding system. 
Further studies will determine the actual efficacy of TA-PEG-Hep nano-shielding system in 
diminishing immune cell activation and free-radical generation. It is anticipated that this nano-shielding 
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In this thesis, islet nano-shielding compositions with minimum diffusion barrier and maximum 
immunoprotection have been investigated and developed. Although advances have been made in 
clinical studies on islet microencapsulation with alginate, transplantation of alginate encapsulated islets 
into the portal vein is not feasible due to its bulky size. Polymers, such as PEG and heparin, have 
potential as nano-shielding materials in islet transplantation besides their application in the field of drug 
delivery. In this thesis, the roles and effects of these polymers have been investigated in different animal 
models to inspect the validity of nano-shielding on islets. The sole aim was to develop a nano-shielding 
system compatible to human islets or other xenogeneic islets for clinical islet transplantation. In the 
beginning, porcine islets were studied as an alternative source to human islets. Porcine and human 
insulin have difference in only one amino acid sequence, as a result, porcine insulin has long been used 
as an exogenous source of insulin in diabetic patients. Porcine islets are recently being studied as an 
abundant source of islets for human xenotransplantation that can overcome human islet shortage. 
However, their intrinsic fragile structure and surface antigens reduce the appeal of using it in clinical 
trials. In this thesis, it has been shown that applying nano-shielding technology both of these problems 
can be overcome, and a significant difference can be attained in graft survival after transplantation 
(Chapter 2). Although the nano-shielded islets did not achieve a considerable period of survival time in 
a mouse xenotransplantation model, more studies are required to develop this system usable for clinical 
studies. Later, focus was turned to NHP islets for NHPs are phylogenetically close to humans with 
similar islet morphology. It was hypothesized, a nano-shielding system compatible to NHP islets would 
also be compatible to human islets. In the first study with NHP islets, PEG nano-shielding was used to 
assess the immunoprotective effects (Chapter 3). PEG nano-shielded NHP islets, when 
xenotransplanted in the kidney subcapsular space of a mouse model, showed 100% survival rate for 
150 days compared to 50% of naked islets. For the next study, the PEG system was modified with a 
layer of heparin (Hep) on the outer surface (Chapter 4). When heparin was incorporated, significantly 
reduced activation of complements and immune cells were observed. Next, the effectiveness of both 
PEG and PEG-Hep nano-shielding were compared in liver allotransplanted NHPs (Chapter 5). Results 
showed, when islets were transplanted via the portal vein, PEG nano-shielding had no better output 
compared to the naked islets. Whereas, PEG-Hep nano-shielding significantly improved survival rate 
with reduced propagation of IBMIR. 
In summary, it can be said that among all the nano-shielding systems used in this thesis, the 
PEG had proven to have excellent immunoprotective effect in kidney subcapsular space transplantation 
in a rodent model. However, transplantation via the portal vein into liver is critical due to the activation 
of the factors related to the IBMIR which causes acute rejection of the transplanted cells. In such case, 
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PEG-Hep nano-shielding showed marvelous outcome in NHP allotransplantation model. From the 
results obtained in this thesis, it is proposed, if the PEG-Hep nano-shielding system were applied on 
human islets along with administration of an optimized immunosuppressive drug protocol, clinical 
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